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Abstract
The Role of the Methyl DNA Binding Domain Protein 2 (MBD2) in Breast Cancer

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
by
Omar Y. Mian
B.S. James Madison University
M.S. Johns Hopkins University
Major Advisor: Gordon D. Ginder, M.D.
Director, Massey Cancer Center
Professor, Internal Medicine, Human Genetics, and Microbiology and Immunology
Molecular Biology and Genetics Program
Virginia Commonwealth University, Richmond, Virginia

Methyl-CpG Binding Proteins (MCBPs) are thought to function as the interpreters of
epigenetic information encoded in cytosine methylation. Their ability to translate DNA
methylation into local transcriptional repression has sparked interest in the role of
Methyl-Binding Domain Proteins (MBDs) in cancer, where repatterning of CpG
methylation is common. In this dissertation I summarize and discuss observations made
in the Ginder Lab linking MCBPs to the progression of neoplastic disease. It is clear
from our work that the Methyl Binding Domain Protein 2 (MBD2) is necessary for the
persistent repression of critical tumor suppressor genes in breast cancer. We show that
stable knockdown of MBD2 also leads to growth suppression in cultured human
mammary epithelial cancer lines (MCF-7, 49% suppression; MDA-MB-231, 77%; MDAMB-435, 94%; SK-BR-3, 92%) with the peak cytotoxicity and anti-proliferative effect
occurring as late as 2-3 weeks after knockdown. MBD2 knockdown also led to a
xv

decrease in viable tumor cells at equivalent doses of the histone deacetylase inhibitor,
SAHA (Vorinostat™), and chemotherapeutic agents Doxorubicin, and Paclitaxel. Stable
MBD2 knockdown in MCF7 cells led to an increased proportion of normal epithelial
structures in 3D culture (70%, [CI=0.55-0.83]) when compared to untransfected (46%,
[CI=0.39-0.53], p≤0.038) or scrambled shRNA transfected (37%, [CI=0.29-0.45],
p≤0.012) controls. In vivo xenograft studies show tumor growth in BALB/C nu/nu mice
was significantly impaired when mice were implanted with human breast cancer cells
harboring MBD2 targeted shRNA. Following MBD2 knockdown, tumor suppressor
promoter methylation remained unchanged despite sustained increases in gene
expression, arguing against the convention that passive demethylation occurs with
increased transcription. Our data suggest that uncoupling CpG methylation from histone
modifications or other repressor functions by removing MBD2 is sufficient to initiate and
maintain anti-tumor gene transcription in the absence of secondary changes in DNA
methylation. In this dissertation I present evidence for the pathologic role of MBD2 in
breast cancer and provide mechanistic support for the prospect of targeting MBDs in
neoplastic disease.

xvi

Overview
Carcinoma of the breast remains the most common cancer in women. Great strides
have been made in early detection and treatment of primary non-invasive lesions;
however treatment options for advanced, aggressive, and disseminated breast cancers
remain woefully inadequate. It is estimated by the National Cancer Institute that there
will be 192,370 new cases and 40,170 deaths from breast cancer in the United States in
2009 (Horner et al. 2009).
While specific concepts are dealt with in greater detail at appropriate points in the
sections that follow, some broad and thematic ideas require introduction. To begin with,
cancer is a complex collection of hyper-proliferative disorders with simultaneous and
indissoluble genetic and environmental components (Hanahan and Weinberg 2000). One
fundamental hallmark of tumors is the loss of appropriate gene regulation, particularly
the inactivation of protective genes within critical gene networks.

A common and

reversible mechanism by which this gene inactivation occurs is a chemical modification
of the DNA known as CpG-methylation (Egger et al. 2004; Jones and Baylin 2007;
Widschwendter and Jones 2002; Esteller 2008). Abnormal DNA methylation is an early
event in carcinogenesis; as such it represents a target for preventing the onset and
progression of disease. For some time we have been exploring strategies to reverse the
pathological effects of DNA methylation in tumors while preserving this necessary
modification in normal tissues. A promising approach has recently emerged involving
the inactivation of Methyl CpG Binding Proteins (MCBPs) which “read” and translate
DNA methylation into changes in local gene expression (Sansom, Maddison, and Clarke
2007b; Ballestar and Esteller 2005; Hendrich and Bird 1998c). We originally set out to
1

explore the general role that MCBPs were playing in human neoplastic disease. Guided
by promising results, the work narrowed in focus to the pathological role of MBD2 in
breast cancer.

Rationale:
It is widely accepted that global hypomethylation of chromosomal DNA with
selective hypermethylation of specific gene promoters leads to chromosomal instability
and down regulation of tumor suppressor genes, both of which can promote cancer
development and progression (Jones and Baylin 2007; Esteller 2008). The observation
that CpG islands at the promoters of protective genes are often methylated led to the
clinical development of DNA methylation inhibitors such as decitabine and azacytidine
(Grant 2009; Jabbour et al. 2008). Unfortunately, the clinical utility of these agents has
been limited by the potential for carcinogenicity and toxicity associated with non-specific
global demethylation (Appleton et al. 2007; Oki and Issa 2006). An alternate strategy for
mitigating the effects of abnormal DNA methylation in tumors is needed.
The effects of DNA methylation on gene expression are mediated in large part by
MCBPs (Boyes and Bird 1991; Hendrich and Bird 1998; Klose and Bird 2006; Ballestar
and Esteller 2005; Prokhortchouk et al. 2001). There has been interest in exploiting the
function of MCBPs to selectively interrupt DNA methylation dependent changes in gene
expression in tumors. However, in order to validate their utility as therapeutic targets,
research to adequately characterize the function of MCBPs in human neoplasia is
required.
One member of the MCBP family, Methyl Binding Domain Protein 2 (MBD2), has
emerged as particularly noteworthy in the context of cancer for several reasons. MBD2
2

binds methylated CpGs with higher affinity than any known MCBP and has been shown
to act upon the highest number of tumor suppressor targets (Lopez-Serra et al. 2008a;
Berger and Bird 2005a; Fraga et al. 2003). In addition, this protein has been shown to
exacerbate mouse models of intestinal carcinogenesis by increasing tumor size and
number (Sansom et al. 2003a). Importantly, complete loss of MBD2 in the mouse does
not generate any significant deleterious effect (Hendrich et al. 2001).

This finding

suggests that MBD2 is not absolutely required for survival either before or after
development and therefore is a potentially selective target for therapy in tumors, where
MBD2 may be playing an acquired pathologic role (Sansom, Maddison, and Clarke
2007a).
Abnormal DNA methylation has been reported in virtually all human cancers.
Breast cancer, however, was of distinct interest to us for several reasons. It is now well
established that CpG island hypermethylation is an early event in mammary epithelial
cell transformation (Corn 2009; Futscher et al. 2004; Honorio et al. 2003b). At such
early time points, prevention is the main therapeutic goal and arresting progression of the
primary lesion remains a curative strategy. Furthermore, genetic testing and improved
screening methods for breast cancer have dramatically increased the probability of
successfully implementing an early intervention strategy. Finally, aggressive forms of
breast cancer (e.g., inflammatory carcinoma, triple negative breast cancer) are poorly
responsive to conventional treatment and alternate tactics, for example effective
epigenetic therapy, are needed (Corn 2009; Lustberg and Ramaswamy 2009).
Therefore, we were very intrigued by the potential of MBD2 as an epigenetic target
in the unique and potentially amenable setting of breast cancer.
3

Hence, the primary

rationale behind this body of work was to explore the role that MBD2 plays in cancer,
specifically in mammary tumor initiation and progression.

4

Hypotheses:
We sought to confirm whether the Methyl DNA Binding Protein 2 (MBD2) acquires
a novel pathologic role within the atypical environment of mammary epithelial tumors.
We asked whether cancer cells which become dependent on DNA methylation
abnormalities simultaneously become „addicted‟ to MCBPs and to MBD2 in particular.

1: We hypothesized that inhibiting the function of MBD2 in tumor cells would lead to
transcriptional reactivation of pathologically silenced tumor suppressor genes.

2:

We further hypothesized that any transcriptional changes induced by MBD2

inhibition would be deleterious to tumor cells; leading, for example, to growth
inhibition and death.

3: Since abnormal methylation is restricted to tumor cells, and since no human pathology
we are aware of is linked to loss of function of MBD2, we hypothesized that the
deleterious effects of MBD2 inhibition would remain restricted to tumor cells;
normal tissues would not be affected to the same degree or at all by inactivation of
MBD2.

4: Given the redundancy within the MCBP family of proteins, we hypothesized that
individual MCBPs might play discrete roles in tumor suppressor silencing. Therefore, we
hypothesized that inhibition of multiple MCBPs, for instance MBD2 and MECP2, in
combination may offer superior anti-tumor activity and/or diminished off target
toxicity in normal tissues.
5

Objectives:
Briefly consider the context in which we initiated this line of investigation. When
we undertook this project, it was unclear to what extent any individual methyl binding
domain protein was required for the pathological behavior of human breast tumors, i.e.,
hyper-proliferation, failure of apoptosis, increased propensity for metastasis, resistance to
therapy, etc. It was reported, however, that MBD2 antagonized several extra-mammary
cancers (Sansom et al. 2003a; Slack et al. 2002). Furthermore, it was established that
MBDs were bound directly to methylated DNA targets and that the gene expression of
these target genes could be changed by perturbing MBD levels (Klose and Bird 2006;
Berger and Bird 2005b; Kransdorf et al. 2006b; Rupon et al. 2006). The nature of MBD
involvement in cancer pathology was to a large extent unknown and the notion of
therapeutic inhibition of MBDs in human disease remained largely speculative. In fact
given what was known about MBD function, it was reasonable to infer that any
interference with these proteins might have a greater destabilizing effect than a
therapeutic one in certain tissues.
Therefore, the chief objective of the studies described in this thesis was to determine
whether the Methyl CpG binding domain proteins were functioning as aggravating
factors in human neoplasia in general and breast cancer in particular. Pursuant to this
objective, we initially sought to identify and characterize any phenotypic changes that
resulted from knocking down the methyl binding domain protein 2 (MBD2) in human
breast cancer cells.
Our prospective goal in performing the experiments outlined in this thesis was to
validate methyl binding proteins as therapeutic targets in human mammary malignancies.
6

An important follow up objective was to build a case for one or more predominant
mechanisms by which MBD2 inhibition resulted in any anti-tumor effects. We asked:
what are the genes that are regulated by MBD2 in our breast cancer models, i.e., induced
by MBD2 knockdown? What cellular programs are invoked by MBD2 knockdown and
how specific are these programs to individual MCBPs? How do these effects differ from
those induced by general methylation inhibitors, e.g., 5-azaC, and other epigenetic
therapies, e.g. histone deacetylase inhibitors? Our hope in seeking the answers to these
questions was to reach a point where the entire constellation of MBD2 dependent
changes pointed to a consistent model for the function of this protein in breast cancer.

7

Chapter I: MBD2 inhibition alters the phenotype of breast cancer in culture and in
the mouse

Introduction:

Epigenetics in Mammals
Deoxyribonucleic acid (DNA) is an elegant molecular database capable of efficiently
storing, duplicating, and transferring genetic information (Watson and Crick 1953).
However, it has become increasingly clear over the past half century that DNA alone
does not provide the complexity required to generate the phenotypic diversity observed
within and between higher order species.

Epigenetic phenomena fill this gap by

significantly expanding the storage capacity and regulatory complexity of the genome.
Conrad H. Waddington, who coined the term, initially defined epigenetics as, “the causal
relationships between genes and their products which bring the phenotype into being.”
(Waddington 1957; Goldberg, Allis, and Bernstein 2007)

Modern epigenetics is

generally defined as the study of those occurrences which generate stable, heritable
changes in phenotype without a corresponding change in the sequence of DNA (Ginder,
Gnanapragasam, and Mian 2008). An important qualification for epigenetic information
is that it can be passed horizontally between cells by somatic transfer or vertically
between parent and offspring through the germ line.

In vertebrates epigenetic

information is transmitted through several principal modes which are discussed below:
Ribonucleic Acid (RNA) intermediates, post-translational modification (PTM) of histone
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proteins (both covalent and non-covalent), nucleosome repositioning, and finally cytosine
methylation.
Non-coding RNAs:
Much recent attention has been paid to small RNAs (miRNA, RNAi) that operate at
post-transcriptional and translational stages to affect gene regulation. These molecules,
however, are not epigenetic modalities in the strictest sense but rather represent alternate
trans-acting regulatory elements within the cell. There are, however, several examples of
bona fide epigenetic phenomena that are mediate by RNA in mammals. The first to be
described and the best characterized among these is dosage compensation of the X
chromosome in eutherian females mediated by the Xist family of small non-coding RNAs
(Payer and Lee 2008; Boumil and Lee 2001). Recently several other non-coding RNAs
have been described that drive analogous gene dosing and imprinting effects at non-sex
linked loci, for example at the imprinted IGF2 locus (Mohammad, Mondal, and Kanduri
2009). These RNAs generally work by nucleating changes in chromatin architecture
which are, once established, reinforced by DNA methylation and histone modifications.
Another recent report describes transgenerational epigenetic inheritance of a
paramutant phenotype of the cKit gene in the mouse, mediated by non-coding RNA
packaged into spermatozoa (Rassoulzadegan et al. 2006). It is clear from these studies
that non-coding RNAs are emerging as an important, multi-tiered regulatory modality for
effecting genetic and epigenetic gene regulation in mammals.

These reports also

highlight an important concept I will refer to thoughout this dissertation, i.e., the
integrative nature of epigenetic regulation. It is evident that significant overlap exists
between RNA, DNA methylation, and chromatin biology with respect to initiating and
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reinforcing epigenetic signals and therefore considering these processes in isolation often
crafts an incomplete understanding of their combinatorial nature.
Covalent Histone Modifications:
DNA methylation and ncRNAs alike mediate their effects on chromatin structure and
function in large part by initiating the „rewriting‟ of histone signals which in turn
reinforce a particular epigenetic transcriptional effect (Kouzarides 2007; Li, Carey, and
Workman 2007). Histone changes occur in two general varieties: covalent modifications
of residues on the exposed N-terminal histone monomer tails and the non-covalent
addition or removal of variant histone monomers into the macromolecular nucleosome.
While there remains some controversy as to the primary heritability of histone
modifications in mammals, it is clear that these marks confer stable transcriptional states
to regional chromatin. Covalent histone marks consist of a heterogeneous collection of
chemical modifications, some of which are assembled in Table 1 along with their putative
functions.
Table 1. Histone Modifications and Their Function
Chromatin
Modifications
Acetylation

Residues Modified

Functions Regulated

K-ac

Methylation (lysines)
Methylation (arginines)
Phosphorylation
Ubiquitylation
Sumoylation
ADP ribosylation
Deimination
Proline Isomerization

K-me1, K-me2, K-me3
R-me1, R-me2a, R-me2s
S-ph, T-ph
K-ub
K-su
E-ar
R > Cit
P-cis > P-trans

Transcription, Repair, Replication,
Condensation
Transcription, Repair
Transcription
Transcription, Repair, Condensation
Transcription, Repair
Transcription
Transcription
Transcription
Transcription

Table 1. A list of modifications to histone proteins and their regulatory functions. Amino acid
abbreviations: K: Lysine, R: Arginine, S: Serine, T: Threonine, E: Glutamate, P: Proline. Adapted
from: (Kouzarides 2007)
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Importantly, these modifications can be arranged in a myriad of permutations across
a given region of chromatin, placing an enormous degree of regulatory complexity at the
disposal of the epigenetic machinery which establishes, edits, and maintains these marks.
Although many modifications are known to be enriched at either actively transcribed or
stably silenced regions of chromatin (see the Table 2 below), in actual fact it is often
difficult to ascertain the transcriptional state of a particular locus based on histone
modifications alone. Moreover, many so called “bi-valent” domains exist which bear
both marks of active and repressed transcription. It is thought that such regions represent
loci which are variable with respect to spatial or temporal gene expression and are poised
for silencing or activation depending on secondary factors such as the presence or
absence of the sequence specific transcription factors. It is worthwhile to note that the
inherent plasticity of bivalent chromatin domains may be critical for establishing
pluripotency and pathologically in the development of neoplasia (Boyer, Mathur, and
Jaenisch 2006; Keenen and de la Serna 2009; Surani, Hayashi, and Hajkova 2007).
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Table 2. Covalent Histone Modifications and Their Association with Transcription

Modifications
Methylation

Position
H3

K4
K9
K27
K36

Arg Methylation

H4
H3

H4
Phosphorylation H3
Ubiquitination
H2B
H2A
Acetylation
H3
H4
Htz1

K79
K20
R2
R17
R26
R3
S10
K120/123
K119
K56
K16
K14

Mammalian
Enzymes
MLL, ALL-1, Set9/7, ALR-1/2,
ALR, Set1
Suv39h, G9a, Eu-HMTase I,
ESET, SETBD1
E(Z)
HYPB, Smyd2, NSD1

Dot1L
PR-Set7, SET8
CARM1
CARM1
CARM1
PRMT1
UbcH6, RNF20/40
hPRC1L
hMOF

Functions in
Transcription
Activation
Repression,
activation
Repression
Recruiting the
Rpd3S to repress
internal initiation
Activation
Silencing
Activation
Activation
Activation
Activation
Activation
Activation
Repression
Activation
Activation
Activation

Table 2. Several well characterized histone modifications and their positions on the N-terminal
tail residues of histone monomers are listed on the left. The mammalian isoforms of enzymes
that catalyze the placement and/or removal these marks are listed to the right of the corresponding
modifications. The predominant effect of each mark on transcription (activation/repression) is
listed on the far right. Table adapted from: (Li, Carey, and Workman 2007)
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Non-covalent Histone Modifications:
Another layer of epigenetic programming appears to have arisen from the
evolutionary divergence of the genes encoding histone proteins. The discovery of histone
variants overturned the long held idea that all nucleosomes are composed of a matching
complement of the eight core histone proteins (Old and Woodland 1984). Instead it seems
that the nucleosome octamer is fairly modular; its individual monomer constituents are
interchangeable with functionally diverse variant proteins that confer a regulatory
multiplicity to the assembled macromolecule. It follows, therefore, that the placement of
nucleosomes in their chromosomal locations is not arbitrary and involves a carefully
orchestrated collaboration between the S-phase machinery and histone chaperone
proteins (Kamakaka and Biggins 2005). Numerous histone variants have now been
described and the list of specialized histone proteins and their functions continues to
grow. A brief list of histone variants involved in transcriptional regulation was compiled
by Li, B. et al., and is given in Table 3.
Nucleosome Position:
In addition to the composition of histone multimers and their covalent modifications,
nucleosome placement and density has profound effects on the epigenetic landscape of a
particular region (Saha, Wittmeyer, and Cairns 2006). Nucleosomes can be partially
dissociated, shifted along the DNA strand, or entirely „evicted‟ from a particular region
by the transcription machinery, histone chaperone proteins, and/or ATP dependent
nucleosome remodeling complexes such as Swi/Snf (Workman 2006). The result is the
transient formation of nucleosome depleted regions which can alter local transcription
dramatically by changing the dynamics of DNA-protein interactions.
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Table 3. Histone Variants Involved in Transcriptional Regulation: Structure and Function
Histone Variant
Forms
H3
H3.3
H2A

Role(s) in
Transcription
Transcription
activation
X
chromosome
inactivation

Localization

Structural Features

Functions

Transcribing
region
Inactive X
chromosome

macroH2A1

Autosomal
gene
repression

Active transcription triggers deposition and
removal.
Repressing initiation but not elongation;
interfering histone acetylation by p300; it
blocks sliding by ACF and remodeling by
Swi/Snf; it inhibits transcription factor binding
(NFkB).
macroH2A1 marks repressed autosomal
chromatin, it positively regulates transcription
when located in the transcribed regions of a
subset of its target genes (Gamble et al. 2010)

H2AZ

Transcription
activation/repression

Repressed
gene
promoters and
a subset of
active genes
Promoter,
heterochromat
in boundary

H2ABbd

Transcription
activation

Active X
chromosome
and autosomes

Different from canonical H3 in
only four amino acids.
C-term nonhistone-like region is
responsible for most of functions;
histone-fold prevents sliding;
prefers to form hybrid
nucleosome.
Variant of the macrodomain
superfamily, shares 60%
homology with canonical H2A, Cterminal macrodomain is
responsible for unique functions
Loop1 differs from H2A, disfavors
formation of hybrid nucleosome;
C-term  helix is essential for
recognition.
Lack of C term; it only organizes
118–130 bp pf DNA and leaves
each side 10 bp free DNA.

H2A.X

Repression

Canonical in
A conserved C-term SQ(E/D)
yeast, generally motif that becomes
distributed
phosphorylated upon DNA
damage.

macroH2A

Facilitates TBP binding; is evicted upon
activation; prevents elongation-associated
modification and remodeling at promoter
Swi and ACF fail to mobilize the H2ABbd
nucleosome but can increase its accessibility.
p300- and Gal4-VP16-activated transcription is
more robust on H2ABbd nucleosomes; H2A.Bbd
histone fold domain is responsible for the
unusual properties of the H2A.Bbd nucleosome.

Table 3. A list of histone monomer variants involved in transcriptional regulation and their function. Table data from: (Li, Carey, and Workman
2007) and (Gamble et al. 2010)
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DNA Methylation
Perhaps the best characterized and most stable epigenetic mark in mammals is
cytosine methylation. In the human genome, 70-80% of cytosines in the context of a
CpG dinucleotide are methylated at the C-5 position (Ehrlich et al. 1982). Patterns of
CpG

methylation

are

established

and

maintained

faithfully

by

the

DNA

methyltransferases (DNMTs), enzymes which catalyze the transfer of a methyl group
from S-adenosyl-methionine to cytosine (Taylor and Jones 1982).
Figure 1. Pyrimidine Methylation and Hydrolytic Deamination Reactions

Figure 1: Shown above are the core reactions in the synthesis and loss of 5-methyl Cytosine in
vertebrates. 5-Methyl Cytosine is generated from cytosine by the action of DNA methyl
transferase enzymes with S-adenosylmethionine as the methyl donor molecule. Hydrolytic
deamination of cytosine produces uracil where as deamination of 5-methyl cytosine generates
thymidine. (R. Singal and G. Ginder, Blood, 1999)
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Three functional DNA methyltransferases are recognized in mammals: DNMT3a and
DNMT3b, which establish de novo patterns of methylation during development (Okano
et al. 1999) and DNMT1, which maintains these patterns of methylation through
replication of the DNA (Leonhardt et al. 1992). However, evidence suggests some
overlap in de novo/maintenance activity exists between the methyltransferases (Liang et
al. 2002; Jair et al. 2006).
DNA methylation is posited to have a number of important functions (Singal and
Ginder 1999).

Among these, methylation inhibits the destabilizing proliferation of

parasitic elements in the genome (i.e., transposons, repetitive elements) (Robertson and
Wolffe 2000). CpG methylation also maintains the mono-allelic expression of imprinted
and X-inactivated genes. At imprinted loci DNA methylation insures a single, parentally
determined allele is expressed (Feinberg 2007). Similarly, inactivation of a single X
chromosome mediated by Xist ncRNAs drives monoallelic DNA methylation which is
thought to stabilize heterochromatinization and transcriptional silencing.

(Wutz and

Gribnau 2007).
As discussed above, histone modifications can also maintain transcriptional states;
however, CpG methylation is intuitively more fixed through DNA replication and cell
division than histone modifications or occupancy. As such it is considered an important
medium for secure, long-term preservation of epigenetic information in the genome
(Bernstein, Meissner, and Lander 2007). Though its primary role in developmental gene
expression patterning is an area of active investigation, it is clear that intact CpG
methylation is indispensable for normal mammalian development (Hendrich et al. 2001;
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Okano et al. 1999; Li, Bestor, and Jaenisch 1992a). In addition, suggestive differences in
CpG methylation are observed in terminally differentiated cells in contrast to the
corresponding loci in histologically distinct cells and pluripotent precursors. This CpG
methylation is thought to provide a “lock off” mechanism for tight control of tissue
restricted patterns of expression in differentiated tissues (Bird 2002a) and perturbation of
this pattern in primary and cultured cells is sufficient to cause phenotypic conversion
(Taylor and Jones 1979; Reik, Dean, and Walter 2001a).
Consistent with their well-described functional importance, the distribution of CpG
sites in the genome is highly non-random.

Across most of the genome, CpG

dinucleotides are present at a fraction of the expected frequency due to the unchecked
deamination of 5-methyl cytosine to thymidine over evolutionary time (Cooper and
Krawczak 1989). CpG islands are an important exception; these are pockets of higher
than expected CpG density, presumably due to a combination of selection forces and the
absence of cytosine methylation within these regions (Cross and Bird 1995; Bird 1986).
They tend to occur close to or overlapping the transcription start sites of protein coding
genes. In fact, more than half of the known coding genes have promoter associated CpG
islands (Jones and Baylin 2002).

CpG Methylation Changes in Cancer:
The normal pattern of CpG methylation is profoundly altered in cancer (Jones and
Baylin 2007; Esteller 2008). Breast cancer is of particular significance because this
differential methylation is known to be an early event in neoplastic transformation
(Futscher et al. 2004; Umbricht et al. 2001; Honorio et al. 2003a; Muggerud et al. 2010).
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Moreover, neoplastic mammary epithelium is clinically distinguishable from normal
tissue simply on the basis of aberrant DNA methylation (Evron et al. 2001; Krassenstein
et al. 2004). This suggestive observation has led to the postulation of a seminal role for
abnormal methylation in the initiation or stabilization of early, preneoplastic and
preinvasive breast cancer (Berman et al. 2005).
Abnormal CpG methylation in the cancer genome can be categorized into two
groups: an overall decrease in widespread DNA methylation (Riggs and Jones 1983) and
a local increase in CpG island associated methylation (see Figure 2). Though opposite in
character, both hypo- and hypermethylation are consistent with a pro-neoplastic role.
Global hypomethylation leads to deregulated oncogene expression, e.g., reactivation of
proto-oncogenes such as R-Ras and loss of imprinting (Nishigaki et al. 2005). Loss of
global methylation may also lead to widespread genomic instability due to de-repression
of transposable elements (Feinberg 2007; Ehrlich 2002).
Conversely, hypermethylation of CpG islands is associated with tumor suppressor
gene inactivation. The list of genes know to be silenced by promoter hypermethylation in
cancer is large and growing rapidly. Though debate exists as to whether CpG island
hypermethylation

is

an

initiating

event

and

the

mechanisms

directing

the

hypermethylation of particular loci are poorly understood, it is now widely believed that
this alteration stabilizes the transcriptional changes implicated in the onset and
progression of cancer (Jones and Baylin 2007; Feinberg 2007; Jones and Baylin 2002;
Jones and Laird 1999; Futscher et al. 2002a; Ting, McGarvey, and Baylin 2006).
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Figure 2. CpG Methylation: Changes in Cancer

Figure 2. CpG methylation changes occur in tumor cells in two major categories: global hypomethylation and local (CpG island associated) hyper-methylation. This figure shows that these
changes occur progressively as cells transition from normal epithelium to invasive neoplasia.
Abnormalities in DNA methylation lead to an altered histone modification pattern and ultimately
contribute to stable gene expression changes. Image: (Esteller 2008).
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Epigenetic Therapy of Cancer
Genetic abnormalities are frequent in tumors; these include DNA deletions,
amplifications, mutations, large scale chromosomal abnormalities, and translocation
events. Of immediate significance when considering epigenetic pathobiology in cancer is
the fact that epigenetic modifications and their effects are more readily reversed than
genetic lesions. A variety of strategies are currently used specifically to target epigenetic
changes in cancer and more are in development. In the clinical setting these strategies fall
into two major classes, DNA methylation inhibitors and histone deacetylase inhibitors
(HDAC). A list of epigenetic drugs currently in use was compiled by Cortez and Jones,
2008 and is listed in Table 4 below (Cortez and Jones 2008).
Table 4. Epigenetic Drugs Currently Used in the Treatment of Cancer
Drug name
DNA methylation inhibitors
5-azacytidine (FDA
approved)
5-aza-2-deoxycytidine (FDA
approved)
MG98
RG108
Procainamide
HDAC inhibitors
SAHA (FDA approved)
PXD101
LBH589
Depsipeptide
Phenylbutyrate
Valproic acid
MS-275
CI-994

Cancer
MDS, AML, CML
AML, CML, MDS
Renal cell carcinoma
Colon cancer cell line
Colon cancer cell line

CTCL, various solid tumors
Various solid tumors
CTCL
Multiple cancer cell lines, MDS, AML
MDS
Neuroblastoma cells
Prostate cancer cell lines, various sold tumors
and lymphoid malignancies
Various solid tumors

Table 4. A list of the compounds currently used to target epigenetic changes in tumors and the
cancer sub-types for which they are used. Table was adapted from Cortez, C. and Jones, P., 2008.
(Cortez and Jones 2008)
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Demethylating agents such as 5-aza-2-deoxycytidine (Decitabine) are thought to
elicit their therapeutic effects through passive demethylation mediated by DNMT
inhibition leading to reactivation of tumor suppressor genes, though a clear link between
their benefit and changes in methylation has yet to be established (Cortez and Jones
2008). Similarly, HDACs such as suberoylanilide hydroxamic acid (SAHA, Vorinostat)
restore activating histone acetylation marks, thereby restoring gene expression and
resensitizing tumors to treatment (Karagiannis and El-Osta 2006).
While epigenetic therapy has shown promise, particularly for certain hematopoetic
malignancies, the utility of this approach in treating solid tumors remains to be
determined. Solid tumors, such as breast cancer, have so far been relatively refractory to
available epigenetic therapies (Appleton et al. 2007; Schrump et al. 2006). This limited
efficacy could be due in part to the fact that strategies inducing widespread CpG demethylation generate dose-limiting acute toxicities and are themselves carcinogenic
through the mechanisms described above. As such, effort is being invested in finding
alternate approaches capable of reactivating tumor suppressor genes in cancer that do not
rely on global DNA de-methylation or on the widespread effects of pleotropic
compounds such as HDACs. One such approach is inhibiting the function of MCBPs, the
proteins which bind to methylated DNA and mediate transcriptional suppression (Figure
3).
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Figure 3. Breaking the Epigenetic Cycle

5-aza-2-deoxy-Cytidine
(Decitabine)

SAHA
(Vorinostat)

DNA
Methylation

Tumor
Suppressor
Silencing

MCBP Inhibitors?

MCBP
Complex
Formation

Histone
Modification

Figure 3. Emerging models suggest DNA methylation and post synthetic histone modifications
depend on one another and reinforce each other. Through recruitment of enzymes and
complexes, either mark appears capable of recapitulating the other, initiating a cycle which
stabilizes gene expression silencing. Vorinostat and Decitabine are inhibitors that act at the
indicated points in the cycle. We are investigating the role of MBD2 as a proof of principle that
MCBP inhibition may be an alternate, and perhaps preferable, strategy for breaking this cycle.
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Methyl CpG Binding Proteins:
The effects of DNA methylation on gene expression (Singal and Ginder 1999;
McGhee and Ginder 1979) are mediated in large part by methyl-CpG binding proteins
(MCBPs) (Hendrich et al. 2001; Rupon et al. 2006; Nan et al. 1998a; Kransdorf et al.
2006a), making these a promising class of proteins to explore for therapeutic targeting
strategies (Lopez-Serra et al. 2008a; Sansom, Maddison, and Clarke 2007a). The MCBPs
encompass several distinct sub classes of proteins, including the MBD family and the
Kaiso protein (Klose and Bird 2006).
The MBD protein family has five members, assembled based on the presence of a
conserved methyl-binding domain (MBD): MeCP2, MBD1, MBD2, MBD3 and MBD4
(Hendrich and Bird 1998a). The MBD motif allows these proteins to recognize and
specifically bind methylated CpGs with one exception, MBD3. Mutations within its
MBD have rendered MBD3 unable to preferentially bind methylated CpGs (Saito and
Ishikawa 2002). MBD3 does retain functional protein interaction and transcriptional
repression capability and, interestingly, this protein is the only member of the MBD
family which is essential for life (Hendrich et al. 2001). MBD4 preferentially binds to
methylated DNA, however this protein is more commonly associated with DNA
repair/glycosylase activity in mammals (Hendrich et al. 1999). (Figure 4)
Unlike the MBD family, the Kaiso protein associates with methyl-CpG containing
DNA through a zinc finger binding domain (Prokhortchouk et al. 2001a) which confers a
degree of sequence specificity to this protein. Similarly, MeCP2 has a preference for
methyl-CpGs flanked by short A-T rich stretches (Klose et al. 2005), however the
remaining MBD proteins do not seem to exhibit any sequence preference beyond their
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affinity for methylated DNA. MeCP2 is further unique among the MBD proteins because
of its association with a debilitating human neurodevelopmental disorder, Rett syndrome
(Amir et al. 1999).
The MCBPs mediate transcriptional repression by recruiting chromatin modifying
protein complexes to sites of increased methyl-CpG density (Klose and Bird 2006).
MBD1, for example, couples CpG methylation to repressive methylation of H3 lysine 9
through its association with the histone methyltransferase, SetDB1, during replication.
MBD2 is known to recruit the histone deacetylase (HDAC) 1 and 2 containing
NuRD/Mi-2 complex, of which MBD3 is thought to be a component in some instances
(Zhang et al. 1999) but not in others (Le Guezennec et al. 2006). Similarly, MeCP2 is
thought to initiate local chromatin condensation through the HDAC containing Sin3a
silencing complex (Figure 4).
The principal interactions of methyl binding proteins in mammalian cells, as
described above, are consistently observed across tissues. However, it is becoming
increasingly clear that these proteins are promiscuous with respect to their biochemical
associations (Bogdanovic and Veenstra 2009). Each individual MCBP associates with
many partners to accomplish its transcriptional function and these interactions can be
tissue specific or locus specific within a given nucleus. This promiscuity is evident in the
list of the MCBPs and their known biochemical interactions summarized in a review by
Bogdanovic and Veenstra (given in Table 5 below).

Once again, implicit in the

widespread communication of MCBPs is the integrative and combinatorial nature of
epigenetic signals. Through alternative arrangement of MCBPs and their partners, the
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cell or organism as the case may be, can fine tune the hardwired transcriptional program
to suit its particular requirements.

Figure 4. Methyl Binding Domain Protein Family and their Co-Repressors

RNA
Pol II

ATF7IP

SetDB1

RNA
Pol II

HDAC1/2
RbAP

HDAC1/2

MTA2

Mi-2/NuRD
Complex

Sin3

Sin3A
Complex

RNA
Pol II

p66

DNMT1
DNMT3a/b

MBD1

MBD2

MeCP2

CpG methylation

MeCP2

DNMT1
DNMT3

DNA methyltransferases

MBD1

Methyl binding domain protein 1

SetDB1

MBD2

Methyl binding domain protein 2

Sin3

HDAC1/2

Methyl CpG Binding Protein 2
Histone deacetylases
Histone methyltransferase
Sin3 Histone deacetylase complex

Figure 2: CpG methylation leads to transcriptional silencing through MCBPs: Cytosine (in the
context of a CpG di-nucleotide) is methylated by DNA methyltransferases (DNMT1, DNMT3a
and DNMT3b) leading to methyl-binding domain protein association (e.g., MBD1, MBD2,
MeCP2). These MCBPs in turn recruit co-repressor complexes (e.g., SetDB1, NuRD/Mi-2, and
Sin3a) which modify the local chromatin environment leading to stable transcriptional silencing.
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Table 5. Methyl DNA Binding Proteins and their Interactions
Protein Interacting partner
MeCP2 Sin3A, HDACs
c-ski, N-CoR
HMGB1

Transcriptional repression
Unknown

Sin3B, HDAC2
Dnmt1
H3K9 methyltransferase
CoREST complex

Transcriptional repression
Targeting of maintenance DNA
methylation
Transcriptional repression
Repression of neural genes

Brm (SWI/SNF complex)

Transcriptional repression

YB-1
ATRX

Alternative splicing
Epigenetic regulation of neural
development
Transcriptional repression
during myogenic differentiation
Transcriptional activation
DNA repair
Transcriptional repression
Transcriptional repression,
inheritance of epigenetic states

HP1

MBD1

MBD2

MBD3

Effects of the interaction
Transcriptional repression

CREB1
MPG
Suv39h1-HP1
MCAF1, MCAF2, SETDB1,
CAF-1 p150
PML-RARα, HDAC3
Mi-2, MTA1-3, P66α/β,
HDAC1/2, RbAp46/48,
DOC-1, PRMT5, MEP50
(NuRD complex)
Sin3A
Tax
TACC3, HATs, pCAF
GCNF
Dnmt1
RFP
Mi-2, MTA1-3, P66α/β,
HDAC1/2, RbAp46/48,
DOC-1 (NuRD complex)

PML-RARα-mediated silencing
Transcriptional repression

Transcriptional repression
Transcriptional activation
Transcriptional activation
Oct-4 silencing
Targeting of maintenance DNA
methylation?
Transcriptional repression
Transcriptional repression
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Reference
Jones et al. (1998), Nan
et al. (1998)
Kokura et al. (2001)
Dintilhac and Bernues
(2002)
Rietveld et al. (2002)
Kimura and Shiota (2003)
Fuks et al. (2003b)
Ballas et al. (2005),
Lunyak et al. (2002)
Harikrishnan et al. (2005),
Hu et al. (2006)
Young et al. (2005)
Nan et al. (2007)
Agarwal et al. (2007)
Chahrour et al. (2008)
Watanabe et al. (2003)
Fujita et al. (2003)
Ichimura et al. (2005),
Reese et al. (2003), Sarraf
and Stancheva (2004)
Villa et al. (2006)
Brackertz et al. (2002), Le
Guezennec et al. (2006),
Zhang et al. (1999)
Boeke et al. (2000)
Ego et al. (2005)
Angrisano et al. (2006)
Gu et al. (2006)
Tatematsu et al. (2000)
Fukushige et al. (2006)
Le Guezennec et al.
(2006), Wade et al.
(1999), Zhang et al.

Dnmt1
CDK2AP1, GCNF
MBD4

Sin3A, HDAC1
FADD

Tcf3
p120

Transcriptional repression
Genome
surveillance/apoptosis?
DNA repair
Enhancement of transcriptional
repression
Suppression of Wnt signaling
Wnt signaling?

N-CoR

Transcriptional repression

MLH1
RFP
Kaiso

Targeting of maintenance DNA
methylation
Oct-4 silencing

(1999)
Tatematsu et al. (2000)
Deshpande et al. (2009),
Gu et al. (2006)
Kondo et al. (2005)
Screaton et al. (2003)
Bellacosa et al. (1999)
Fukushige et al. (2006)
Ruzov et al. (2009)
Daniel and Reynolds
(1999), Prokhortchouk et
al. (2001)
Yoon et al. (2003)

Table 5. Methyl DNA Binding proteins are listed along with the proteins and protein complexes
with which an association has been demonstrated. The function associated with each biochemical
interaction is also given as are the relevant references. The data for this table was compiled from:
(Bogdanovic and Veenstra 2009)
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The precise role that MCBPs play in cancer is not well understood. One could make
a convincing case that their presence promotes the repression of protective genes and
therefore drives cancer progression; the opposite argument could be made as well by
considering the beneficial repression of tissue restricted oncogenes and parasitic
elements. To date, a few studies have demonstrated a functional role for MCBPs in
promoting extra-mammary tumor progression (Berger and Bird 2005a; Sansom et al.
2003a; Pulukuri and Rao 2006). In addition, isolated gene expression changes in breast
cancer cell lines mediated by MCBPs have been demonstrated (Lin and Nelson 2003).
However, functional studies examining the role of MCBPs in promoting the pathogenesis
of breast cancer are needed.

The Special Role of MBD2 in Development and in Cancer
Substantial evidence now exists that supports a role for MBDs in the transcriptional
silencing of genes in tumors (Esteller 2008; Ballestar and Esteller 2005). Among methylbinding proteins, MBD2 is unique in that it binds the largest known proportion of genes
in human tumors.

Moreover, MBD2 is commonly the only MBD found at tumor

suppressor gene promoters; important exceptions do exist where other MBDs are
simultaneously present (Lopez-Serra et al. 2008a).
MBD2 null mice develop normally and are completely viable and fertile, with the
exception of a mild maternal behavioral phenotype (Hendrich et al. 2001). A recent
study cast suspicion on the idea that MBDs play redundant roles during development; a
triple knockout mouse with loss of function of MBD2, MeCP2 and Kaiso displayed only
the MeCP2 dependent Rett syndrome phenotype (Martin Caballero et al. 2009). This
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study essentially rules out compensation by other MCBPs as an explanation for the lack
of developmental lethality in MBD2 knockout animals.
Several studies have shown a role for MBD2 in gene expression patterning and
differentiation in post developmental mice. For example, MBD2 is required for the
complete silencing of fetal hemoglobin in adult human betaYAC transgenic mice (Rupon
et al. 2006). In addition, MBD2 contributes to the suppression of the Xist gene in
fibroblasts from male mice, in which this gene is not required for X-inactivation (Barr et
al. 2007). Interestingly, this repression was exclusive to MBD2; MeCP2, MBD1, and
Kaiso were not able to mediate a similar repression of Xist. MBD2 is also required for
the proper repression of IL-4 in the Th-1 subset of mouse helper T-cells (Hutchins et al.
2002; Hutchins et al. 2005). In MBD2 null animals, GATA-3 is no longer required for
activation of IL-4 expression and it is ectopically expressed in a subset of the MBD2 null
animal‟s T-cells. Similarly, pancreatic genes are ectopically expressed in inappropriate
segments of the MBD2 null mouse gut (Berger et al. 2007). These examples further
illustrate the integrative nature of activating (e.g., GATA-3) and repressive (e.g., MBD2)
signals in maintaining appropriate temporal and spacial gene expression in mammals. It
is interesting to note despite these MBD2 dependant effects there is not overt phenotypic
effect on animal viability.
Of particular relevance to the current work is the evidence for the exacerbating role
of MBD2 in tumorigenesis. Anti-sense RNA mediated knockdown of MBD2 in human
lung and colo-rectal cancer cells diminished their ability to form tumors in nude mice
(Campbell, Bovenzi, and Szyf 2004).

Furthermore, MBD2 null animals showed

decreased adenoma formation and enhanced survival when bred with an ApcMin mouse
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model of spontaneous colo-rectal cancer, shown below in a figure from the relevant work
(Figure 5, (Sansom et al. 2003a).

By contrast, MBD4 null animals demonstrated

increased adenoma formation in the same model, consistent with the DNA repair function
associated with this MBD protein (Millar et al. 2002).
Given the known exacerbating role of MBD2 in tumor models, we sought to
examine the role MBD2 was playing in breast cancer, where abnormal methylation is an
early event and predicts a poor prognosis (Corn 2009; Lustberg and Ramaswamy 2009;
Dumont et al. 2009; Martens et al. 2009).

Figure 5. Loss of MBD2 reduces adenoma formation and promotes survival in a
mouse model of colon cancer.

Sanson, OJ et al, Nature Genetics, 2003
Figure 5. In breeding experiments conducted by others, MBD2 heterozygote and null mice
showed a reduction in the occurrence and size of neoplastic lesions in the ApcMin mouse model of
colon cancer. In addition, MBD2 +/- and -/- animals demonstrated increased survival. On the left
is charted the progressively decreased tumor number and increased survival in MBD2 +/+, +/and -/- mice. On the right a survival curve is shown. The effects on tumor burden and survival
were MBD2 dose dependent, that is heterozygotes demonstrated an intermediate phenotype with
respect to adenoma formation and survival. Image: (Sansom et al. 2003)
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Materials and Methods:
Cell culture
MCF-7, MDA-MB-231, MDA-MB-435, and MDA-MB-468 cells (ATCC,
Manassas, VA) were cultured in DMEM (Gibco, Carlsbad, CA) supplemented with 10%
v/v FBS and penicillin/streptomycin. SK-BR-3 cells were cultured in McCoy‟s 5A
medium (Mediatech Inc, Manassas, VA) supplemented with 10% v/v FBS. MCF-10a
cells were cultured in DMEM F12 Hams (Gibco, Carlsbad, CA) media supplemented
with 5% v/v horse serum, penicillin/streptomycin, 20ng/ml recombinant human EGF
(Invitrogen, Carlsbad, CA), 10 ng/ml of insulin, and 20 ng/ml of Dexamethasone (SigmaAldrich, St. Louis, MO). All cells were held at 37 degrees C under 95% air and 5%
carbon dioxide and sub-cultured before complete confluence. DNA methylation patterns
are unstable over time in culture conditions; these cell lines were maintained in limited
passage states by returning to frozen stocks regularly. Low passage frozen stocks were
stored in a mixture of 10% DMSO, 20% FBS, and 70% DMEM. Cells were frozen in
cryo-storage tubes initially placed in controlled cooling vessels at -80 deg C (to maximize
post-thaw viability) and subsequently kept under liquid nitrogen.

Reverse Transcriptase PCR (cDNA synthesis)
Total RNA was purified from cultured breast cancer cells by disruption in 1mL of
TrizolTM reagent (Invitrogen, Carlsbad, CA). RNA purification was performed according
to the product directions, briefly by chloroform based (0.2mL) aqueous phase extraction,
isopropanol precipitation, rehydration in DEPC treated water and storage at -80 deg C..
One microliter of purified RNA was quantified by measuring absorbance at 260nm using
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a Nanodrop spectrophotometer (NanoDrop Products, Wilmington, DE). Complementary
DNA (cDNA) was generated from mRNA by reverse transcriptase PCR (iScript Kit, BioRad Labs, Hercules, CA) using 1ug of total RNA. A negative control with no reverse
transcriptase enzyme (-RT control) was always included to verify amplification of cDNA
only (and not residual co-purified DNA) in subsequent PCR assays. Reactions were
performed by incubation at 42 deg C for 45 min, after which cDNA was diluted 1:10 and
stored at -20 deg C or used for subsequent qPCR reactions.

SYBR Green fluorescence based quantitative real-time PCR
Gene specific mRNA levels and enrichment by ChIP were both measured using
quantitative PCR essentially as described previously (Rupon et al. 2006; Barrett et al.
2004).

Gene quantification, primers were designed either manually, using the

PrimerQuest tool (Integrated DNA Technologies), or auto-generated using the
qPrimerDepot tool (http://primerdepot.nci.nih.gov/) (Cui, Taub, and Gardner 2007). All
primers were verified through a 4 log range using serial dilutions of reference cDNA or
gDNA followed by standard curve analysis. A list of qPCR primers is given in Appendix
B of this dissertation. All amplifications were performed using 40 cycles of „standard‟
two step PCR plus dissociation curve program on either and ABI 7300 or ABI 7900 HT
instrument (Applied Biosystems). All reactions were performed in either 96 or 384 well
microtiter plates using SYBR green chemistry. A commercially available 2X master mix
was used containing enzyme and PCR additives. (Applied Biosystems, CA) To this mix
was added molecular biology grade water, approximately 5ng of RNA (cDNA) per
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reaction, and oligonucleotide primers at a final concentration of 100nM (from a 1 pM/ul
working stock).

Analysis of qPCR data
Quantitative PCR data was analyzed in MS Excel by relative quantification using the
2CT method as described previously (Schmittgen and Livak 2008). Endogenous control

primers were included from at least one reference gene (Cylcophillin A, Glyceraldehyde
Phosphate Dehydrogenase [GAPDH], or beta-actin) on every plate.

Relative

quantification results are reported as a ratio of means for each sample, e.g.,
MBD2/GAPD of at least two replicate reactions per gene per plate. Error is reported as
standard deviation adjusted for the ratio of means operation according to the following
formula where 𝑧𝜎 represents the cumulative error,

x
y

is the ratio of means and 𝑥𝜎 and 𝑦𝜎

are the individual standard deviations of the mean for each set of qPCR replicates:

𝑧𝜎 =

x
y

𝑥𝜎
𝑥

2

+

𝑦𝜎
𝑦

2

A simple approximation of the cumulative error given by this formula is the sum of
the individual errors for each set of qPCR replicates (≈ 𝑥𝜎 + 𝑦𝜎 ), for example the
standard deviation of all MBD2 replicates plus the standard deviation of all Cylcophillin
A replicates for a given biological sample.

Western Blots:
Protein immunoblots were performed following SDS polyacrylamide gel
electrophoresis of Bradford/Lowry normalized protein lysates in 4% SDS plus protease
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inhibitors essentially as described previously (Kransdorf et al. 2006a). Antibodies for
MBD2 were obtained from Upstate and Santa Cruz Biologicals (SC-D15). Antibodies
for MeCP2 and Beta-Actin, were obtained from Abcam Inc. Antibodies for DNMT1
were a generous gift from Shirley Taylor, PhD.

3DlrECM Culture
Human mammary adenocarcinoma cells were grown in 3 dimensional culture media
composed of laminin rich extracelluar matrix (3D-lrECM, Cultrex ®, Trevigen,
Gaithersburg, MD) as previously described (Genee Y. Lee et al. ). This basement
membrane substitute functions to provide a scaffold for formation of higher order
epithelial structures characteristic of in situ epithelial tissues (Nelson and Bissell 2005).
Briefly, basement membrane extract (BME) was thawed overnight at 4 deg C and kept on
ice at all times as it irreversibly solidifies into a gel at 15 deg C or above. Culture vessels
were pre-coated with a thin layer of BME and incubated at 37 deg C for 5 min to insure
that cultured cells are not were not in direct contact with plastic. Cells were trypsinized,
pelleted and resuspended in Matrigel by slowly pipetting to prevent bubble formation, all
cultures were started at a cellular concentration between 5x105 and 1x106 cells per ml.
Following a5 minute incubation at 37 deg C, the BME gel was overlaid with complete
growth medium and returned to the 37 deg C incubator. Overlaid media was changed
every 2 days. 3D structures were visualized by collecting whole BME aspirates in
chamber slides, complete dehydration of matrigel and a 10 minute fixation in 50%
Methanol 50% Acetone solution at -20 deg C. Fixed BME specimens were visualized
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with light microscopy or stained with 1X Hoechst nuclear stain (Sigma-Aldrich, St.
Louis, MO) in PBS and visualized by fluorescence microscopy.

Lentivirus cloning and infection
Lentiviral vectors and packaging was accomplished essentially as previously
described (Wiznerowicz and Trono 2003). Briefly, the lentivirus system was used to
mediate the efficient delivery, integration and stable expression of shRNA that was
rapidly FACS selectable. Rapid selection was essential to avoid the loss of populations of
interest, i.e., those cells whose growth or survival was negatively affected. Infectious
lentiviral particles were generated by co-expressing the virion packaging elements and
the vector genome containing engineered components (e.g. shRNAs and transgenes) into
packaging cells (in this case the 293T human embryonic kidney cell expressing a
temperature-sensitive version of SV40 Large T antigen). The core and enzymatic
components of the virion were originally derived from HIV-1, while the envelope was
derived from vesicular stomatitis virus (VSV) due to the high stability and broad tropism
of its G protein. By convention, the former elements are designates as the LV packaging
system the latter as the envelope. Currently, three generations of HIV-based LV
packaging systems have been successively developed for production of lentivirus by
transient transfection. The first generation LV packaging system encompasses all HIV-1
genes besides the envelope. The second generation LV packaging system is additionally
deleted in all viral auxilliary genes, i.e. vpr, vif, vpu and nef. The third generation LV
packaging system comprises only gag, coding for the virion main structural proteins, pol,
responsible forthe retrovirus-specific enzymes, and rev, which encodes a post35

transcriptional regulator necessary for efficient gag and pol expression. The third
generation packaging system offers maximal biosafety but is more cumbersome,
involving the transfection of four different plasmids in the producer cells. We used the
second generation LV packaging system in our studies (see Appendix C for plasmid
maps). For this system, the vector itself is the only genetic material transferred to the
target cells. It typically comprises the shRNA expression cassette flanked by cis-acting
elements necessary for its encapsidation, reverse transcription and integration. In this
system, the reverse transcription rearrangement is used to generate self-inactivating (SIN)
HIV-1-derived vectors, which lose the transcriptional capacity of the viral long terminal
repeat (LTR) once transferred to target cells (Wiznerowicz and Trono 2003; Choi et al.
2001). This minimizes the risk of emergence of replication competent recombinants
(RCR) and avoids problems linked to promoter interference. The bicistronic pLV-THM
vector allows for the simultaneous expression of a transgene and GFP marker to facilitate
tracking of transduced cells.
In order to insert shRNA hairpin forming oligos the pLVTHM vector was digested
with MluI and ClaI and the siRNA oligonucleotide was designed with the appropriate
complementary ends. Otherwise annealing and ligation was performed as described
above for pSuperior cloning. Oligos and target sequences used to generate the pLVTHM clones are given in Table 1.
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Table 6. Lentivirus shRNA Oligos and Sequencing Primers
MBD2 B Target Sequence
MeCP2 Target Sequence
Maspin Target Sequence
DAPK1 Target Sequence
KLK10 Target Sequence
Scramble Target Sequence

GGGTAAACCAGACTTGAAT
AAGCCTTTCGCTCTAAAGTGG
GCCGTTGATCTGTTCAAACAA
AAGCATGTAATGTTAATGTTA
AACACAGTGGGTGGTGAGTTC
ACGCGTAACGCGGGAATTT

shMBD2-B-Aa
shMBD2-B-Aas
shMBD2-B-Bs
shMBD2-B-Bas
shMeCP2-Aa
shMeCP2-Aas
shMeCP2-Bs
shMeCP2-Bas
shMaspin-Aa
shMaspin-Aas
shMaspin-Bs
shMaspin-Bas
shDAPK1-Aa
shDAPK1-Aas
shDAPK1-Bs
shDAPK1-Bas
shKLK10-Aa
shKLK10-Aas
shKLK10-Bs
shKLK10-Bas

CGCGCCCCGGGTAAACCAGACTTGAATTTCAA
TTCTCTTGAAATTCAAGTCTGGTTTACCCGGGG
GAGAATTCAAGTCTGGTTTACCCTTTTTAT
CGATAAAAAGGGTAAACCAGACTTGAA
CGCGCCCCAAGCCTTTCGCTCTAAAGTGGTTC
CTCTTGAACCACTTTAGAGCGAAAGGCTTGGGG
AAGAGACCACTTTAGAGCGAAAGGCTTTTTTTAT
CGATAAAAAAAGCCTTTCGCTCTAAAGTGGT
CGCGCCCGCCGTTGATCTGTTCAAACAATTCA
TCTCTTGAATTGTTTGAACAGATCAACGGCGGG
AGAGATTGTTTGAACAGATCAACGGCTTTTTAT
CGATAAAAAGCCGTTGATCTGTTCAAACAA
CGCGCCCAAGCATGTAATGTTAATGTTATTCA
TCTCTTGAATAACATTAACATTACATGCTTGGG
AGAGATAACATTAACATTACATGCTTTTTTTAT
CGATAAAAAAAGCATGTAATGTTAATGTTA
CGCGCCCAACACAGTGGGTGGTGAGTTCTTCA
TCTCTTGAAGAACTCACCACCCACTGTGTTGGG
AGAGAGAACTCACCACCCACTGTGTTTTTTTAT
CGATAAAAAAACACAGTGGGTGGTGAGTTC

shScramble-Aas
shScramble-As
shScramble-Bas
shScramble-Bs

CGCGCCCCACGCGTAACGCGGGAATTTTTCAA
TTCTCTTGAAAAATTCCCGCGTTACGCGTGGGG
GAGAAAATTCCCGCGTTACGCGTTTTTTAT
CGATAAAAAACGCGTAACGCGGGAATT

H1 Forward Sequencing Primer

GAATTCGAACGCTGACGTC

Table 1: Lentivirus shRNA cloning oligonucleotides and sequencing primers. Sequences are
given in the 5‟ to 3‟ direction for all oligonucleotides. Four complementary fragments were
annealed for each shRNA targeting construct in the following orientation: Vector 3‟ – A oligo
pair – B oligo pair – 5‟ Vector.
The “A” and “B”, sense (“s”) and antisense (“as”)
oligonucleotides are marked accordingly. Oligonucleotide ends are MluI and ClaI compatible.
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MTT Assay
The MTT Assay was performed as described previously (Scudiero et al. 1988).
Briefly, cells were trypsinized and diluted to between 50,000 and 100,000 cells/ml.
100ul of cells were plated in each well of a 96 well culture dish (5000 to 10000 cells).
For drug sensitivity assays, all cells were treated after 24 hours keeping the final culture
volumes at 100ul per well. A series of two-fold serial dilutions of untreated cells was
included in each assay as a standard reference. At the time of assay analysis, 20ul of a
5mg/ml filtered solution of Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma Aldrich)
was added to each well. Dishes were incubated for 2-4 hours (depending on cell density)
and media was removed.

Cells and formazan crystals were solubilized in acid

isopropanol, 150ul per well (4mM HCl, 0.1% NP-40 in isopropyl alcohol). Absorbance
was read on a 96 well plate reader at 595nm with a reference read at 620nm. All
absorbances were normalized to the standard dilution curve and reported as standardized
relative cell densities.

Xenograft growth, hematogenous seeding of the lung, and in vivo bioimaging of
nude mice
Human tumor xenograft growth and in vivo hematogenous metastases to the lung
was assayed essentially as described previously (Welch 1997; Klerk et al. 2007).

For

xenografts, 6 week old female Balb/C nu/nu mice were injected with 5x105 or 1x106 cells
(GFP positive, SC and KD lentivirally transduced and sorted MDA-MB-231 and MDAMB-435). Cells were suspended in a 1:1 DMEM:lrBME mixture (Gibco, Carlsbad, CA
and Cultrex Inc) and 50ul was injected with a 25½ gauge needle and 1cc syringe
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symmetrically in the subcutaneous space overlying the dorsolateral aspects of both hind
flanks. Each mouse acted as its own control, receiving scramble (left) and knockdown
(right) cells in opposite flanks.

Mice were observed 2-3 times per week until the

appearance of a palpable mass.

Upon the detection of a palpable tumor, caliper

measurements and bioimaging using GFP fluorescence filters. (IVIS 200, Xenogen Corp.
Almeda, CA) was performed every second day. Standard IVIS 200 fluorescence
acquisition settings were used including an exposure time between 4-10 seconds, normal
background subtraction, medium binning, and a 1.5cm focal plane height.
Lung tumors were seeded in 6 week old female BalbC nu/nu mice by tail vein
canulization and injection of 5x105 or 1x106 cells in 500ul of PBS. Mice were observed
for signs of respiratory distress and for hemodynamic stabilization at the injection site.
Mice were observed daily following injection for signs of distress. Mice were sacrificed
at 4 weeks post injection. Lungs and heart were perfused with PBS and the airspaces
were dilated with saline prior to extraction of the thoracic block and immediate fixation
in formalin or flash freezing in optimum cutting temperature (OCT) media. Sections
were stained in hematoxylin and eosin as described elsewhere and tumors appeared as
basophilic (cellular) regions in the otherwise cell poor lung parenchyma upon gross
macroscopic and microscopic examination. Approval for all animal work was obtained
from the VCU Institutional Animal Care and Use Committee and all procedures were
conducted according to VCU DAR guidelines.
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Results:

MBD2 knockdown leads to growth inhibition of breast cancer cells
Our initial objective was to identify whether loss or attenuation of MBD2 leads to a
detectable change in the growth or behavior of breast cancer cells. To this end, we
designed a drug selectable MBD2 shRNA delivery system (pSuperior, described in detail
in Chapter 2) and attempted to select stable MBD2 knockdown breast cancer cells.
Despite significant effort, these early attempts to select stable MBD2 shRNA expressing
cell lines met with limited success. We surmised that a growth or survival penalty was
indeed being imposed in breast carcinoma cells lacking MBD2 and we began searching
for alternate methods. We settled on two alternatives: transient siRNA transfection and
lentiviral transduction.
We used targeted siRNA double stranded oligonucleotides (Qiagen) to knockdown
both MBD2 and MeCP2 in MCF-7, MDA-MB-231 and SK-BR-3 human breast cancer
cell lines. We confirmed knockdown of these genes by quantitative PCR, using a siNEG
control siRNA as a reference for nonspecific gene expression changes. Immediately
there were several problems with this approach. We found that the mRNA knockdown
using siRNA peaked at between 48hrs and 96hrs post transfection and then gene levels
began to rise again (time course not shown). Furthermore, non-specific toxicity from the
Lipofectamine transfection reagent was a significant confounding factor, with maximal
toxicity occurring at the precise timepoints corresponding to peak mRNA knockdown.
Nevertheless, we were able to detect an increase in apoptosis by Annexin V staining and
flow cytometry analysis (Vybrant Assay, Invitrogen, Carlsbad, CA). The overall effect
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was small in magnitude (see Chapter III results), however, and no persistent change in
growth was apparent.
It became clear that we needed a more rapid and persistent method of knocking
down MBD2 in order to test its full spectrum of anti-cancer effects on our breast cancer
lines. We chose to try an anti-MBD2 lentiviral shRNA transduction system which
allowed rapid FACS based selection of stable knockdown populations. This system had
several advantages over transient siRNA and antibiotic selection methods.

The

transduction was immediately stable and required no selection yet was highly efficient in
terms of the percentage of cells infected. Moreover, we could eliminate noise from the
uninfected cells because we were able to sort by GFP co-expression. We were left with
an essentially pure population of stable knockdown breast cancer cells and corresponding
controls within 1 week (or slightly less) from the date of viral infection (as compared to
3-6 weeks with antibiotic selection). In addition, there was very little apparent toxicity
from the virus or the low serum infection conditions.
The pLV-THM viral genome vector was cotransfected into HEK-293T packaging
cells along with two helper plasmids (lacking any regions of homology capable of
generating recombinant virions). One of the helper plasmids contained the lentiviral
structural proteins and another encoded the vesicular stomatitis virus envelope protein to
give the virus enhanced epithelial tropism.

The resulting virus was shed into the

supernatant of the HEK-293T cell supernatant; this supernatant was collected and filtered
to eliminate any cellular carryover, complexed with 1 ug/mL of polybrene (Sigma
Aldrich) to improve the viral transduction, and was used to infect subconfluent breast
cancer cells (24 hour incubation with gentle rocking at 37 deg C in a CO2 incubator). As
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mentioned above, GFP fluorescence was used to trace successful transduction in the
breast cancer cells, appearing 24 to 48 hours following the overnight infection and
gradually peaking in intensity over the next 48 hours (Figure 6). MBD2 knockdown was
confirmed in sorted populations by qRT-PCR and western blot (Figure 7).
As we hypothesized, we found that MBD2 knockdown using the lentivirus method
led to significant growth inhibition when we compared MBD2 shRNA transduced cells
against scramble control virus transduced cells (Figures 8 and 9). Surprisingly, however,
the growth suppression was not immediate.

In fact the cells were essentially

indistinguishable in terms of growth for the first two weeks following infection (1 week
following FACS). At that point the MBD2 knockdown cells began to proliferate at a
significantly reduced rate compared to scramble controls in every breast cancer cell line
tested.
We found that MCF-7 cells were least sensitive to MBD2 knockdown, with a
maximum of 49% growth inhibition as measured by MTT assay. Other breast cancer cell
lines were somewhat more sensitive to MBD2 deficiency, with anti proliferative effects
ranging from 77% for MDA-MB-231; 92% inhibition of SK-BR-3; and 94% inhibition of
MDA-MB-435 cells. Importantly, anti-proliferative effects required between 5-7 days of
sustained MBD2 protein deficiency to manifest, and the peak effect took several weeks to
develop. To determine the mechanism of death or growth inhibition, we performed
apoptosis assays (PARP cleavage) and measured senescence associated betagalactosidase levels and found no significant increase in either PARP cleavage or
senescence (not shown).
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Figure 6. GFP positivity in shRNA lentivirus transduced breast cancer cells
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Figure 6. Verification of lentivirus transduction and expression by GFP fluorescent microscopy of
breast cancer cell lines prior to FACS segregation of positive cells. Cells were infected with
filtered supernatant from 293T helper (packaging) cells. Shown are representative phase contrast
and GFP fluorescent microscope images from SK-BR-3 (A), MDA-MB-435 (B), MDA-MB-231
(C), MDA-MB-468 (D), MCF-7 (E), and MCF-10a (F) breast cancer cells. These images were
obtained prior to sorting at 5 days post infection. GFP positivity confirmed by microcopy and
subsequently by FACS ranged from 85% to 98% indicating sufficient lentiviral titers in crude
supernatant to produce high infection efficiencies in all lines.
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Figure 7. shRNA knockdown lines: qPCR and Immunoblots
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Figure 7. Quantitative RT-PCR (above) and anti-MBD2 immunoblots (below, 25 ug total protein)
were used to confirm knockdown of MBD2 mRNA and protein. A pLV-THM Vector and
Scramble control virus were used as references for comparison of relative MBD2 levels. qRTPCR data is normalized to an internal control gene (Cyclophilin A) to account for differences in
total RNA levels between samples. Error bars represent the standard error of the ratio of the
mean calculated as described in qPCR methods from three qPCR replicates per sample. A
Coomasie stained gel is shown as a loading control for the immunoblots.
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Figure 8. Cell proliferation Assay Demonstrates Growth Arrest in MBD2
Knockdown Breast Cancer Lines

MTT Assay: Cell Proliferation
MDA231

MDA435

SKBR3

100%
75%
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0%
Vector Only

Scramble shRNA

MBD2 shRNA

Figure 8. Cell proliferation was measured by MTT assay for MDA-MB-231, MDA-MB-435, and
SK-BR-3 breast cancer cells. Each bar represents the mean and error bars are 95% CI for the
595 nm absorbance normalized to vector controls from 3 replicates at 72 hours following plating
of equal cell numbers in a 96 well dish. This assay was performed approximately 14 days
following lentivirus infection and subsequent FACS sorting. Three cell lines showing significant
growth inhibition are shown (left to right, MDA-MB-231, MDA-MB-435, and SK-B3-3). Little
difference was observed between vector only and scramble controls, however MBD2 knockdown
virus (Right) was significantly growth inhibited.
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Figure 9. Breast Cancer Cell Line Growth Curves
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Figure 9. Breast cancer cell line growth curve analysis. Cells were counted (Coulter counter)
every 24 hours for 5 days (beginning 14 days post virus infection and 7 days post FACS sorting.
The starting point of the 5 day growth assay is indicated here as time 0 hours). Each point
represents a mean count from three wells of a 24 well culture plate and error bars are the
corresponding 95% confidence intervals. Error bars are plotted for all time points, though small
variations are obscured at some data points. Top row, left to right: MDA-MB-231, MDA-MB435, and MDA-MB-468. Bottom Row, left to right: SK-BR-3 and MCF-7.
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MBD2 knockdown leads to increased tumor cell death but not sensitization to antineoplastic agents
A significant problem in the treatment of certain breast cancers is the lack of an
additive biological modifier; for example in advanced and triple negative tumors where
estrogen receptor or Her2/neu targeted therapies provide no benefit. Even when available
therapies initially provide benefit, the appearance of resistance following an initial period
of tumor regression is common. This is likely due to two factors: the presence of a small
subpopulation of resistant cells within a heterogeneous tumor which are enriched during
therapy and the dosing limitations imposed by generalized toxicity which thwart
complete eradication of the tumor. We were therefore interested in the response of our
MBD2 knockdown lines to chemotherapeutic agents. We hypothesized that, if we were
able to identify those compounds capable of acting synergistically with MBD2
knockdown, we would find substantially increased killing of the knockdown cells
compared to scramble controls using standard doses of these anti-tumor agents. We
chose several chemotherapeutic agents that are used as first line therapy in breast cancer
and several others which we thought might act in concert with MBD2 knockdown to
sensitize tumor cells.

Endocrine therapy (hormone therapy, e.g., Tamoxifen) and

biologic therapies (e.g., humanized anti-Her2, Herceptin) were not used for these studies
for reasons discussed later. The DNMT inhibitor 5-aza-2-deoxy cytidine (Decitabine)
was likewise not tested because we knew from our methylation studies (described later)
that knockdown cells were not significantly more sensitive to this compound. The drug
classes commonly used as first line chemotherapy include nitrogen mustard derivatives
(cyclophosphamide, Cytoxan), anthracyclines (Doxorubicin) and taxanes (Paclitaxel).
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We also tested the activity of two additional classes of therapy: the HDAC inhibitor,
Vorinostat, and a platinum compound, Cisplatin based on our suspicion and that of others
(Steele et al. 2009) that these compounds may be effective in combination with other
epigenetic strategies.

To isolate any altered sensitivity, we tested the compounds

individually rather than in combinations.

We found that the principal predictor of

survival of the breast cancer lines we examined was MBD2 knockdown alone, as shown
in Figure 10. All the compounds tested exhibited dose dependent toxicity in control and
MBD2 knockdown lines, albeit variable in magnitude. However, when normalized for
the effect of MBD2 knockdown, none of the drug/cell line combinations tested exhibited
significantly enhanced sensitivity to therapy. Nonetheless, the dose normalized death of
breast cancer cells was uniformly higher in MBD2 knockdown lines.

The percent

survival was determined by MTT assay at 96 hours following a single doses of 0.2, 1.0,
or 5.0 uM Vorinostat, Cytoxan, Doxorubicin, and Cisplatin and 0.01, 0.1, or 1.0 uM
Paclitaxel.

The mean and standard deviation of the percent survival from three

experimental samples was normalized to untreated scramble controls and is plotted
individually for each compound in Figures 11-15. Dose response curves were also
plotted for each compound (Figures 16 and 17) and a representative MTT assay plate is
shown (Figure 18).
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Figure 10. Cell lines used for drug assays and their baseline sensitivity to MBD2
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Figure 10. Relative proportion of metabolically active cells after 96 hours (assay time, 14 days
post virus infection and 7 days post FACS sorting) measured by MTT assay as described above.
These lines were infected with lentivirus (SC or KD) and cultured in parallel with the drug
treatment experimental samples, although the lines shown here were not treated with any
chemotherapeutic compound. The baseline sensitivity of these lines to MBD2 knockdown varied
from 63% residual viability for MCF-7 cells to 7% viability for MDA-MB-435 cells. Each well
of a 96 well culture plate was seeded with 1x104 cells at 0 hours. Vertical bars represent the mean
and standard error of the mean for three assay replicates per cell line normalized to Scramble
controls. This assay was repeated with on each 96 well assay plate (shown in subsequent figures)
with no significant variation in baseline sensitivity to MBD2 knockdwon.
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Figure 11. MBD2 Knockdown and Scramble Control Cell Percent Viability
Following Cytoxan Treatment
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Figure 11. Metabolically active cells following 96 hours of drug treatment measured by MTT
assay as described above. Breast cancer cell lines were transduced with Scramble or shMBD2
lentivirus, sorted by FACS, and duplicate 96 well plates were seeded with 1x10 4 cells (0 hours).
Cells were treated with 0.2uM, 1.0uM, or 5uM Cytoxan at 24 hours. Vertical bars represent the
mean and standard error for three replicates from a single assay plate. Samples were normalized
to untreated Scramble controls.
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Figure 12. MBD2 Knockdown and Scramble Control Cell Percent Viability
Following Doxorubicin Treatment
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Figure 12. Metabolically active cells following 96 hours of drug treatment measured by MTT
assay as described above. Breast cancer cell lines were transduced with Scramble or shMBD2
lentivirus, sorted by FACS, and duplicate 96 well plates were seeded with 1x104 cells (0 hours).
Cells were treated with 0.2uM, 1.0uM, or 5uM Doxorubicin at 24 hours. Vertical bars represent
the mean and standard error for three replicates from a single assay plate. Samples were
normalized to untreated Scramble controls.
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Figure 13. MBD2 Knockdown and Scramble Control Cell Percent Viability
Following Paclitaxel Treatment
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Figure 13. Metabolically active cells following 96 hours of drug treatment measured by MTT
assay as described above. Breast cancer cell lines were transduced with Scramble or shMBD2
lentivirus, sorted by FACS, and duplicate 96 well plates were seeded with 1x10 4 cells (0 hours).
Cells were treated with 0.01uM, 0.1uM, or 1.0uM Paclitaxel at 24 hours. Vertical bars represent
the mean and standard error for three replicates from a single assay plate. Samples were
normalized to untreated Scramble controls.
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Figure 14. MBD2 Knockdown and Scramble Control Cell Percent Viability
Following Vorinostat Treatment
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Figure 14. Metabolically active cells following 96 hours of drug treatment measured by MTT
assay as described above. Breast cancer cell lines were transduced with Scramble or shMBD2
lentivirus, sorted by FACS, and duplicate 96 well plates were seeded with 1x10 4 cells (0 hours).
Cells were treated with 0.2uM, 1.0uM, or 5uM Vorinostat at 24 hours. Vertical bars represent the
mean and standard error for three replicates from a single assay plate. Samples were normalized
to untreated Scramble controls.
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Figure 15. MBD2 Knockdown and Scramble Control Cell Percent Viability
Following Cisplatin Treatment
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Figure 15. Metabolically active cells following 96 hours of drug treatment measured by MTT
assay as described above. Breast cancer cell lines were transduced with Scramble or shMBD2
lentivirus, sorted by FACS, and duplicate 96 well plates were seeded with 1x10 4 cells (0 hours).
Cells were treated with 0.2uM, 1.0uM, or 5uM Cisplatin at 24 hours. Vertical bars represent the
mean and standard error for three replicates from a single assay plate. Samples were normalized
to untreated Scramble controls.
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Figure 16. Dose Response Curves for Paclitaxel, Cytoxan, and Doxorubicin

Figure 16. Chemotherapy sensitization data plotted as dose response curves. Drug dose (uM) is given on the x-axis and the y-axis represents
percent cell viability (note the y-axis is logarithmic). Scramble control and knockdown curves are plotted as separate lines (KD-dark gray, SClight gray).
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Figure 17. Dose Response Curves for Paclitaxel, Cytoxan, and Doxorubicin

Figure 17. Chemotherapy sensitization data plotted as dose response curves. Drug dose (uM) is
given on the x-axis and the y-axis represents percent cell viability (note the y-axis is logarithmic).
Scramble control and knockdown curves are plotted as separate lines (KD-dark gray, SC-light
gray).
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Figure 18. MTT Drug Sensitivity Assay (Vorinostat Plate)
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Figure 18. A representative image of the 96 well format MTT assay used for drug sensitivity
screening. V: Vector only, SC: Scramble, KD: MBD2 Knockdown. One blank well is present in
the top left well for each of the four cell lines; this blank was used to baseline the 96-well plate
reader. The doses (Vorinostat plate is shown) varied from untreated (No Tx) to 5uM as labeled
on the left.
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MBD2 knockdown inhibits xenograft tumor growth in BALB/c nu/nu mice.
We next explored whether MBD2 knockdown had any effect on the ability of
aggressive breast cancer lines to form tumors in animals. This experiment was a logical
progression from our observation that MBD2 knockdown significantly impaired the
growth of our breast cancer cell lines in culture. The rationale behind this progression is
the widely held idea that measuring the growth of human xenograft tumors in a mouse is
a more physiologically relevant system in for studying the in vivo biology of cancer
(Welch 1997). Using the same method, stable lentiviral transduction of MBD2 targeted
shRNA, we infected and FACS purified sufficient cells to establish xenograft tumors in
the subcutaneous space of immunocompromised mice (we determined empirically that
5x105 to 1x106 cells per injection were required as fewer cells were incapable
establishing tumors).

We hypothesized that MBD2 knockdown would diminish the

ability of breast cancer cells to grow in mice, paralleling the effect on their growth in
vitro.
We implanted the MBD2 knockdown and scrambled control transformed lines in
opposite flanks of 8 week old female BALB/c nu/nu nude mice as described above and
schematically below (Figure 19).

We assayed subsequent tumor growth using two

independent methods. We followed the mice daily until a palpable mass appeared at the
site of injection and then made regular caliper measurements of the mass, from which a
tumor volume was calculated. In addition to caliper measurements we took advantage of
the GFP positivity of our lentivirally transduced cells using in vivo bio-fluorescent
imaging to non-invasively follow tumor growth in live anesthetized mice. We found that
MBD2 knockdown lead to a substantial decrease in the ability of aggressively
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tumorigenic lines (MDA-MB-231 and MDA-MB-435) to form tumors in mice. Mean
GFP fluorescence and median tumor volume calculated from caliper measurements was
significantly greater in control lines compared to MBD2 knockdown tumors for all time
points following the initial appearance of a palpable tumor (Figures 20-24). Knockdown
tumors demonstrated steady, unrelenting growth and mice were eventually sacrificed due
to the large unilateral masses which resulted. Knockdown derived tumors, on the other
hand, were slow to grow. In the case of MDA-MB-435, the initial fluorescent density at
the site of implantation was cleared within 1 week (Figure 20). A single recurrent tumor
appeared late at the MDA-MB-435 knockdown injection site.

In order to verify

persistent knockdown, this tumor was resected and examined by qPCR and
immunohistochemistry. We found that MBD2 protein and mRNA remained at low levels
in this tumor (Figure 24).

Interestingly, the recurrent (resistant) tumor no longer

expressed the MBD2 dependent tumor suppressor gene, Maspin (discussed in greater
detail in Chapter II).

We conclude that MBD2 knockdown imposes a significant

impediment to tumor growth in nude mice, however, at least one mechanism of
escape/resistance exists which can lead to late recurrence of Knockdown tumors.
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Figure 19. GFP expressing tumor Xenografts
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Figure 19. Shown above is a schematic representation of xenograft experimental design. (Top)
The subcutaneous space of nude mice was injected with GFP expressing Scramble (SC) control
cells on the left and MBD2 Knockdown (KD) cells on the right dorsolateral aspects of the flanks.
FACS sorted cells were injected 14-16 days following lentivirus infection. Following injection,
residual cells in their respective microtubes were imaged with the fluorescent bioimager to insure
adequate signal and consistent fluorescence intensity between samples (bottom, left: B&W
photograph; bottom, right: overlayed GFP fluorescence.)
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Figure 20. In vivo biofluorescent imaging shows clearance of MBD2 knockdown xenograft tumors in nude mice.

Figure 20. In vivo biofluorescent images captured with the IVIS Xenogen 200 imager show initial bilateral fluorescence (mouse on the left) from
MDA-MB-435 Scramble (left flank) and Knockdown (right flank) tumor injections. Images 2-5 were taken at 5 day intervals following the
appearance of a palpable tumor in nude mice. This progression demonstrates clearance of the initial Knockdown tumor and unrelenting growth of
the Scramble control tumor. Mice were given a single challenge of 5x105 MDA-MB-435 cells.
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Figure 21. In vivo biofluorescent imaging of MDA-MB-231 tumors in nude mice.

Figure 21. In vivo biofluorescent images captured with the IVIS Xenogen 200 imager show large
fluorescent densities corresponding to growing GFP expressing tumors on the left flanks of three
nude mice (Scramble controls) and no or relatively small fluorescent signal on the right (MBD2
Knockdown). Images were taken 14 days after xenograft injection.
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Figure 22. In vivo biofluorescent imaging of MDA-MB-435 tumors in nude mice.

Figure 22. In vivo biofluorescent images captured with the IVIS Xenogen 200 imager show large
fluorescent densities corresponding to growing GFP expressing tumors on the left flanks of three
nude mice (Scramble controls) and no fluorescent signal on the right (MBD2 Knockdown).
Images were taken 14 days after xenograft injection.
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Figure 23. In vivo growth of MDA-MB-231 and MDA-MB-435 xenograft tumors in
nude mice.
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Figure 23. Caliper measurements were made of palpable tumors and used to calculate the mean
and standard error (SEM) of tumor area (determined by multiplying length x width with length
held constant as the longest tumor diameter and the corresponding orthogonal axis as width) of
Scramble and Knockdown tumors from 3 nude mice per cell line. Measurements were taken at
approximately 5 day intervals.
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Figure 24. Recurrence of an MBD2 negative Maspin Positive Tumor in a Nude
Mouse
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Figure 24. A single large and aggressive tumor developed in an MDA-MB-435 MBD2
knockdown injected mouse (above). We examined this tumor by immunohistochemistry and
found MBD2 expression was still low (anti-MBD2 IHC and H&E stained sections of resected
tumor). Upon further examination, we determined this tumor expressed very low levels of the
MBD2 knockdown induced gene, Maspin (qRT-PCR graph, below). Note MBD2 and Maspin
expression is plotted on separate Y-axes. We took this to mean there was a compensatory
mechanism capable of resilencing MBD2 induced genes and providing an escape mechanism
from MBD2 knockdown mediated growth suppression.
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MBD2 knockdown restores normal epithelial morphology in 3D culture
We noticed that MBD2 knockdown cells exhibited distinctive characteristics upon
microscopic examination of cultured cells. Knockdown (KD) cells were less fusiform in
shape compared to untreated and scramble control transfected cells. In addition, the
knockdowns grew more diffusely on tissue culture treated plastic, without forming the
tight overlapping colonies observed in controls (Figure 25). Though the effect was
variable between cell lines, in general the dense „cobble stone‟ morphology of control
cells was replaced by a more diffuse, „fried egg‟ appearance, which more closely
resembled the relatively normal morphology of the immortalized non-transformed MCF10a line (Soule et al. 1990) (shown for comparison, bottom panel, Figure 25).
We hypothesized that MBD2 may be required for tumor related epithelial dedifferentiation and to test this we examined the knockdown cell growth in 3 dimensional
laminin-rich extracellular matrix extracts. In these basement membrane-like extracts
normal epithelial cells and differentiated (low grade) epithelial populations form
structures which recapitulate in situ morphology (i.e., acini, ducts, terminal lobules etc.)
while poorly differentiated (high grade) populations do not (Xiang and Muthuswamy
2006). We found that knocking down MBD2 was sufficient to induce an increase in the
number of differentiated epithelial structures formed in 3D cultures.

Stable MBD2

knockdown MCF-7 cells formed normal epithelial structures 70% of the time, [CI=0.550.83], while untransfected and scrambled shRNA transfected controls formed these
structures with reduced frequency, 46% (CI=0.39-0.53, p≤0.038) and 37% (CI=0.290.45, p≤0.012) respectively (Figures 26 and 27). Furthermore, MBD2 knockdown cells
were able to form higher order structures in 3D lrECM cultures which grossly
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recapitulated in situ epithelial multicellular morphology, e.g., ducts and terminal lobules
(Figure 28).
These observations suggested to us that the overall effect MBD2 had on epithelial
tumor cell differentiation was to promote and maintain a state of de-differentiation to a
precursor state or trans-differentiation to a more mesenchymal-like population. The
former is associated with a subpopulation of stem like cells thought to contribute to tumor
formation, adaptation, and resistance (Visvader 2009). The latter trans-differentiation
(epithelial to mesenchymal transition or EMT) has been associated with the acquisition of
invasive characteristics which are the hallmark of pathological progression in
carcinomas, i.e., invasion and metastasis (Thiery et al. 2009).
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Figure 25. 2D Morphology of MBD2 knockdown cells
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Figure 25. MBD2 knockdown cells change their morphology in culture. Knockdowns (KD) cells
are less fusiform in shape and colonies grow more diffusely on the plate. The effect is variable
between cell lines but in general the dense „cobble stone‟ morphology is replaced by a more
diffuse, „fried egg‟ appearance, which more closely resembles the relatively normal morphology
of the MCF-10a line (shown for comparison, bottom). All images were captured at the same
magnification using a 40X phase contrast objective.
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Figure 26. 3D lrECM Culture
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Figure 26. MCF-7, MCF-7 Scramble, MCF7 Knockdown and SK-BR-3 cells grown in 3D lrECM
for 10 days. Representative images taken of control and MCF-7 Knockdown cells show
knockdowns form significantly more organized „mammospheres‟ (acini) than controls or than the
disorganized SK-BR-3 cells. All cells were stained with 1X Hoechst in PBS for 10 minutes and
imaged with a 40X objective, DAPI filter. Fluorescent nuclear staining allows visualization of
individual cells within 3D colonies; these cells are difficult to distinguish by light microscopy.
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MBD2 K/D Cells form differentiated structures
Figure 27. Mammosphere Formation Assay
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Figure 27. MCF-7 shMBD2 knockdown cells form significantly more organized mammosphere
structures in 3D lrECM cultures when compared to MCF-7 and MCF-7 Scramble control lines.
Cells stained with 1X Hoechst in PBS, 40X objective, DAPI filter. Mammospheres were only
counted if they contained greater than 15 cells and organized and disorganized colonies were
manually distinguished based on spherical morphology and evidence of polarization such as a
clearly defined lumen. Counts are charted in the lower right hand panel. Total counts for each
category are indicated below vertical bars and p values (*) were derived by students T-test. (n =
organized + disorganized colonies). In contrast to control cells (MCF-7 and MCF-7 SC),
knockdowns (KD) formed a significantly increased proportion of organized structures.
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Figure 28. MBD2 knockdown promotes higher order structure formation
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Figure 28. MCF-7 shMBD2 cells form organized structures that recapitulate in situ epithelial
morphology, e.g., ducts and terminal lobules. Higher order structures were imaged between day
15 and 20 in lrECM culture as described in methods and in the legend for Figure 26.
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Discussion
MBD2 is required for the rapid growth of breast cancer cells.
Normal mammalian epithelial cells do not require MBD2 for survival. In order to
live through malignant transformation, tumor cells must inactivate the sentinel genes
which protect against cancer by promoting death and clearance of neoplastic cells.
Because many of these sentinel genes are silenced by abnormal DNA methylation, we
asked whether breast cancer cells develop a dependence on MBD2. If this was the case,
then we would expect a survival penalty to be paid if MBD2 protein was removed. As
summarized below, we observed precisely such a penalty in human breast cancer cell
lines in which double stranded RNA interference was used to reduce MBD2 protein
levels. We took this observation as a confirmation of our hypothesis: human breast
cancer cells become dependent on the Methyl DNA Binding Domain Protein 2 for
growth, albeit to variable degrees in different lines. In the process, we made some
interesting and unexpected observations regarding the specifics of the role of MBD2 in
promoting growth; these are discussed further below.
We found that MBD2 knockdown by stably integrated, lentivirally delivered shRNA
led to nearly complete growth inhibition in certain human breast cancer cell lines (MDAMB-435, MDA-MB-468, and SK-BR-3) and significant but somewhat less growth
inhibition in several others (MCF-7 and MDA-MB-231), Figures 8 and 9. Several factors
presumably underlie the variable response to MBD2 knockdown. First, as discussed
briefly above, the pattern of abnormal methylation is highly inconsistent between tumors
and between divergent populations within a single tumor. As such, a variable response to
a strategy that targets abnormally methylated and silenced genes is not all that
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unexpected. Second there is the inherent inconsistency in our experimental knockdown
approach. It is clear from our studies that a high degree of knockdown, approximately
80% reduction of mRNA or greater, is necessary to produce a phenotype. This degree of
change in message, in our experience, corresponds to an even greater (90% or higher)
reduction in MBD2 protein as measured by immunoblot, Figure 7. We make several
inferences here. First, some amplification occurs from transcription to translation of
MBD2; this is an indirect sign that regulation of MBD2 occurs largely at the
transcriptional level. In addition, MBD2 protein is present in sufficient excess in breast
cancer cells that a considerable reduction is necessary to reach the functional threshold
required for growth inhibition. The implication here is that any pharmacologic inhibition
of MBD2 will need to be potent enough to achieve similar reduction in MBD2 function
to induce growth inhibition.
Our observations are largely consistent with the two inferences made above, i.e.,
variability in response is due to variable methylation and that significant knockdown is
required to produce a phenotype. MCF-7 cells are somewhat less aggressive and slower
growing than MDA-MB-435 cells to begin with. Their blunted response to MBD2
inhibition can be taken to mean that the degree and character of abnormal methylation in
MCF-7 cells is less developed than that in MDA-MB-435 cells. Furthermore, we found
efficient MBD2 knockdown was difficult to achieve in MDA-MB-231 cells compared to,
for example MDA-MB-435 and SK-BR-3, as illustrated in Figure 7. The relatively high
proliferative rate observed for MDA-MB-231 (Figure 8 and 9) may in fact be due to
residual MBD2 rather than inherent insensitivity to MBD2 knockdown.
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The timing of MBD2 knockdown is important
An important difference between our methodology and previous reports of MBD2
knockdown in tumor cells was the use of a lentiviral shRNA system. This method
allowed us to avoid what we believe were the twin pitfalls of previous studies: short lived
transient knockdowns and long selection times for stable transformants.

Transient

knockdowns do not persist for the two to three weeks we found to be required for growth
inhibition to fully manifest.

Conversely, the long periods (3-6 weeks) required for

antibiotic selection and regrowth of stable clones by the standard method allow for
copurification of cells that have developed resistance to MBD2 imposed growth
inhibition. Lentivirus transduction and FACS purification circumvent these pitfalls and
provide the best approach we have found for observing the delayed growth inhibition
imposed by MBD2 knockdown.
The temporal relationship between MBD2 knockdown and growth inhibition was
itself quite surprising. Following lentivirus infection on day 1, cells were passaged and
recovered for 5-7 days in culture. Next, GFP expression was confirmed by fluorescent
microscopy before the cells were sorted by FACS. The purified knockdown cells were
divided for qPCR, western blot, and growth analysis after sorting. The cells were grown
for another week to expand the sorted populations. They were subsequently harvested for
qPCR and western blot analysis or counted and replated for growth analysis in 96 well
plates (MTT assay, drug sensitivity) or 24 well plates (growth curves). Therefore, the
temporal window used for in vitro growth analysis occurred somewhere between 14 and
20 days post transduction. It appears somewhat serendipitous that the processing delay
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which preceded the analysis window allowed the growth inhibitory effects of MBD2
knockdown to fully develop.
The reason for the delay in growth suppression is not clear. We know from transient
MBD2 knockdown studies conducted in our lab that 3-4 days is sufficient time for MBD2
mRNA and protein levels to be significantly reduced (see Chapter III for details). We
also know that 3-4 days following MBD2 knockdown is sufficient time for secondary,
MBD2 induced, expression changes.

For example, increased expression of gamma

globin in erythroid populations is observed at 72 and 96 hours after knockdown. It is
possible that tumor suppressor expression is being induced with similar timing in our
breast cancer cell lines although the maximal effect on growth takes longer to evolve.
On the other hand, it is possible that stable re-expression of MBD2 regulated tumor
suppressor proteins in breast cancer takes longer; complete target gene derepression may
take several weeks, corresponding to 10-20 cell divisions. Moreover, an extended period
may be required for passive epigenetic reprogramming following MBD2 knockdown, not
unlike the time required for induced pluripotent stem (iPS) cell reprogramming. A time
course of exogenous inducible factor expression in the generation of iPS cells showed
that at least two weeks of expression were required before pluripotent iPS cells were
formed.

Moreover, iPS formation was enhanced by longer periods of expression

(Brambrink et al. 2008).
Our analysis of gene expression changes in MBD2 knockdown breast cancer cells is
reported in the following chapter; however, the analyses described in Chapter II were
conducted at timepoints corresponding to peak growth suppression. Therefore, a time
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course study to fully interrogate the temporal relationship between MBD2, target gene
induction, and resulting phenotype remains to be performed.

Combining MBD2 inhibition with chemotherapy
An important goal of our study from the outset was to determine whether MBD2
knockdown would sensitize breast cancer cells to chemotherapy. In many ways, this was
our most promising hypothesis; it seemed plausible that MBD2 would restore expression
of tumor suppressors (DNA damage response genes, for example) that would sensitize to
compounds targeting the corresponding pathways (e.g., DNA damaging agents like
anthracyclines, cyclophosphamide, platinum compounds, etc.)

Surprisingly, MBD2

knockdown had a greater direct effect on growth than as sensitizing agent for any of the
compounds we tested.
Using stable MBD2 knockdown and control lines, we tested the dose dependent
toxicity of several compounds, corresponding to classes of chemotherapy commonly used
as first line treatment in breast cancer: a nitrogen mustard derivative (cyclophosphamide,
Cytoxan), an anthracycline (Doxorubicin), and a taxane compound (Paclitaxel). We also
tested the activity of two additional classes of therapy: the HDAC inhibitor, Vorinostat,
and a platinum compound, Cisplatin. Several endocrine and biologic therapies are now
used commonly in breast cancer. These include Selective Estrogen Receptor Modulators
(SERMs), aromatase inhibitors, and monoclonal antibodies against Her2/neu. These
were not used in for these studies because either their clinical utility depends on
preclassification of tumors and/or their mechanism of action was not amenable to an in
vitro study (i.e., aromatase inhibitors function at sites away from the tumor and Herceptin
depends largely on the immune system and type 2 antibody dependent cell mediated
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cytotoxicity, ADCC). However, in the case of SERMs, for example Tamoxifen, there
may be some combined effect of estrogen receptor inhibition and an anti-MBD2 strategy;
this compound merits testing in future studies.
We found that the effect of MBD2 knockdown was observed in treated and untreated
populations. However, at the doses we tested, there was no conclusive evidence of any
synergistic (supra-additive) effect of MBD2 knockdown plus another compound.
Alternatives to synergy include additive effects, non-additive (mutually exclusive) effects
and protective or negative effects (i.e., where two compounds used together are less
effective than either alone).

We found there was an additive effect which was

particularly evident at low doses of Paclitaxel, Doxorubicin, and SAHA (Figures 16 and
17). This was important to establish because we hypothesize that the consequence of
MBD2 inhibition will remain largely restricted to tumor cells. In other words, a specific
inhibitor of MBD2 will likely be very well tolerated and therefore can have significant
clinical utility in lowering effective doses of more toxic therapies when used in
combinations.
Two important points need to be made here. First, any successful combined therapy
strategy depends of course on choosing the right combination. We have tested only a
small subset of available therapies and have therefore covered only a small fraction of the
potentially synergistic compounds that might act through pathways crippled by epigenetic
dysregulation in breast cancer. Second, the doses we tested corresponded to therapeutic
levels often used in the clinical setting. These doses led to significant toxicity in our in
vitro studies. It would be informative to repeat the treatments, doxorubicin and paclitaxel
in particular, at lower doses to determine if any synergy is unmasked at lower ranges.
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Functional inhibition of MBD2 significantly impairs the growth of tumors in mice.
Immunocompromised mice provide a useful experimental model for studying the
biology of human tumors in an environment that more closely resembles their in situ
physiology. These mice offer the ability to explore tumor-host interactions including
endocrine/paracrine regulation, innate immune response, and direct tumor-stromal
interactions. In contrast to in vitro growth, a xenograft tumor must be able to extract
nutrients from its interstitial environment, recruit a blood supply as it grows, and evade
clearance by any residual elements of the mammalian innate and adaptive immune
system. The athymic nude mice we used have a leaky immunocompromised phenotype
(as opposed to SCID mice which completely lack B and T cell function). Therefore,
these mice retain the ability to clear certain tumors and are a slightly more stringent
xenograft model than fully immunodeficient animals. From a practical standpoint, this
affected our study in several ways.

First, we were unsuccessful in grafting less

aggressive tumor cell lines in these mice (MCF-7, MDA-MB-468, and SK-BR-3), despite
repeated attempts with large starting cell numbers. Even highly tumorigenic lines, MDAMB-231 and MDA-MB-435, required relatively high starting tumor cell numbers to
establish successful xenografts.

However, once successfully established, Scramble

control tumors rapidly outgrew their Knockdown counterparts in our studies (Figures 2023). The effect of MBD2 knockdown on in vivo tumor growth was somewhat more
dramatic than the one observed for tumor growth in vitro. MDA-MB-435 knockdown
cells were completely cleared in 5 out of 6 mice and though MDA-MB-231 knockdown
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cells were able to grow, they formed significantly smaller and slower growing tumors
than control cells (Figures 21 and 22).
Out of 6 mice implanted with MBD2 knockdown MDA-MB-435 cells, a single
exceptional tumor was able to escape the MBD2 knockdown imposed growth inhibition
in our xenograft study. We resected this tumor and examined the expression of MBD2
protein (Figure 24). MBD2 was still significantly suppressed in this rapidly growing and
invasive mass. We further examined the expression of Maspin, an MBD2 induced gene
and found it to be resuppressed to pre-MBD2 knockdown levels. This observation
suggests that at least one mechanism for evading MBD2 knockdown imposed growth
inhibition in vivo exists. As this tumor developed after 40 days, and given a doubling
time of 24 hours for this cell line, it is possible that it arose from a single clone within the
original population (240 = 1.1x1012). Further studies are necessary to determine the
precise mechanism of resistance in this clonally derived population. Based on the
assumption of clonal origin, we concluded that this mechanism of phenotypic conversion
was highly improbable for any given MBD2 knockdown cell. A further discussion of
resistance mechanisms can be found in the summary section of Chapter IV.
Our in vivo studies illustrate an important point: a cytostatic effect can be a highly
effective anti-tumor strategy. By significantly impairing the growth of breast cancer
cells, even without outright killing, the balance between growth and clearance was tipped
towards clearance.
Several other mechanisms of in vivo growth inhibition may be at work as well. By
restoring the expression of epigenetically silenced genes, it is quite possible that we have
blunted the ability of MBD2 knockdown cells to perform any of a number of acquired
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functions necessary for in vivo growth. Among these functions is the ability to survive
and proliferate in a relatively oxygen poor environment, in stark contrast to their
environment in a culture vessel.

In other words, MBD2 knockdown cells may be

sensitized to hypoxia induced cell death, a feature of normal epithelial cells which are
heavily dependent on oxidative metabolism. Tumor cells circumvent this obstacle in
several ways, including the upregulation of the anaerobic metabolic machinery and the
expression of angiogenic factors that aggressively recruit a de novo blood supply.
Furthermore, it is known that the expression of carcinoembryonic antigens is a red
flag for the immune system during cancer surveillance. These antigenic factors are
inappropriately expressed by neoplastic cells and subsequently detected by the innate and
adaptive immune system. Not surprisingly, these antigens are often silenced in tumors
which must evade the immune system to survive. It is conceivable that these silenced
auto-antigens are reactivated by MBD2 knockdown in breast cancer cells, particularly
given the likelihood that such antigenic elements are hypermethylated during tumor onset
and/or progression. It is also possible that they are being recognized by conserved and
intact elements of the nude mouse‟s innate immune system (e.g., macrophages in the
subcutaneous space or circulating NK cells). In order to fully evaluate the mechanism of
clearance of MBD2 knockdown derived tumors, further studies are needed.

Epithelial morphology is restored in MBD2 knockdown MCF-7 cells
A common distinguishing feature of cancer cells in contrast to their normal
counterparts is a variable degree of dedifferentiation. In fact, certain high grade tumors
bear little morphologic resemblance to their tissue of origin; in fact molecular markers
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are required to identify and classify these tumors for the purposes of treatment.
Importantly, high grade (poorly differentiated) tumors are correlated strongly with poor
prognoses.
One of the first significant observations made during the course of the studies
described in this dissertation was that MBD2 knockdown cells developed a strikingly
different cellular morphology and pattern of growth. Upon microscopic examination it
became clear that stable populations of MBD2 knockdown cells were less fusiform in
shape compared to untreated and scramble control transfected cells. In addition, the
pattern of growth of knockdown cells was more dispersed. Instead of forming the
overlapping colonies observed in controls (Figure 25), MBD2 knockdown cells seem to
form a more uniform monolayer that is evenly distributed in the culture vessels. In
addition, the dense „cobble stone‟ morphology of control cells became a more diffuse,
„fried egg‟ shape, with a decreased relative profile of nucleus to cytoplasm. MBD2
knockdown morphology more closely resembled the relatively normal morphology of the
immortalized non-transformed MCF-10a cell line (Figure 25).
In order to better study the morphological differences between knockdown and
control cells, we cultured these populations in collagen and laminin based extracellular
matrix extracts which allowed the formation of three dimensional structures capable of
recapitulating in situ morphology. We observed a significant difference in the formation
of structures resembling epithelial rests, acini, terminal lobules and ducts in MBD2
knockdown MCF-7 cells compared to scramble control and untransfected cells (Figures
26-28).

Similar observations were not made in other cell lines, which remained

disorganized in 3D cultures, in contrast to their morphology differences in standard 2D
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plastic culture plates.

MCF-7 cells were unique in that they formed acini

(mammospheres) at a lower frequency even in control populations (~40%). However, the
percentage of mammospheres compared to disorganized multicellular colonies was
significantly enhanced in highly knocked down MBD2 clones (~70%).
We are able to garner from these observations that MBD2 is not the only factor
involved in maintaining the epithelial disorganization in breast cancer cells, but that it is
playing an exacerbating role in the disorganized growth of certain populations. The
utility of this observation in isolation is limited; however, taken together with growth
inhibition and a decrease in the in vivo turmorigenic potential, it suggests that MBD2
plays a pleotropic role in the pathologic dedifferentiation of breast cancer.
In addition, the changes in morphology apparently maintained by MBD2 in breast
cancer cells are reminiscent of a phenomenon termed the epithelial to mesenchymal
transition (EMT). In pathological EMT, epithelial cells transdifferentiate to resemble
fusiform mesenchymal cells which acquire the ability to migrate, invade locally, and
metastasize to distant sites (Thiery et al. 2009). Since only a subset of cells within a
heterogeneous tumor are capable of this transition (a population thought to have stem cell
like characteristics) it is noteworthy that our observation is not an all-or-nothing effect
but rather a shift in the probability of organized growth. Similarly it is not altogether
surprising that only one of the cell lines we examined was capable of producing a change
of the magnitude necessary for detection in a our mammosphere formation assay, which
offers rather limited sensitivity and is suitable for distinguishing relatively dramatic
differences only.
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In summary, more sensitive assays to characterize the differentiation state of these
cells are required to provide a less ambiguous picture of the mechanism(s) underlying the
changes described in this Chapter. We have undertaken several studies with the express
purpose of shedding light on MBD2 dependent changes in breast cancer. In the Chapters
that follow, we attempt to characterize the gene expression differences, CpG methylation
status, and compensatory adaptations that underlie the phenotypes described above and,
more generally, the mechanistic basis for the pathologic role of MBD2 in breast cancer.
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Chapter II: MBD2 is required for transcriptional inhibition of a subset of
methylated tumor suppressor genes in breast cancer

Introduction:
DNA Methylation, CpG Islands and Transcription
Most mammalian genomes have high levels of DNA methylation and are depleted of
CpGs due to the frequent deamination of methyl-cytosine to thymidine. Deamination
results in methylCpG:TpG mismatches which are later repaired during DNA replication
causing the genome to have more A/T than G/C content. The remaining CpGs are
unevenly distributed throughout the genome. Approximately 60% gene promoters in
mammals are imbedded in unmethylated stretches of DNA with high CpG density,
known as CpG islands (Klose and Bird 2006). It is not clear how the CpG islands are
maintained in an unmethylated state and what protects them from the action of DNA
methyltransferases. It is clear that these sequences are not intrinsically immune to
methylation since some of them acquire DNA methylation during normal development
(Suzuki and Bird 2008) or are found to be aberrantly methylated in cancers (Jones and
Baylin 2007). Given that most of the gene promoters are methylation-free, the question of
whether DNA methylation is essential for regulation of gene expression on a global scale
has been a subject of debate. One model of how DNA methylation exerts its repressive
effect on transcription involves CpG methylation which alters binding sites of
transcription factors and directly interferes with gene activation (Clouaire and Stancheva
2008). In the second and significantly more frequently cited model, methylated cytosines
are thought to serve as docking sites for proteins that specifically recognize and bind to
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methylated CpGs and repress transcription indirectly via recruitment of corepressors that
modify chromatin.
It is widely accepted that aberrant methylation is involved in cancer development
(Jones and Baylin 2007). In particular, the importance of promoter cytosine methylation
in tumor suppressor gene silencing has been established repeatedly and is discussed
throughout the present work. In general, it is thought that methylated CpG islands in
tumors are not a permissive setting for the initiation of transcription unless the
methylation signal can be overridden by alterations in factors that modulate chromatin, a
notable example being the removal of methylated cytosine binding proteins (Pulukuri and
Rao 2006; Bakker, Lin, and Nelson 2002; Martin et al. 2008). The study of CpG island
promoter methylation has been a driving force in DNA methylation research, particularly
as it relates to cancer. Presumably, the reason for this focus on CpG islands has been the
demonstrable ability of CpG-island associated hyper-methylation to permanently silence
genes both physiologically during mammalian development and pathologically in cancer
cells (Jones and Baylin 2007; Suzuki and Bird 2008; Gronbaek, Hother, and Jones 2007).
This exists in stark contrast to the role of methylation at non-CpG island promoters,
which have been largely overlooked because the correlation between methylation and
transcription is far weaker (Jones and Takai 2001; Takai and Jones 2002).
Because approximately 40% of human genes are non CpG island genes, methylation
dependent regulation at these loci cannot be ignored. Recent work has shown strong
correlations between tissue-specific expression and methylation of non-CpG island
associatied genes, for example Maspin (Futscher et al. 2002b). Maspin has a CpG rich
promoter that does not meet established criteria for a CpG island. The MAGE gene
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family is another example of genes that are commonly upregulated by epigenetic therapy
even though their promoters do not fall within canonical CpG islands (Wischnewski et al.
2007). At least one report suggests non-CpG island containing genes are not responsive
to 5-aza-dC and that observed transcriptional reactivation at these sites might be
occurring through indirect mechanisms (Wozniak et al. 2007). The work in this chapter
and the next deals to some extent with the role of MBD2 in the transcriptional silencing
of Maspin, and the nature of MBD2‟s effects on CpG sparse genes.

Epigenetic dysregulation of transcription in cancer
Mammalian DNA methylation has been implicated in a diverse range of cellular
functions and pathologies, including tissue-specific gene expression, cell differentiation,
genomic imprinting, X chromosome inactivation, regulation of chromatin structure,
carcinogenesis, and aging (Bird 2002b). DNA methylation is essential for normal
development and remains indispensable for the survival of differentiated cells (Okano et
al. 1999; Jackson-Grusby et al. 2001). Mechanistically, a methylated cytosine base can
function to promote or preclude recruitment of regulatory proteins. The methyl mark is
read through the MBD family of methyl-CpG binding proteins including MBD2 which
are thought to mediate transcriptional repression through interactions with histone
modifying complexes (Klose and Bird 2006; Hendrich and Bird 1998b). Alternatively,
the methyl mark can exclude DNA binding proteins from their target sites, as has been
shown for CTCF binding at the H19 locus (Hark et al. 2000). An important property of
DNA methylation is that the patterns are dynamic and change throughout stages of
development and disease. Importantly, the DNA methylome undergoes characteristic
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changes during the pathogenesis of cancer. These include a genome wide loss of
methylation which occurs concurrently with an aberrant local gain of methylation marks
at certain loci. In particular, tumor suppressor gene promoters are targets of
hypermethylation, which typically results in their transcriptional silencing (Jones and
Baylin 2007; Jones and Baylin 2002). Moreover, recent models suggests that cancer may
evolve from a population of nonneoplastic, polyclonal, epigenetically disrupted
stem/progenitor cells, potentially with additional genetic lesions (Feinberg, Ohlsson, and
Henikoff 2006).

Contrasting the pathologic role of DNA methylation and histone modifications
While the present work deals primarily with DNA methylation and the related
function of MBD2, it is useful to remember that these factors exist in equilibrium with
local chromatin states. Histone modifications have been implicated in a number of
cancer related epigenetic phenomena. The use of the term „„heritable‟‟ is often dropped
from discussions of the epigenetic nature of histone modifications; in this context
„epigenetic‟ has taken to mean information carried by the genome (e.g., on chromatin)
that is not coded by DNA. Despite this loosening of definitions, histone modification
must be distinguished from DNA methylation which provides non-genetic memory of
function that is reliably transmitted from generation to generation (consider imprinting, X
chromosome inactivation, heterochromatin organization, and gene silencing). In addition
there are environmentally induced changes, which are passed on from generation to
generation, without the need for the original stimulus (best studied in plants)
(Martienssen et al. 2008). However studies suggest genomic methylation is the basis for
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transgenerational epigenetic stability in plants (Mathieu et al. 2007).

There is no

disputing that histone modifications are involved in epigenetic processes. If epigenetic
memory is mediated by one or more of the histone modifications, then there should be a
mechanism for the transmission of such modifications onto the chromatin of the
replicating DNA. Such a mechanism has been proposed for H3K9 methylation in the
transmission of heterochromatin (Hublitz, Albert, and Peters 2009). It is thought that
lysine methylation of nucleosomes on the daughter strand occurs through a mechanism
involving recruitment of HP1 and secondary targeted H3K9-methylation. This process
ensures the transmission of the H3K9 methylation mark. This mechanism of
transmission, along with the observation that patterns persist, have given histone lysine
methylation an epigenetic status. The issue that remains, however, is whether the
modification pattern inherited by the daughter chromatin is sufficient to impose the
correct chromatin structure originating from the mother cell. In other words, a question
remains as to whether lysine methylation is dictating memory of chromatin structure. In
contrast, the epigenetic function of CpG methylation in this regard is more firmly
established (Suzuki and Bird 2008).
The position-effect variegation exhibited during gene expression in Drosophila
demonstrates a key property of epigenetic silencing; its ability to spread over genomic
regions in a progressive way. In Drosophila, it seems to involve the cooperation of
multiple processes, including noncoding RNAs, covalent modifications of chromatin,
physical alterations in nucleosomal positioning, and DNA methylation. The high degree
of mitotic stability of DNA dependent gene silencing coupled with the progressive nature
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by which it is achieved makes pathological silencing of growth controlling and other
genes an important factor in the development of cancer (Jones and Baylin 2007).

The central role of MBDs in epigenetic dysregulation
While the importance of DNA methylation in cancer has been well established, the
focus in the field continues to shift towards related mechanisms such as chromatin
modifications, which can also play a role in cancer development. It is widely
acknowledged that covalent modifications of histones can control gene activity. Histone
deacetylation and methylation of specific lysine residues such as lysine 9 in histone H3 or
lysine 27 in histone H3 clearly participate in transcriptional silencing (Jenuwein 2006).
However, as discussed above, the primacy of these marks is a matter of controversy. A
key link between these covalent histone modifications and the stable epigenetic mark,
DNA methylation, was established by pioneering experiments that showed that cytosine
methylation could attract methyl DNA binding proteins (Nan et al. 1998a; Denslow and
Wade 2007; Feng and Zhang 2001a; Fujita et al. 2003; Sarraf and Stancheva 2004). In a
related example, a recent study showed that Brahma (Brm), which is a catalytic
component of the SWI/SNF chromatin-remodeling complex, was recruited by the
methylated DNA binding protein MeCP2 (Harikrishnan et al. 2005). Such experiments
provide the most plausible mechanism for long term stability and transmission of histone
modifications and architecture, specifically by exploiting the stability of CpG
methylation. In addition they highlight the central role of MBDs in tying together the
principal modalities associated with epigenetic effects on transcription.
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As discussed in Chapter I, significant crosstalk is likely to exist between different
epigenetic modalities. Heritable gene silencing involves, among other processes, the
interplay between DNA methylation, histone covalent modifications, and nucleosomal
remodeling. Some of the enzymes that contribute to these modifications include DNA
methyltransferase (DNMTs), histone deacetylases (HDACs), histone methyltransferases
(HMTs), and complex nucleosomal remodeling factors (NURFs). While DNA
methylation remains the most stable long term modification, it is clear that once
established histone modifications and chromatin architecture are capable of recapitulating
one another through the activity of multiple biochemical mediators within the nucleus.
A review of transcriptional dysregulation in cancer suggests that those factors which
bind the epigenetic machinery into macromolecular repressive machines thereby
maintaining persistent silencing of tumor suppressor genes at multiple levels were critical
targets. We reasoned that one such target was MBD2, which (as discussed in Chapter I)
links the two best characterized processes involved in stable long term transcriptional
inactivity, namely CpG methylation and chromatin modifications.

In the previous

chapter we found that MBD2 knockdown cells were significantly altered from their
control counterparts, consistent with our hypothesis that MBD2 was an important target
in breast cancer. Here we sought to better define the specific influence of MBD2 on the
maintenance of epigenetic dysregulation in tumors and thereby gain insight into the
transcriptional basis for MBD2 dependent phenotypes in breast cancer cells.
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Materials and Methods:

Design and cloning of shRNA vectors
We used the pSuperior Vector system (OligoEngine, Seattle, WA) for stable delivery
of short harpin RNA (shRNA). This system allows rapid selection of a stable population
by G418 resistance. This system also incorporates an inducible H1 promoter, which we
thought may provide future utility for applications requiring tight regulation of shRNA
expression:
Inducible H1 promoter (from 35nt upstream of BglII / HindIII cloning site
AGATCTaagctt):
5‟…GAATCTTATAAGTTCCCTATCAGTGATAGAGATCTaagctt…3‟
We designed and ordered sense and anti-sense oligonucleotides that included the
following features: terminal BglII and HindIII overhang complementary sites, a region
corresponding to a 19bp target sequence in the gene being silenced, in this case MBD2,
and a non-complementary loop region. The mechanism of RNAi involves loading the
antisense strand of the siRNA duplex into a silencing protein complex which targets the
corresponding messenger RNA molecule for cleavage. Using universal RNA design
features, Shou Zhen Wang in our lab generated two targeted sequences and a nontargeting scrambled sequence to be used as a negative control. This control is necessary
to account for any confounding effects of a non-sequence dependent response to double
stranded RNA, for example a type one (alpha/beta) interferon response. It is worthwhile
to note that the scramble control doesn‟t account for sequence specific induction of the
interferon response. Four oligonucleotides were ordered for each target to reduce the cost
of synthesis (sequences are given in Table 1). These oligonucleotides were annealed by
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slow cooling from 95 deg C, and ends were phosphorylated to increase the efficiency of
ligation into the vector with T4 polynucleotide kinase (NEB, Ipswich, MA) at 37 deg C
for one hour. The pSuperior vector was cut with the appropriate restriction enzymes and
a 12kb band was resolved and cut from a 1% agarose gel and purified using a Qia-quick
Gel purification kit (Qiagen, Valencia, CA). The annealed and phosphorylated oligos
were cloned between the unique BglII and HindIII or between the HindIII and XhoI sites
and ligated overnight at 16 deg C in the presence of T4 DNA ligase (NEB). This
positions the forward oligo at the correct position downstream from the H1 promoter‟s
TATA box to generate the desired siRNA duplex. 4ul of the ligation was transformed by
heat shock at 42 deg C for 20 sec into DH5-alpha chemically competent cells (Invitrogen,
Carlsbad, CA) and positive clones were selected on ampicillin containing LB agar plates.
Individual colonies were selected and grown overnight at 37 deg C with agitation in
LB/amp media.

Plamids were purified from the overnight cultures using column

purification kits (Qiagen) and were subsequently validated by fluorescent automated
sequencing (VCU Molecular Biology Core).

The shRNA target sequences, shRNA

cloning oligos and H1 Forward sequencing primer sequences are given in Table 7 below.
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Table 7. shRNA Targets, Cloning and Sequencing Primers
MBD2 B Target Sequence
MBD2 C Target Sequence
Scramble Target Sequence

GGGTAAACCAGACTTGAAT
GAACAGCCACGTCAGCTTT
ACGCGTAACGCGGGAATTT

shMBD2-B-Aas
shMBD2-B-As
shMBD2-B-Bas
shMBD2-B-Bs

CTCTTGAAATTCAAGTCTGGTTTACCCGGG
GATCCCCGGGTAAACCAGACTTGAATT
AGCTTAAAAAGGGTAAACCAGACTTGAATT
TCAAGAGAATTCAAGTCTGGTTTACCCTTTTTA

shMBD2-C-Aas
shMBD2-C-As
shMBD2-C-Bas
shMBD2-C-Bs

CTCTTGAAAAAGCTGACGTGGCTGTTCGGG
GATCCCCGAACAGCCACGTCAGCTTTT
AGCTTAAAAAGAACAGCCACGTCAGCTTTT
TCAAGAGAAAAGCTGACGTGGCTGTTCTTTTTA

shScramble-Aas
shScramble-As
shScramble-Bas
shScramble-Bs

CTCTTGAAAAATTCCCGCGTTACGCGTGGG
GATCCCCACGCGTAACGCGGGAATTTT
AGCTTAAAAAACGCGTAACGCGGGAATTTT
TCAAGAGAAAATTCCCGCGTTACGCGTTTTTTA

H1 Forward Sequencing Primer

GAATTCGAACGCTGACGTC

Table 7: Table shows shRNA target sequences along with cloning and sequencing primers used
to generate and verify shRNA clones. Sequences are given in the 5‟ to 3‟ direction for all
oligonucleotides. Four complementary fragments were annealed for each shRNA targeting
construct in the following orientation: Vector 3‟ – A oligo pair – B oligo pair – 5‟ Vector. The
“A” and “B”, sense (“s”) and antisense (“as”) oligonucleotides are marked accordingly.
Oligonucleotide ends are BglII and HindIII compatible.
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Transfection of breast cancer cell lines
All cell lines were transfected in 6cm culture vessels between 80 and 95%
confluency. Transfections were performed using the Lipofectamine

TM

2000 reagent

(Invitrogen) using maxi scale purified plasmid DNA essentially as detailed in the product
insert/protocol with optimization of DNA concentrations when required to maximize
transfection efficiency and minimize toxicity.

Selection and isolation of knockdown Clones
Transfected populations were subcultured at a 1 to 10 dilution 24-48 hours post
transfection by disruption in the presence of a 0.25% trypsin/EDTA solution (Gibco,
Carlsbad, CA). Cultures were placed in antibiotic selection media (Geneticin or Zeocin,
Invitrogen, Carlsbad, CA) at a cell line dependent concentration predetermined by killing
curve analysis. Antibiotic media was changed every 72 hours for 2 to 4 weeks until the
appearance of single colonies of resistant clones.

Single clones were isolated and

replated in 6 well tissue culture plates and allowed to grow in selection antibiotic. Clonal
populations were subsequently screened by SYBR green based real-time quantitative
PCR as well as immunoblot analysis for gene knockdown.

Cluster Analysis of qPCR Data:
Cluster analysis was performed and heat map figures were generated from tabular
gene expression data essentially as described previously (Eisen et al. 1998). The Cluster
analysis tools are designed primarily for manipulation and display of microarray data so
some minor reformatting of quantitative PCR results was necessary prior to import. A
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detailed explanation of formatting input data is available in the software help files and
therefore will not be provide here. The analysis operations performed on raw data were
limited to log transformation (to provide consistency in fold change intensity) and gene
normalization; array normalization was never performed to preserve quantitative
relationships between biological samples. The preferred algorithm for clustering small
data sets is self organizing map (SOM) analysis and therefore this algorithm was used
almost exclusively. A modified Java treeview platform with an improved and userfriendly graphical interface was used to generate heat map figures (Saldanha 2004). All
analysis software is available online from the developer‟s websites at no cost.
(http://rana.lbl.gov/EisenSoftware.htm, and http://jtreeview.sourceforge.net/).
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Results:
Gene expression profiling of MBD2 Knockdown Breast Cancer Cells
To determine the extent to which MBD2 was required for tumor suppressor gene
silencing in breast cancer and to determine which genes were mediating the effects
presented in the previous chapter, we conducted a series of gene expression analyses.
Since many of the effects we observed in MBD2 knockdown cells are not known to be
induced by the DNA methylation inhibitor, Decitabine (5-aza-dC), we also sought to
determine how MBD2 knockdown gene expression changes differed from those induce
by 5-aza-dC. We chose to use quantitative PCR for our analysis for reasons discussed
below. Changes in the mRNA levels of 48 tumor suppressor genes were probed in our
cell lines. The list of genes we chose to screen was compiled from independent reports
indicating methylation dependent silencing specifically in breast cancer. The complete
names and function of each gene is given in Appendix A along with NCBI accession
numbers and primer sequences in Appendix B. We validated all primers generated for
our array of tumor suppressor genes using SYBR Green based fluorescent quantitative
PCR. Figure 30 shows the results of this validation; the template used was serially diluted
cDNA from MCF-7 cells.

As expected, several genes were undetectable at higher

dilutions, most likely due to the low starting mRNA copy number of these epigenetically
silenced genes in breast cancer. Only primer sets that were quantitative over at least an
order of magnitude were considered valid and used for subsequent tests.
In order to minimize transcriptional noise from a heterogeneous pool, we next
selected stable clones expressing shRNA against MBD2 in the human mammary
epithelial carcinoma line, MCF-7 (Figure 29). These clones were compared against
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identically derived control shRNA expressing lines using high throughput quantitative
PCR. In our comparison we included additional samples to ascertain how MBD2
dependent changes differed from those induced by the DNA methyltransferase inhibitor,
5-aza-2-deoxy-cytidine. Prior to extraction of RNA for analysis, these samples were
treated for 96 hours with 4 uM 5-aza-dC. RNA was purified by Trizol extraction and
reverse transcribed into cDNA; a 1:10 dilution of this cDNA was used for subsequent
SYBR Green based qPCR analysis. Quantitative PCR results were clustered into groups
using self-organizing map analysis (Figure 31). Though the starting RNA amount was
held constant for all samples, several housekeeping genes were included in order to
correct for small differences in starting material or changes in gene expression not related
to our experimental variables. The normalized levels of housekeeping genes (GAPDH,
b-Actin, CyclophilinA) did not vary appreciably between samples (Green arrows, Figure
31). In contrast, the levels of a number of tumor suppressor genes we examined were
markedly induced by MBD2 knockdown.

Representative genes were selected for

subsequent analysis (bisulfite sequencing and ChIP) described in Chapter III; these genes
are indicated on the heat map by red arrows in Figure 31.
Cluster analysis allowed us to distinguish several categories of gene response in our
panel. The largest category of genes were those induced primarily by 5-aza-dC (4uM,
number of genes: n=30, 67%). Another group of genes was simultaneously induced by
MBD2 knockdown and 5-aza-dC in additive fashion (n=11, 24%). Finally a smaller
subset of genes appeared to respond to MBD2 knockdown alone (n=7, 15%) in our stable
cells. Genes in this subset were designated MBD2 responsive target genes and were of
particular interest to us as candidates for mediating the growth inhibition and morphology
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phenotypes elicited by MBD2 knockdown; these target genes were used for several
subsequent analysis experiments as discussed further below.
We inferred from the clustering pattern that MBD2 knockdown acts on a specific
subset of genes in breast cancer independently of global methylation changes, such as
those induced by 5-aza-dC and that perhaps these two perturbations had unrelated and
locus specific mechanisms of action.
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MBD2/GAPDH

MBD2
shRNA (KD)

Scramble MCF MBD2
siRNA
siRNA

Scrambled
shRNA (SC)

MCF7

MCF7

Relative Expression

Figure 29. Stable shRNA mediated knockdown of MBD2 in MCF-7 clones

MBD2a
b-actin

Figure 29. We selected and screened MCF-7 clones for high level knockdown of MBD2. A
representative clone is shown, mRNA levels were measured by qPCR and immunobloting for
MBD2 was used to confirm mRNA (above) and protein levels (below) in untransfected, scramble
control transfected and MBD2 shRNA transfected cells.
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Figure 30. Testing and standardization of qPCR array primers

cDNA Dillution
10 -1 10 -2 10 -3 10 -4

Figure 30. Quantitative PCR primers for
epigenetically silenced breast cancer specific
genes were validated using serial dilutions
of MCF-7 cDNA. This figure shows the
results of quantitative PCR gene expression
analysis as a color coded heat map. Heat
maps illustrate relative expression changes
for each gene (rows) using a continuum of
color, in this case blue (low expression) to
red (high expression).
Undetectable
expression is shown in gray.
Not
surprisingly, many of these genes are
expressed at low levels in wild type MCF-7
breast cancer cells.
Only primers
quantitative through at least an order of
magnitude were used for subsequent tests.
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Figure 31. Gene expression changes following MBD2 knockdown and 5-deoxyAzacytidine treatment.

+ + - - + + - - Scrambled siRNA
- - + + - - + + MBD2a siRNA
- - - - + + + + 5aza-dC

+ + - - + + - - Scrambled siRNA
- - + + - - + + MBD2a siRNA
- - - - + + + + 5aza-dC

A
Figure 31. This figure shows the results of
quantitative PCR gene expression analysis
as a color coded heat map. Heat maps
illustrate relative expression changes for
each gene (rows) using a continuum of
color, in this case blue (low expression) to
red (high expression). Undetectable
expression is shown in gray. In this figure,
B
the columns correspond to duplicate
experiments using cells stably transformed
with scramble or MBD2 shRNA and/or 2‟deoxy-5-azacytidine [5aza-dC] treatment
Panel on the left: qRT-PCR based
expression displayed as cluster/heat map
C
[red, high expression; blue, low
expression] measured in MCF7 cells.
[Arrows indicate KLK10, DAPK1, Maspin
(red arrows) and MBD2 (blue arrow)]
Panel above: Genes with little or no
D
change are shown separately; heat map
intensity was matched for both panels,
[arrows indicate GAPDH, Cyclophilin A,
β-Actin controls].
On the left, the gene clusters labeled A, B, C, and D correspond to differentially regulated
groups of genes. Cluster A contains genes predominantly induced by 5aza-dC and
relatively unaffected by MBD2 knockdown. Cluster B contains genes induced by 5azadC and MBD2 knockdown in additive fashion. Cluster C contains MBD2 dependant
genes which were not induced by 5aza-dC. Finally, cluster D contains those genes which
were downregulated by MBD2 shRNA, including MBD2 itself [Blue Arrow].
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Tumor suppressor gene expression is altered in growth restricted lentivirally
transduced breast cancer cell lines.
We used high throughput quantitative PCR as described above to examine the
expression of epigenetically silenced genes in lentivirally transduced MBD2 knockdown
and scramble control SK-BR-3, MDA-MB-231, and MDA-MB-435 cells. These cells
were of particular interest because of the changes in in vitro and in vivo growth described
in Chapter I. We found that, in similar fashion to our previous gene expression analyses,
specific subsets of tumor suppressor genes from the panel of genes tested were
reexpressed in MBD2 knockdown cells (Figure 31). Not surprisingly, there was some
degree of cell line specificity with respect to MBD2 induced changes in gene expression,
for instance DAPK1 was induced in MDA-MB-231 and MDA-MB-435 cells but not in
SK-BR-3 cells. Other MBD2 responsive genes identified in our initial examination of
MCF-7 cells were responsive in all three of the lentivirally transfected cell lines (e.g.,
Maspin, KLK10, GPC3 and THRB). Of all the genes examined, Maspin, DAPK1, and
KLK10 were the most uniformly and/or robustly induced tumor suppressors, raising the
possibility that these genes may play a role in mediating MBD2 dependent growth
inhibition of breast cancer cells. Once again control genes (Cyclophilin A and GAPD)
were used for normalization and as before the expression level of these genes remained
relatively constant across all samples.
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Figure 32. Tumor Suppressor Gene Expression Changes in Lentivirus Transduced
Breast Cancer Cell Lines.

Scramble shRNA
SK-3

435

MBD2 shRNA
231

SK-3

435

231

Figure 32. Quantitative RT-PCR was used to measure the gene expression levels of known
hypermethylated and transcriptionally silenced genes in breast cancer. Three cell lines which
demonstrated significant growth inhibition were analyzed, MDA-MB-231, MDA-MB-435, and
SK-BR-3. Scramble controls are shown in the left half of the figure and knockdowns are on the
right. Red is used to show relatively high expression and blue for relatively low expression for
each gene. GAPD and Cyclophilin A control genes were included and cluster near the lower
middle region, corresponding to relatively little change across samples. MBD2 levels
(confirming knockdown) are shown in the last row.
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MBD2 target genes vary independently of each other but knocking them down
individually does not rescue MBD2 dependent morphological differences.

We attempted to identify the MBD2 target gene responsible for mediating the
epithelial morphology changes by using siRNA to knockdown each gene in the MBD2
dependent cluster individually. We transfected MBD2 knockdown MCF-7 cells with
double stranded siRNA oligonucleotides targeted against each gene in the MBD2
dependent cluster and verified the magnitude and specificity of the resulting gene
knockdowns by quantitative RT-PCR. The genes in the MBD 2 dependent cluster are
listed in Table 8 along with the siRNA target sequences used to knock them down
individually. We found that the siRNAs were both effective and specific for each gene
(Figure 33). It was clear from our analysis that MBD2 target genes varied independently
of each other; only one target gene was affected in each case. The significance of this
observation was to confirm that these genes were indeed downstream targets of MBD2
rather than indirect targets of one another. We next sought to determine if any of the
MBD2 responsive genes were mediating the changes in the morphology of these MBD2
knockdown MCF-7 cells by carrying out 3D culture assays on each siRNA transfected
population. We found that while we were able to specifically knock down the individual
genes, no single tumor suppressor target we tested was able to reverse the organized
growth of MBD2 knockdown cells (Figure 34). This finding suggested to us that the
morphology changes we observed in these cells were being driven by another MBD2
dependent effector, or more likely, multiple downstream effectors.
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Table 8. siRNA oligonucleotide sequences

Gene

Description

Accession

siRNA Sequence

ADAM23

NM_003812

CGCGGGTGACATTTCACTATA

DAPK1

ADAM metallopeptidase domain
23
death-associated protein kinase 1

NM_004938

AAGCATGTAATGTTAATGTTA

FHIT

fragile histidine triad gene

NM_002012

TTCGCTCTTGTGAATAGGAAA

GPC3

glypican 3

NM_004484

CAGCCGAAGAAGGGAACTAAT

HOXA5

homeobox A5

NM_019102

CCTCTCCGAGAGACAAATTAA

SERPINB5

serpin peptidase inhibitor, clade B
(ovalbumin), member 5
thyroid hormone receptor, beta
(erythroblastic leukemia viral (verb-a) oncogene homolog 2,
avian)

NM_002639

GCCGTTGATCTGTTCAAACAA

NM_000461

TCCAGAATGATTACTAACCTA

THRB

Table 8. Listed in this table are the seven MBD2 dependant genes found in cluster C of Figure 31.
MBD2 target gene names, description are shown on the left and the siRNA sequences used to
knock these genes down individually are shown on the right.
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Figure 33. siRNA mediated knockdown of individual target genes

Figure 33. Transfection of stable MBD2 knockdown lines with short double stranded RNA
oligonucleotides (siRNA) led to specific silencing of downstream target genes. A negative (nontargeted) siRNA oligonucleotide was used as a control (siNEG). All siRNA oligo based
knockdowns were performed using MBD2 KD MCF-7 cells at approximately 80% confluence in
a 24 well tissue culture plate. Each transfection was performed using 20 pico moles of siRNA
(Qiagen) and 1 ul of Lipofectamine 2000 transfection reagent (Invitrogen) diluted in Opti-MEM
serum free media (Gibco).
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Figure 34. Acini formation is not affected by individual target gene knockdown.

*p ≤ 0.04
100%

**p ≤ 0.02

80%
60%
40%
20%
0%

Figure 34. Mammosphere formation assay using MBD2 target gene knockdown cells. As
described above, we measured percent mammosphere formation in our target gene siRNA treated
lines in order to determine whether any specific gene was responsible for the increased proportion
of mammospheres in knockdowns lines (Chapter I). No significant reversion to disorganized
growth was observed in any of the MBD2 target gene knockdown populations.

106

Discussion
MBD2 dependent gene repression in breast cancer
The only recognized function of MBD2 in humans is its role in binding to genomic
cytosine methylation and initiating transcriptional repression through downstream
changes in chromatin. As discussed throughout the current work, the obvious mechanism
of action of MBD2 in aggravating breast cancer is the inhibition of tumor suppressor
gene expression. Until now, however, a link between MBD2 function and breast cancer
pathogenesis has not been made. With this in mind, we sought to prove that MBD2
knockdown restored the expression of tumor suppressor genes in breast cancer and
determine whether these genes were mediating any MBD2 dependent phenotypes. We
went about this by probing the mRNA levels of putative MBD2 target genes in breast
cancer cell lines, both MBD2 knockdown and control. We found that the expression of
specific tumor suppressors known to be silenced in breast cancer was increased with
MBD2 knockdown. Moreover, we found that many of the genes induced by MBD2
knockdown were different from those induced by 5-aza-dC. Given the known differences
in cytosine methylation between individual tumors, it was not surprising to learn that the
gene expression changes induced by MBD2 varied somewhat between cell lines. Though
we currently lack sufficient evidence to support a central role for any single downstream
gene in mediating MBD2 dependent phenotypes, it was interesting that several genes
were consistently re-expressed in all cell lines which demonstrated growth inhibition. As
discussed further below, our observations leave some doubt as to whether a single critical
target is responsible for mediating the full spectrum of MBD2 activity in breast cancer.
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A quantitative PCR assay for epigenetic silencing in breast cancer
The gene expression analyses described in this chapter was performed using SYBR
green based quantitative PCR. This methodology was chosen over other global gene
expression profiling approaches (e.g., including microarrays, SAGE, or massive multiparallel sequencing) for several reasons. The first reason was one of practicality; we
have all the equipment and reagents to perform high-throughput 384 well quantitative
PCR in our laboratory (ABI Prism 7900 HT, Applied Biosystems). In addition, this
technique requires the lowest initial investment while providing the highest quantitative
reliability. Case in point: microarray results, even of the highest significance, must be
subsequently verified by quantitative PCR in order to be considered valid; as such we
went straight to the current gold standard for quantitative gene expression analysis. Most
importantly, previous experience with microarrays in our laboratory (Rupon et al. 2006)
demonstrated a significant limitation of this approach. The strength of microarrays is that
they provide parallel gene expression data for large set of genes in contrast to PCR based
assays which are primer dependent. However, we were interested specifically in the
direct effects of MBD2 on hypermethylated tumor suppressor genes.

We found

previously that microarrays include a considerable amount of noise from secondary and
tertiary genes which are not directly regulated by MBD2. Sifting through this data to
identify candidate genes can be time consuming and ultimately fruitless.
Importantly, the list of genes reported to be transcriptionally inactivated by promoter
hypermethylation in breast cancer remains relatively limited (Hoque et al. 2009; Esteller
2005). We discovered that we could adequately cover this set of genes, the targets of
highest interest to us, using high throughput quantitative PCR. The list of genes we
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chose for our analysis is given in Appendix A along with their putative functions and the
pathways in which they have been shown to interact.
We must concede an obvious limitation of our methodology: analyzing a restricted
set of genes will, by definition, generate an a priori biased data set. In contrast to
unbiased genome wide approaches (e.g., ESTseq, Affymetrix Human Genome Arrays),
we are unable to comprehensively evaluate transcriptome level changes. Moreover, it is
quite likely we have omitted interesting primary target and secondary effector genes from
our analysis.

However, this analysis is more than adequate considering our stated

purpose: to evaluate whether MBD2 maintains transcriptional silence of a specific set of
tumor suppressor genes in breast cancer. Despite its limitations, our gene expression
analysis has successfully met this objective and in the process provided interesting and
novel information regarding the unique function of MBD2 in breast cancer.

MBD2 and 5-aza-deoxy-cytidine activate different genes in breast cancer
The DNMT inhibitor, 5-aza-dC, is a nucleotide analog that is incorporated into
genomic DNA and acts to irreversibly inhibit methylation by forming covalent adducts
with catalytic residues in the active site of DNA methyltransferase enzymes. While there
remains some question as to whether the efficacy of 5-aza-dC in cancer depends on its
effect on methylation or the non-specific effects of protein-DNA adduct formation, it is
accepted that this compound leads to passive, replication dependent demethylation and
changes in gene expression (Patra and Bettuzzi 2009). Because of the toxicity and
carcinogenicity associated with 5-aza-dC, the present work is geared toward the
development and testing of an alternate strategy for reactivating methylated tumor
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suppressor genes in breast cancer. Consequently we were interested in comparing the
gene expression changes induced by MBD2 knockdown to those induced by 5-aza-dC
treatment. We found that MBD2 and 5-aza-dC did indeed act on different subsets of
genes in MCF-7 cells. As expected, the widely acting 5-aza-dC induced the transcription
of a larger number of genes than MBD2 knockdown, in fact more than twice as many out
of those tested (85% vs 35%). From the panel of 48 genes only 10 (21%) were additively
induced by MBD2 knockdown and 5-aza-dC. Only 7 genes (15%) were induced by
MBD2 knockdown alone (Table 8). Finally, while none of the genes tested were found
to be repressed by 5-aza-dC, 5 genes (11%) were repressed in MBD2 knockdown cells.
We presume this last group of genes are indirect targets; though highly unlikely given
what is known about the function of MBD2, we cannot completely rule out the possibility
that MBD2 may act as an activator of transcription at certain loci. Taken as a whole,
these data support our initial hypothesis that MBD2 knockdown is a more targeted
method for reactivating methylated tumor suppressor genes than treatment with 5-aza-dC.
Implicit in these results is the idea that these two strategies can have independent, gene
specific mechanisms of action and that MBD2 binds and represses a specific subset of
methylated tumor suppressor genes in breast cancer leading to more targeted gene
disruption in tumors.
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MBD2 maintains transcriptional silence of a specific subset of tumor suppressor
genes
As discussed above, MBD2 was found to act specifically at a subset of tumor
suppressor genes which accounted for only 35% of those tested. If we assume that all
MBD2 and 5-aza-dC induced genes are methylated in MCF-7, and that all the MBD2
induced genes are direct targets of MBD2, then the percentage of methylated genes
bound by MBD2 is 47%. Extrapolating further from this assumption, approximately half
of the tumor suppressor genes methylated in breast cancer are targets of MBD2 mediated
repression. This extrapolation is in line with previous reports of the high affinity of
MBD2 for CpG rich tumor suppressor promoters (which represent approximately half of
all promoters) in cancer (Lopez-Serra et al. 2008a; Fraga et al. 2003; Ballestar 2003) and
is a provocative indicator of the fundamental role of MBD2 in breast cancer
pathogenesis.
An important point needs to be stressed here regarding the results presented in this
section and their implications. It is clear that MBD2 inhibition is able to restore tumor
suppressor expression in a targeted way. This targeted gene restoration is both effective
in limiting the growth of breast cancer (Chapter I) but equally important is the inherent
source of selectivity built into the mechanism of action of MBD2. By reactivating a
subset of tumor suppressor from a pool which is pathologically hypermethylated only in
cancer, MBD2 holds promise as a target for selective killing of tumor cells without
affecting the viability of normal tissues.
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MBD2 regulated genes vary between breast cancer cell lines
In addition to a detailed analysis of gene expression changes in the MCF-7 cell line,
we conducted parallel gene expression studies in 3 other human mammary epithelial
lines: MDA-MB-231, MDA-MB-435 and SK-BR-3. These cell lines were of interest
because in contrast to MCF-7 they demonstrate substantial growth inhibition.

It is

worthwhile to note that all three of these lines are considered somewhat more aggressive
in terms of their growth and tumorigenic potential in animal models (Perou et al. 2000;
Sorlie et al. 2001). It can be inferred here that increased tumorigenicity correlates with a
greater degree of genetic and epigenetic dysregulation. Based on this assumption, the
fact that these lines are more sensitive to MBD2 knockdown is intriguing and supports
the selectivity hypothesis we have put forward: targeting epigenetic silencing of tumor
suppressors will have the greatest destabilizing effect in those cells with the greatest
degree of abnormal methylation, i.e., aggressive breast cancer cells.
We found that the pattern of gene expression changes varied to some degree between
all the breast cancer cell lines we compared following MBD2 knockdown.

This

observation is consistent with the idea that hypermethylation events occur following a
stochastic model that will vary between tumors. Another possible explanation for the
variability observed is the differential expression of transcription factors and epigenetic
modifiers in cell lines of distinct origin. Recall that MBD2 knockdown in and of itself is
not an activator of transcription; this perturbation is more accurately thought of as the
removal of a component of the repressive machinery. In order for this removal to lead to
the robust transcriptional activation of a particular hypermethylated target, the relevant
activating machinery must be intact in a given cell. This activating machinery consists of
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sequence specific transcription factors, targeting components of the transcriptional
machinery, and epigenetic modifiers that act in opposition to MBD2, for example histone
acetyl transferases (HATs).

As a result, variability in these factors is likely to be

influencing the pattern of gene expression in MBD2 knockdown cells.

Do MBD2 dependent gene expression changes underlie phenotype?
An interesting phenomenon we currently have no explanation for was the repression
of several tumor suppressor genes by MBD2 knockdown. It is likely that this repression
is indirect, i.e., through the action of an intermediary MBD2 induced genes. In this group
of genes, i.e., MBD2 induced genes, one stood out to us and bears mentioning here, p53.
This tumor suppressor is mutated in nearly half of all human cancers and is often referred
to as the „guardian of the genome‟ for its role as a critical checkpoint protein in halting
growth and promoting apoptosis of transformed cells. In our analysis, we found that p53
was uniformly down regulated in MBD2 knockdown breast cancer cells.

The

significance of this finding is not entirely clear, particularly given the fact all the lines we
examined with the notable exception of MCF-7 bear well described mutations in p53
(Petitjean et al. 2007). Though opposite in character from the expression change one
might assume would be protective, this observation is in fact consistent with growth
inhibition in the setting of mutant p53. Bearing in mind that mutant p53 can acquire a
gain of function whereby it can exacerbate pathological phenotypes, it is interesting to
speculate whether MBD2 knockdown may in fact be acting somehow indirectly through
the downregulation of mutant p53 in breast cancer. This observation is further unique in
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that upregulation of mutant p53 is typically due to increased protein stability, not
increases at the transcriptional level.
Among the genes we examined, several stood out as uniformly induced by MBD2
knockdown in all cell lines examined. Among these genes were Maspin (Mammary
Associated Serine Protease Inhibitor) and KLK10 (Kalikrein 10). Epigenetic silencing of
of these genes has previously been shown to be pathologically involved in the
progression of breast cancer (Khalkhali-Ellis 2006; Zhang et al. 2006). We became
interested in the possibility that all or some of the phenotypic consequences of MBD2
knockdown were mediated through one of these targets. However, as discussed below,
we have been unable to show that MBD2 acts through a single target and it is more likely
that the growth inhibition and morphologic changes induced by MBD2 knockdown are
the result of the combined effects of multiple downstream target genes.

MBD2 likely acts through multiple targets to affect the phenotype of breast cancer
We maintain that the effects of MBD2 knockdown on the behavior of breast cancer
cells are mediated through target gene expression changes and we have shown that
MBD2 is indeed acting as a modifier of methylated tumor suppressor gene induction. In
order to evaluate the importance of individual MBD2 target genes, we used siRNA
directed against the 7 exclusively MBD2 induced genes in MCF-7 knockdown cells and
tested whether any of the resulting knockdown lines reverted to the abnormal
morphology characteristic of control (MBD2 expressing) MCF-7 cells. We found that
none of the single target gene knockdowns was effective in „rescuing‟ MBD2 knockdown
induced changes. This analysis was, however, limited to the morphologic changes in
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MCF-7 cells and we have not yet addressed the growth inhibition in other breast cancer
cell lines in a similar manner.

We cannot discount an important limitation inherent in our siRNA based knockdown
strategy, namely the transient nature of the resulting gene repression. We know from our
earlier studies that stable MBD2 knockdown, lasting weeks rather than days, is required
to bring about the full magnitude of the growth inhibition we observed. It is quite
possible that a similar, sustained knockdown of MBD2 induced genes is required to
reverse these effects.

Taken at face value, we interpret the failure of MBD2 target gene knockdown to
rescue phenotype to mean one of two things. First, it is possible that a gene not included
in our panel (and therefore one which we remain unaware of) is responsible for mediating
MBD2 knockdown induced morphologic changes. The second explanation and the one
we consider to be more likely based on general probability and the pleotropy exhibited by
cell lines, is that the combined effect of multiple downstream targets underlie MBD2
dependent changes. It is experimentally difficult to address multiple targets directly in a
rescue experiment; we are currently conducting studies which involve the restoration of a
shRNA immune MBD2 mutant to verify that the changes we are observing are indeed
mediated solely by lack of MBD2 function in breast cancer.

We have shown that MBD2 is required for maximal growth of breast cancer cells,
abnormal morphology of poorly differentiated populations, and for the transcriptional
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repression of pathologically methylated tumor suppressor genes. Up to this point we
have considered MBD2 largely in isolation from other aspects of epigenetic
dysregulation in breast cancer. While a useful model for evaluating the specific function
of MBD2, this reductionist approach artificially discounts the complex network of events
that occur simultaneously to drive pathogenesis of breast cancer. Among these events are
changes in CpG methylation and feedback regulation of and by other epigenetic
modifiers, notably other methyl binding proteins and DNA methyltransferases.

As

detailed in the following chapter, an examination of these interconnected elements
confirms important coregulatory phenomena are indeed occurring.
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Chapter III: The interplay of transcription, methylation, epigenetic factors and
MBD2 target genes

Introduction:

DNA Methylation in different species
Non-vertebrate species have very low levels of methylation. Neurospora Crassa for
example, has low levels of methlylation which are thought to correspond to ancient
transposition events (Selker et al. 2003). Neurospora utilizes DNA methylation which is
dependent on the H3K9 DNA methyltransferase dim-5, perhaps establishing a functional
convergence at the invertebrate level between histone and DNA methylation. (Tamaru
and Selker 2001). It is interesting that Drosophila Melanogaster whose genome has very
high levels of mutation from transposable elements, has very low levels of methylated
DNA (Yoder, Walsh, and Bestor 1997). Despite the low levels of methylation, two
potential methylase-like genes have been indentified in Drosophila. Of these two genes,
deletion of Dnmt-2 in Drosophila resulted in complete abolishment of methylation. In
contrast, the overexpression of Dnmt-2 resulted in hypermethylation at CpT and CpA
dinucleotides (Kunert et al. 2003). Drosophila also contains a single homolog that
corresponds to mammalian MBD2/3 (Roder et al. 2000). GST-fusions and two hybrid
experiments have revealed that the Drosophila MBD2/3 interacts with Mi-2/NuRD
complex via p55 and Mi-2 subunits (Marhold, Brehm, and Kramer 2004). Bandshift
experiments using MBD2/3 and the mammalian homolog MBD2 demonstrated that the
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fly MBD2/3 interacted with CpA and CpT methylated oligonucleotides, but could not
bind CpG methylated probes. These experiments may indicate that Drosophila MBD2/3
is similar in function to human MBD2, however it is not fully understood whether
MBD2/3 targets Mi-2/NuRD complexes to CpA/T methylation sites or if it facilities other
protein-protein or protein-DNA interactions. In Drosophila, it is likely that DNA
methylation plays a more important role during embryonic development. Liquid
chromatography has demonstrated that the highest levels of DNA methylation occur
during early stages of fly embryogenesis (Lyko, Ramsahoye, and Jaenisch 2000).
Compared to Drosophila, other insect species such as cabbage moth Mamestra
brassicae, the peach potato aphid Myzus persicae, and the mealy bug Planococcus citri
exhibit somewhat higher levels of DNA methylation (Field et al. 2004). In the honeybee
Apis Melifera, DNA methylation plays an important role in the division of social
structures. Honeybee larvae treated with small interfering RNA targeting a de novo DNA
methyltransferase, Dnmt3, developed into queens with fully functional ovaries, while
control RNAi treated larvae did not (Kucharski et al. 2008).
In stark contrast to invertebrates and fungi which are virtually methylation free,
vertebrate genomes are highly methylated (Tweedie et al. 1997). Xenopus laevis and
zebrafish, Danio rerio, have a high content of genomic DNA methylation as well as
functional DNMTs and MBDs (McGowan and Martin 1997; Stancheva and Meehan
2000a; Veenstra and Wolffe 2001).

Mammals use DNA methylation for parental

imprinting; that is allele-specific regulation in which parental origin determines
expression of a single allele (Reik, Dean, and Walter 2001b).

Put another way,

imprinting is able to affect the differential expression of maternal and/or paternal alleles
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based on a DNA methylation pattern established during sex specific gametogenesis.
Several severe diseases such as Beckwith–Wiedemann, Prader–Willi, and Angelman
syndromes and even various types of cancer result from defects in imprinting (Bittel and
Butler 2005; Lalande and Calciano 2007).

Dynamics of DNA methylation during development
During mammalian embryogenesis the de novo methyltransferases, DNMT3a and
DNMT3b methylate previously unmethylated CpG sequences. A third methyltransferase
called DNMT1 functions both as a maintenance methylase, copying the pre-existing
methylation marks onto the new strand during replication and as a de novo DNA
methyltransferase (Jeltsch 2006; Fatemi et al. 2002; Gowher et al. 2005). The precise
mechanism of targeting of de novo methylation is not fully understood, however it is
clear that the DNMT family of methyltransferases are critical for normal embryonic
development.
Knock-out studies of DNMT1 in embryonic stem (ES) cells and in mouse embryos
resulted in significantly reduced levels of DNA methylation. The loss of DNMT1 proved
to be lethal with the majority of embryos not passing mid-gestation, although the ES cells
remained viable and proliferative (Li, Bestor, and Jaenisch 1992b). Similar experiments
involving DNMT1-knockouts in X. laevis embryos, resulted in a hypomethylated genome
and the embryos displayed a premature expression pattern of several mesodermal
markers (Stancheva and Meehan 2000b). The knockouts also exhibited p53-induced
apoptosis and embryonic lethality (Stancheva, Hensey, and Meehan 2001). Similar
observations have been made on cultured fibroblasts derived from conditional DNMT1
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mouse knockouts that undergo p53-dependent programmed cell death (Jackson-Grusby et
al. 2001). Theses DNMT1-depleted fibroblasts showed a reactivation of placental and
germ line markers. These results suggest an important role for DNMT1, and therefore
CpG methylation, in establishing a footprint of tissue-specific gene expression during and
after embryonic development.
Knockdown studies of DNMT1 in zebrafish appeared to recapitulate the effects
observed in mice and Xenopus. Approximately 40% of the embryos died as a result of
DNMT1 depletion (Rai et al. 2006). An important finding of this study was that the
response to DNMT1 deficiency is largely organ-specific. One of the most affected organs
was the gut. The reduced intestinal differentiation also caused the loss of expression of
fabp2, a marker of terminally differentiated epithelial cells. Markers of eye development
such as otx-2 and otx-5 appeared to be expressed at similar levels in both control embryos
and DNMT1 knockdowns. Histological evidence did suggest a severe disorganization of
retinal structures.
Collectively these studies have emphasized the importance of DNMT1, and
indirectly CpG methylation, in establishing a blueprint for tissue-restricted gene
expression during development. DNMT1 has been reported to interact with methyl-CpG
binding proteins as well as with HDACs and histone methyltransferases to repress
transcription (Kimura and Shiota 2003; Fuks et al. 2003; Tatematsu, Yamazaki, and
Ishikawa 2000). In addition, DNMT1 has been found to interact with the Rb tumor
suppressor protein to repress transcription from promoters containing E2F binding sites.
This interaction serves to link DNMT1 to a growth regulatory pathway that frequently is
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disrupted in cancer (Robertson and Wolffe 2000). To date however, no association
between DNMT1 and MBD2 has been established in human malignancy.

Demethylation and remodeling of methylation patterns in development
DNA methylation patterns are both stable and heritable in somatic cells. There are
two distinct periods during mammalian development when the normally stable DNA
methylation patterns are dynamically remodeled. The first global remodeling of DNA
methylation occurs during gametogenesis (Mann and Bartolomei 2002). During
gametogenesis there is an erasure of DNA methylation marks, which serves to reset the
existing imprinting in gametes. This demethylation event is followed by a wave of
remethylation which is necessary to reestablish the parental imprint. The second global
remodeling of DNA demethylation occurs following fertilization during the
preimplantation period of the embryonic development. This demethylation does not
appear to affect imprinted regions established during gametogenesis. In contrast to the
DNA methylation patterns in the oocyte, sperm DNA is highly methylated (Morgan et al.
2005). The high level of methylation correlates with its inactive chromatin state and
compact structure. Immunohistochemistry and bisulfite conversion experiments in mice
showed that the male pronucleus gets rapidly demethylated shortly after fertilization,
while the maternal genome displays a slow but progressive drop in DNA methylation
levels consistent with passive demethylation (Oswald et al. 2000; Mayer et al. 2000).
Later during implantation, the global DNA methylation levels of both the paternal and the
maternal contributions to the genome steadily increase. Similar developmental changes
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involving a wave of demethylation followed by increasing levels of DNA methylation
post fertilization have also been described in other placental mammals (Dean et al. 2001).
Despite the general observation regarding changes in global methylation, any direct
observations of active demethylation remain controversial. Moreover, it is not fully
understood how DNA methylation and demethylation are targeted or regulated. The
physiological role of DNA demethylation in vertebrate development is also speculative.
One recent study in zebrafish embryos identified demethylase activity involving an AID
deaminase, MBD4 glycosylase, and Gadd45a during the late gastrula to segmentation
stage (Rai et al. 2008). The protein Gadd45a has also been implicated with other
demethylation events associated with DNA repair (Barreto et al. 2007). It is interesting to
note that Gadd45a knockout mice did not exhibit any global or site specific
hypermethylation which leaves the role of Gadd45a in demethylation in dispute (Engel et
al. 2009). Similarly, a controversial DNA demethylase function has been proposed for
MBD2 and MBD3 (Bhattacharya et al. 1999; Brown et al. 2008; Hamm et al. 2008). The
biochemical energetics of direct demethylation of 5-methyl-cytosine (i.e., the direct
enzymatic cleavage of the sigma carbon-carbon bond of the 5- methyl group without
partial or complete reclamation of the heterocyclic ring) are unfavorable casting doubt on
the possibility that MBD2 or MBD3, or any other single protein for that matter functions
in this capacity (Klose and Bird 2006; Berger and Bird 2005a; Hendrich et al. 2001;
Ginder, Gnanapragasam, and Mian 2008). An active process of demethylation likely does
exist, given the rapid waves of global demethylation during development. A more
plausible mechanism than direct demethylation is likely to involve a cooperative
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deaminase/glycosylase (i.e., AID/MBD4) step followed by resolution of the apyrimidinic
site by the nucleotide excision repair machinery (Rai et al. 2008).

Another look at the MCBPs and their specific roles in gene repression
MBDs and Kaiso-like proteins are the two major families of methyl CpG binding
proteins in mammals. MeCP2 was the first methyl-CpG binding protein discovered
during a screen to identify factors that bind to unmethylated DNA. Instead, protein
factors, initially named MeCP1 and MeCP2, that bind specifically to methylated DNA
were isolated (Meehan et al. 1989). MeCP2 is a 53-kDa protein containing a N-terminal
methyl-CpG binding domain (MBD) and a C-terminal transcriptional repression domain
(TRD) (Nan et al. 1998a). Later screens based on mammalian expressed sequence tag
(EST) database homology searches for sequences encoding a conserved MBD domain led
to the identification of four additional proteins currently known as MBD1, MBD2,
MBD3 and MBD4 (Hendrich and Bird 1998b). The MBD family proteins, including
MeCP2, are highly conserved in all vertebrates (Clouaire and Stancheva 2008). MBD2
and MBD3 are closely related to each other and share 77% identity outside the MBD
domain (Hendrich et al. 2001). It is likely MBD2 and MBD3 represent the ancestral
MBD family founders since a homologous MBD2/3-like protein is present in
invertebrates, including Drosophila, where low levels of DNA methylation are detectable
only in early development (Marhold, Brehm, and Kramer 2004). All MBD proteins,
except MBD3, specifically recognize and bind to methylated DNA in vitro and in vivo
(Hendrich and Bird 1998a). Mammalian MBD3, contains a critical mutation in the MBD
domain and therefore does not bind preferentially to methylated DNA.
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Figure 35. The Methyl Binding Proteins

Figure 35. Families of methyl-CpG binding proteins. MBD family proteins share a conserved
MBD domain, which is required for binding to methylated DNA. MBD3 carries a mutation
(shown in orange) in the MBD domain and does not bind to methylated CpGs. MeCP2 has two
AT-hook motifs (ATh) which potentially could bind AT-rich DNA. These motifs are not required
for highaffinity binding to sequences containing a methylated CpG followed by an [A/T]4 run.
MBD1 is characterized by two (or three in some isoforms) CxxC-type zinc fingers. The third
CxxC motif (orange) binds unmethylated CpGs. TRD indicates transcriptional repression
domains mapped by functional and deletion analyses. GD indicates the glycosylase domain of
MBD4, which is involved in excision of CG:TG mismatches. The (GR)11 motif of MBD2 is a
stretch of glycine and arginine residues that can be methylated by PRMT5 protein methylase [98].
(E)12 is a glutamate rich domain. The Kaiso family of proteins is characterized by three
homologous C2H2 zinc finger motifs that are required for binding to methylated and in some
instances unmethylated DNA. In addition, all proteins of this family carry a BTB/POZ domain
likely to be involved in either homo- or heterodimerization or protein-protein interactions.
ZBTB4 and ZBTB38 have additional three and seven, respectively, zinc finger motifs. (Figure
from T Clouaire and I Stancheva. Cell. Mol. Life Sci. (Clouaire and Stancheva 2008)
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The individual MBD Proteins and their Function in Transcriptional Repression
MeCP2
MeCP2 is a potent transcriptional repressor and studies have suggested that MeCP2
might serve as a global transcriptional silencer (Nan et al. 1998a). In addition to binding
methylated DNA, MeCP2 associates with various co-repressor complexes such as Sin3a,
NCoR, and c-Ski at the sites of its occupancy (Jones et al. 1998; Kokura et al. 2001).
Given its well described association with Rett Syndrome, it was surprising that
transcriptional profiling of MeCP2-null mice brains displayed only subtle changes in
gene expression (Tudor et al. 2002). Recent microarray studies have confirmed this
finding using RNA isolated from the cerebellum of MeCP2 mutant mice (Jordan et al.
2007). The microarray study did not reveal any large changes in expression. The greatest
change was in the Irak1 gene, which showed a twofold increase in expression. Special
AT-rich sequence binding protein 1 (SATB1) was identified as one of the few genes
upregulated in two MeCP2-null mouse models. SATB1 is known to specifically bind to
nuclear matrix attachment regions (MARs) and mediate formation of chromatin loops
(Horike et al. 2005). In a similar large scale expression study using cultured fibroblast
cell lines from two RTT patients revealed only 49 upregulated and 21 downregulated
potential MeCP2 targets, some of which were known to be expressed in brain tissues
(Traynor et al. 2002). The most compelling result of this study was the striking
differences observed in different clones obtained from the same RTT patients, which may
be indicative of epigenetic pleomorphism between individual clonal populations, not
unlike the variability between breast cancer cell lines in the current work.
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MBD1
MBD1 is also a transcriptional repressor which acts through its repression domain
like other family members. It is has been shown to function as a transcriptional repressor
both in vivo and in vitro, and depending on the splicing isoform, it can bind methylated
as well as unmethylated DNA (Ohki et al. 1999; Fujita et al. 2000). MBD1 is the largest
protein in the MBD family, and Like the other family members, it associates with
chromatin modifiers such as the Suv39h1–HP1 complex to enhance DNA methylationmediated transcriptional repression (Fujita et al. 2003). Experiments using human HeLa
cells demonstrated that MBD1 associated with the H3K9 methyltransferase SETDB1
(Sarraf and Stancheva 2004). During S phase the MBD1–SETDB1 complex is recruited
to chromatin by the chromatin assembly factor CAF1 to establish new H3K9 methyl
marks.bFunctional experiments showed that removal of DNA methylation disrupted the
formation of MBD1–SETDB1–CAF1 interaction on the p53BP2 promoter, which lead to
the loss of H3K9 methylation. An MBD1 mouse knockout has been obtained, but no
severe developmental defects were found. MBD1-null mice had a normal morphology
and appeared healthy, although they carried a number of minor neural defects like
reduced hippocampal neurogenesis and had problems with spatial learning. Another
interesting feature of this knockout was reduced genomic stability and an increase in
expression of the Intracisternal-A particle retrotransposon (Zhao et al. 2003). This is the
likely resulting from the lack of proper H3K9 methylation . Because H3K9 methylation is
involved in the silencing of genomic repetitive elements, a reactivation of retrotransposon
sequences in the MBD1-null mice was observed.
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MBD2
MBD2, is a 44-kDa protein which shares extensive sequence homology with MBD3
(Hendrich and Tweedie 2003). MBD2 is been shown to bind methylated CpGs in vitro
and in vivo; like the other MBD family members, it confers DNA methylation mediated
transcriptional silencing through its repression domain (Wade 2001). MBD2 associate
with HDAC1 and HDAC2 in the Mi-2/NuRD chromatin remodeling complex (Zhang et
al. 1999). For a more detailed review of the function of MBD2 in development and
cancer, see the introductions for Chapter I and Chapter II.

MBD3
MBD3 unlike the other MBD family members does not preferentially bind
methylated DNA. In contrast, MBD3 in lower vertebrates such as amphibians does
preferentially bind methylated DNA. It is an essential subunit of at least some or most of
the Mi-2/NuRD chromatin remodeling complexes (Zhang et al. 1999; Sakai et al. 2002).
MBD2 and MBD3 both associate with Mi-2/ NuRD. However the association appears to
be mutually exclusive, forming two distinct complexes (Le Guezennec et al. 2006;
Denslow and Wade 2007; Bowen et al. 2004; Feng and Zhang 2001b). In spite of the
striking sequence similarity between MBD2 and MBD3, the two proteins do not carry out
redundant functions during early development. The MBD3 knockout is lethal at
embryonic day 8.5. This is in stark contrast to MBD2-null mice which only displayed a
mild maternal phenotype as discussed above. MBD3-null ES were seriously
compromised in their ability to differentiate as they failed to shut down the expression of
undifferentiated ES cell markers such as Oct4, Nanog, and Rex1 (Kaji et al. 2006).
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Aberrant gene expression in MBD3-null cells is the most probable reason why cells of
the inner cell mass fail to develop into late epiblasts after implantation (Kaji, Nichols, and
Hendrich 2007).

MBD4
The last member of the MBD family, MBD4, has a very distinct functional role.
MBD4 is a thymine glycosylase and serves as a DNA repair protein at targeted sites of
cytosine deamination (Hendrich et al. 1999). The CpG dinucleotide is under-represented
in methylated genomes because of spontaneous hydrolytic deamination of methylated
cytosine which causes mCpGTpG transitions (Bird 1980). Because of the spontaneous
deamination, any non-methylated CpG can mutate to UpG. MBD4 has been shown to
excise and repair both mutated nucleotides. Because of this important repair function, it is
not surprising that mutations in MBD4 have been found in various human carcinomas
associated with microsatellite instability (Riccio et al. 1999). MBD4-null mice had a two
to three times higher number of mCpG-TpG transitions showing that MBD4 acts to
reduce the mCpG-TpG mutation rate (Millar et al. 2002). MBD4-null mice exhibited
mild phenotypic abnormalities. Importantly, when they were crossed with mice carrying
a germline mutation in the Apc (adenomatous polyposis coli) gene MBD4-null animals
show an accelerated tumor formation and accelerated tumor progression (Millar et al.
2002).

Kaiso (ZBTB33), ZBTB4, and ZBTB38
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Kaiso is a zinc finger domain protein that like the MBD family, can preferentially
bind methylated DNA (Prokhortchouk et al. 2001a; Filion et al. 2006). Kaiso appears to
have several important functions in lower vertebrates. Kaiso antisense knockdown in X.
laevis caused a premature activation of zygotic transcription which eventually led to
apoptosis and developmental arrest (Ruzov et al. 2004). This phenotype closely
resembled the one induced by the DNMT1 antisense depletion, suggesting that DNA
methylation-mediated repression mechanisms are partly responsible for repression of
embryonic transcription before the mid-blastula transition (Stancheva and Meehan
2000a). Unlike the experiments in X. laevis, Kaiso knockout in mice resulted in no
apparent abnormalities; however, when Kaiso-null mice were crossed with ApcMin/+
mice susceptible for intestinal tumorigenesis, it resulted in a delayed onset of tumor
formation (Prokhortchouk et al. 2006).

Structural predictions and patterns of MBD Occupancy of Methylated DNA
The molecular functions of methyl-CpG binding proteins depend on their recognition
and occupancy of methylated DNA. Differential binding properties are essential to their
roles in vivo. Deletion analyses identified a minimal region of MeCP2 responsible for the
interaction with methylated CpGs (Nan, Meehan, and Bird 1993). Further comparison
with other MBD proteins defined the MBD domain to a protein motif of about 75 amino
acids (Nan et al. 1998b). Since the classical MBD was described, proteins containing
MBD-like domain, including ESET/SETDB1 and TIP5, have also been identified in
different species (Clouaire and Stancheva 2008). However, these MBD-like domains are
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not predicted to form specific interactions with methylated DNA and likely serve other
functions.
Sequence comparison of all human MBD family proteins show the presence of 16
strictly conserved amino acids within the MBD domain. MBD3, which does not bind
preferentially to methylated DNA, lacks four of these conserved residues (Hendrich and
Bird 1998a). The structural information available so far does not explain why MBD4,
whose MBD domain is related to MeCP2 more than any other, would display an altered
DNA binding specificity (Hendrich et al. 1999).
About 70 – 80% of CpGs are methylated in mammalian genomes, creating a
relatively high number of potential binding sites for MBD proteins. It is not clear what
determines the pattern of occupancy at CpG sites, though several models have been
proposed (Clouaire and Stancheva 2008). One possible model would be that each MBD
protein randomly occupies any available methylated CpG site. In such a model, the
relative abundance of each MBD protein within a cell together with the methylation
density will dictate the occupancy of individual methylated sites. This random behavior
supports the idea of functional redundancy between MCBPs and was, until recently, the
principal argument to explain the relatively mild phenotypes of MBD1, MBD2 and Kaiso
null mice. This, however, does not appear to be the case at least in mice (Martin
Caballero et al. 2009). In a second model, other factors may influence the distribution of
MBD proteins within a cell nucleus, making it non-uniform and non-random, with each
MBD protein occupying unique sites in the genome. This “solo” model would predict
that a subset of genes might be affected by the loss of one MBD protein but not another.
Examples of genes misexpressed in the absence of specific MBD proteins have been
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identified, and the phenotypes of MBD-deficient mice, although subtle, are slightly
different (Hendrich and Bird 1998c; Martin Caballero et al. 2009).
It remains unclear which type of binding is retained in cancer cells, which tend to
accumulate aberrant DNA methylation patterns. If the various members of the MBD
family display different DNA binding specificity, this would infer that they recognize and
bind to more complex sequences than a single methylated CpG. In vitro experiments have
shown that, unlike MBD2, MeCP2 requires a run of four or more A/T base pairs adjacent
to methylated CpG for high affinity binding (Klose et al. 2005).

These findings

constitute the first example where the enhanced binding specificity towards a particular
set of methylated sequences allows discriminative binding site occupancy of an MBD
protein. Whether this is the case for other MBD proteins remains to be determined. As
discussed earlier, our data support a slightly modified “overlapping + solo” model, where
some genes are bound by MBD2 alone, while other methylated targets are either unbound
or occupied by different methyl-binding proteins, as has been suggested by others
(Lopez-Serra et al. 2006; Lopez-Serra et al. 2008b).
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Materials and Methods:
Cloning of mutant MBD2 expression constructs
A full length MBD2 clone was obtained from the IMAGE Consortium and the
coding sequence was subcloned into the pCDNA 4.0 plasmid using PCR amplification to
introduce restriction complementary ends and followed by ligation into a TA cloning
vector, amplification, BamH1-HindIII restriction product purification, and ligation. A V5
antigen coding oligonucleotide was cloned into the pCDNA 4.0 vector using an in frame
restriction site on the 3‟ side of MBD2 to generate a C-terminus tagged MBD2 protein.
Site directed mutagenesis was performed to generate shRNA a shRNA immune mutant
using the QuickChange II kit (Stratagene, La Jolla, CA). Oligonucleotides used for PCR,
V5 tag cloning and mutagenesis are given in Table 3.
Table 9. MBD2 Tagging, Cloning, and Mutagenesis Primers
5’ MBD2 Cloning PCR (BamHI)
3’ MBD2 Cloning PCR (EcoRI)
V5 – Sense Strand (EcoR1-XhoI)
V5 – Anti-sense Strand (EcoR1-XhoI)
shRNA B Target Sequence
Sense B-Mutagenesis Primer (TC)
Anti-Sense B-Mutagenesis Primer
shRNA C Target Sequence
Sense C-Mutagenesis Primer (T G)
Anti-Sense C-Mutagenesis Primer

GGATCCATGCGCGCGCACCCGGGGGGAGGC
GAATTCTTAGGCTTCATCTCCACTGTCCATTTCAA
TATCCATC
AATTCGGTAAGCCTATCCCTAACCCTCTCCTCGGT
CTCGATTCTACGTAAC
TCGAGTTACGTAGAATCGAGACCGAGGAGAGG
GTTAGGGATAGGCTTACCG
GGGTAAACCAGACTTGAAT
ATCAAAATAAGGGTAAACCAGACCTGAATACAA
CATTGCCAATTAGA
TCTAATTGGCAATGTTGTATTCAGGTCTGGTTTA
CCCTTATTTTGAT
GAACAGCCACGTCAGCTTT
ACAGCCACGTCAGCTGTTCTGGGAGAAGAGG
CCTCTTCTCCCAGAACAGCTGACGTGGCTGT

Table 9: MBD2 Tagging, Cloning, and Mutagenesis Primers used to restore shRNA immune and
tagged MBD2. Restriction complementary overhangs were included in all cloning
oligonucleotides for vector acceptance and ligation. Mutagenesis primers were designed using
Stratagene‟s QuickChange II web tools. Start and Stop codons (for frame reference) are indicated
in bold, as are the mutagenized bases.
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Bisulfite conversion
Bisulfite conversion reactions were performed as described previously by members
of the Ginder Lab (Rupon et al. 2006; Singal et al. 2002). Briefly, purified genomic
DNA was collected by stepwise detergent based lysis, alkaline protein precipitation, and
isopropanol precipitation (Aquapure Genomic DNA Isolation Kit, Bio-Rad Labs,
Hercules, CA). The 500ng to 1ug of gDNA was denatured and unmethylated cytosines
were hydrolytically deaminated to uracil in the presence of a sodium bisulfite conversion
reagent at 50 degrees C overnight (Methyl-Detector Kit, Active Motif, Carlsbad, CA).
Converted DNA was purified following an on-column desulfonation step.

Purified

converted DNA was stored at -20 deg C.

Bisulfite sequencing primer design and data analysis
Regions of interest were PCR amplified using methylation insensitive primers. These
primers were designed using the web based primer design tool, MethPrimer
(http://www.urogene.org/methprimer/index1.html).(Li and Dahiya 2002) Primers were
optimized to specifically amplify bisulfite converted DNA only. PCR thermal cycling
program was a modified touchdown PCR with an initial 20 cycles of progressively lower
annealing temperatures from 60 to 50 deg C (-0.5 deg C per cycle) and subsequently 25
more cycles of standard 3 step PCR with an annealing temperature of 45 deg C.

PCR

products were checked for appropriate size bands by gel electrophoresis and were
subsequently cloned (pGEM T-Easy kit, Promega, Madison, WI). At least 10 clones
from each converted sample were sequenced by fluorescent automated sequencing. The
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resulting sequence traces were analyzed for complete conversion as well as methylation
using

the

open

source

Java

BiQ

Analyzer

software

package

(http://biq-

analyzer.bioinf.mpi-sb.mpg.de/).(Bock et al. 2005) This software and the associated web
tools were used also to generate all „lollipop‟ style methylation diagrams.
Table 10. Bisulfite PCR Primers
DAPK1 Promoter Bis PCR F1
DAPK1 Promoter Bis PCR R1
DAPK1 Promoter Bis PCR F2
DAPK1 Promoter Bis PCR R2
MASPIN Promoter CpG island Bis PCR F1
MASPIN Promoter CpG island Bis PCR R1
MASPIN Exon2 CpG island Bis PCR F1
MASPIN Exon2 CpG island Bis PCR R1
MASPIN Exon4 CpG island Bis PCR F1
MASPIN Exon4 CpG island Bis PCR R1
KLK10 Promoter Bis PCR F1
KLK10 Promoter Bis PCR R1
KLK10 Promoter Bis PCR F2
KLK10 Promoter Bis PCR R2

TAGTTTAGTAATGTGTTATAGGTGGGG
AAAAAACAAAATCCCCRAC
TTTTTATTTATTTTTTAGTTGTGTTTT
CCTTAACCTTCCCAATTACTC
TTGTTAAGAGGTTTGAGTAGGAGAG
CCCACCTTACTTACCTAAAATCACA
TTTTATTATGTGGTTAGGTTGGTTT
TAATTACCCAACAAATCTCCAAATT
ATTTTAGTATTTTGGGAGGTTAAGG
TTTTTAAAACAAAATCTCACTCTATC
TTGAGAAAGAGGTTTTTATTGGTTT
CAAACACCCTTTTAACCTACAAC
ATATATTTTAGTAGATTTTGGTTATGAGAG
AAAAAAACCCAACTAACTTAAAAAC

Table 10: Bisulfite PCR primers designed using the MethPrimer tool. Sequences are given in the
5‟ to 3‟ direction for all oligonucleotides. Note the absence of “C” from any of the sense strand
primers indicating specificity for bisulfite converted DNA.

Chromatin Immunoprecipitation Assay
Chromatin Immunoprecipitation assays were performed to determine whether/where
MBD2 binds to its target genes and to map patterns of histone acetylation essentially as
described previously (Rupon et al. 2006; Kransdorf et al. 2006a). We used commercially
available ChIP grade antibodies (Upstate, Temecula, CA; Abcam, Cambridge, MA)
recognizing MBD2 and various post-translational histone modifications to map
MBD2/co-repressor mediated changes in chromatin architecture. Briefly, we crosslinked
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adherent cells in culture vessels (150mm dishes) using 1% formaldehyde in growth
medium for 10 minutes at room temperature. Formaldehyde was quenched with 125mM
glycine. We washed twice with 1X PBS and then collected cells by scraping into 1X
lysis media containing 1mM PMSF and CompleteTM Mini - protease inhibitor cocktail
tablets (Roche, Indianapolis, IN). Chromatin was subsequently sheared DNA (water bath
type sonicator, Diagenode, Sparta, NJ) according conditions optimized to produce
fragments between 200 and 500 base pairs. Precipitations were performed using sheared
chromatin from approximately 1x106 cells at 4 degrees C, overnight using 5g of
affinity purified ChIP grade anti-bodies. Positive control (anti-acetyl H3K9,14) and
negative (normal IgG) controls were included and probed with GAPDH primers. In our
experience, background and non-specific contamination was reduced by using magnetic
protein-G coated beads (Active Motif, Carlsbad, CA) to isolate immune-precipitates. We
then performed SYBR green based qRT-PCR to measure target sequence enrichment
(~200-500bp resolution promoter proximal CpG rich regions) in column purified,
immunoprecipitated DNA (Active Motif, Carlsbad, CA). Enrichment is reported as a
proportion of starting chromatin (input) under both specific (e.g., anti-MBD2, antiacH3K9, etc.) and non-specific (normal IgG) conditions.
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Results:
Tumor Suppressor CpG islands remain methylated after gene expression is
restored.
Though it is now widely accepted that CpG methylation varies inversely with
transcription, the primacy of either methylation or transcription at tumor suppressors in
cancer remains a matter of controversy. We recognized that our system provided a model
to investigate a temporal relationship between DNA methylation and changes in
transcription, specifically at the hypermethylated promoters of tumor suppressor genes in
breast cancer.

We used bisulfite sequencing to examine CpG methylation at the

promoters of the genes which became transcriptionally active following MBD2
knockdown both before and after transcription was restored. Based on conventional
wisdom regarding passive demethylation at actively transcribed genes, we hypothesized
methylation levels would be decreased following transcriptional activation. However,
there were no formal grounds on which to rule out the possibility that methylation levels
remained stable at genes induced by MBD2 knockdown. This experiment allowed us to
distinguish between these two possibilities by establishing the methylation state of
promoter proximal CpGs under both transcriptionally active and repressed conditions.
We found that methylation remained remarkably stable through large swings in
expression following MBD2 knockdown (Figure 36). At the promoter KLK10 and
DAPK1, which were heavily methylated in MCF-7 cells, there was virtually no change in
methylation levels. Similarly at the Maspin promoter in MDA-MB-231 cells, which was
relatively CpG sparse and significantly less methylated than the other genes examined,
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overall methylation levels were stable between stable Scramble and Knockdown cells
although methylation at single CpG sites varied.

MBD2 binds to Methylated CpG Island associated promoters and methylCpGbound MBD2 is decreased in shRNA knockdown cells.
We confirmed that MBD2 protein was bound directly at the promoter CpG islands of
methylated target genes, DAPK1 and KLK10, by Chromatin Immunoprecipitation in
control MCF-7 cells. When we used chromatin from MBD2 knockdown cells for ChIP,
we found significantly reduced enrichment of DAPK1 and KLK10 promoter DNA.
Recall that the methylation levels at the gene promoters remained unchanged in
knockdown cells; nonetheless there was significantly less MBD2 protein present in
knockdown cells and ChIP assays confirmed there was proportionately less MBD2 bound
at methylated loci (Figure 37). Taken together with the bisulfite sequencing and gene
expression data, we concluded that by reducing MBD2 bound at promoter associated
CpG islands in tumor cells we were essentially uncoupling CpG methylation from its
repressive effect on transcription.
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Figure 36. Bisulfite Sequencing Showed No Change in the Methylation of Activated
Genes in MBD2 Knockdown Cells

Maspin Promoter
Scramble shRNA

Maspin Promoter
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Scramble shRNA
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Figure 36. Bisulfite conversion and sequencing was performed to assess the degree of CpG
methylation at the promoters of (top to bottom) Maspin, KLK10, and DAPK1 in breast cancer
cell lines where these genes were found methylated at baseline and were transcriptionally
activated following MBD2 knockdown. Sequencing data was decoded using the BiQ analyzer
software package. Filled black circles represent methylated sites and empty (white) circles are
unmethylated sites. The relative position of CpGs is not illustrated, see Appendix C for maps of
promoter CpG distribution and bisulfite primer position. The bisulfite sequencing analysis shows
that no appreciable decrease in methylation occurs at promoter associated CpGs in MBD2
knockdown cells.
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Figure 37. Chromatin Immunoprecipitation shows MBD2 binds to target genes
DAPK1 and KLK10 directly
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Figure 37. Quantitative RT-PCR was used to probe anti-MBD2 or normal IgG control
immunoprecipitated chromatin (ChIP) from Scramble (SC) and shMBD2 knockdown (KD) MCF7 cells. Binding of MBD2 to DAPK1 and KLK10 promoters is evident in SC cells (SC MBD2);
this binding is reduced to background levels in KD cells (KD MBD2). There is no enrichment of
the actively transcribed GAPD promoter DNA by anti-MBD2. This control gene was included to
verify the absence of non-specific enrichment or genomic DNA contamination.
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Restoration of MBD2 expression in knockdown cells leads to resilencing of MBD2
dependent genes
Up to this point, we had not addressed an important limitation of the shRNA driven
knockdown methodology we were using. Though we attempted to control for the nonspecific effects of shRNA expression in our tumor cells by using a scrambled shRNA
which did not target any known gene, we could not account for the possibility that there
were sequence specific effects mediating gene expression and phenotypic differences
which did not depend on the loss of function of MBD2 protein. In other words, we had
not formally excluded the possibility that the observations we attributed to a reduction in
MBD2 protein were not the result of a non-specific response to anti-MBD2 shRNA (e.g.,
Interferon alpha/beta response). Furthermore, we could no longer entertain the notion
that MBD2 dependent changes relied on transcription associated demethylation of MBD2
repressed genes. We therefore dismissed the assumption that MBD2 knockdown was
initiating an irreversible „hit-and-run‟ effect on target gene expression.
It was important to establish that restoration of MBD2 led to the reversal of MBD2
dependent changes. Given this realization, and in order to nail down MBD2 as the sole
mediator of genotypic and phenotypic changes in breast cancer, we conducted a rescue
experiment. We hypothesized that restoring MBD2 protein in knockdown cells would reestablish tumor suppressor gene silencing and reverse knockdown dependent phenotypic
changes.
We obtained a full length MBD2 cDNA clone from the IMAGE consortium and
generated a shRNA immune expression construct by site directed mutagenesis.
Specifically, we introduced a single, silent (amino acid neutral) nucleotide substitution
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within the shRNA binding site of the MBD2 coding sequence. This allowed us to
express the normal MBD2 protein in our stable shRNA expressing breast cancer lines.
We added an N-terminal V5 epitope tag to our mutant MBD2 expression construct in
order to follow the in situ expression of the exogenously expressed protein.

We

confirmed expression of the mutant MBD2 protein and the specificity of the V5 epitope
tag in knockdown breast cancer cells by Western Blot analysis (Figure 38). We further
confirmed nuclear localization and gross DNA binding capacity of exogenous V5 tagged
MBD2 protein by fluorescent immunocytochemistry (Figure 39). We found that the
shRNA binding site mutant (pCMV-B mutant) was capable of restoring near endogenous
levels of MBD2 protein; wild type MBD2 (pCMV MBD2) and a second expression
construct with an off target mutation (pCMV-C mutant) were not expressed (Figure 38,
top).
As hypothesized, we found that restored MBD2 expression in stable knockdown
lines led to resuppression of target gene expression (Figure 38, bottom), consistent with
our earlier observation that promoter methylation remained stable despite transcriptional
activation.
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Figure 38. Expression of shMBD2-B mutant cDNA is able to restore MBD2
expression in a stably knocked down cell line.
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Figure 38. Western blot analysis shows expression of MBD2 shRNA (-MBD2) binding site
mutant in stably knocked down MCF-7 cells. Expression of a double mutant used for functional
analysis and a V5 epitope tagged mutant MBD2 is shown as well. Blotting with an anti-V5
antibody demonstrates specificity of this antibody for the tagged MBD2 only (far right bands).
Note the slightly decreased mobility in the tagged MBD2 indicating the small increase in
molecular weight conferred by the V5 tag. Also note the absence of detectable MBD2 in this
knockdown line with transfection of a pCDNA vector only control only (Far left, absent bands).
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Figure 39. Immunocytochemsitry shows nuclear localization and DNA binding of
Exogenous V5-Tagged MBD2 in MCF-7 Cells
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Figure 39. Anti-V5-FITC fluorescent immunocytochemistry against untagged (3 images on the
left) and V5 Tagged (right) MBD2 demonstrates the specificity of anti-V5 to recognize the tagged
MBD2 only. Exogenous MBD2 localizes to the nucleus (DAPI) and retains the ability to bind
DNA in mitotic forms (white arrowheads).
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Figure 40. MBD2 Rescue with Exogenous shRNA Binding Site Mutant cDNA
Expression Construct Leads to Resilencing of MBD2 target genes.
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Figure 40. Westen blot analysis of MBD2-B shRNA expression in Scramble and Knockdown
cells demonstrates the ability to restore endogenous levels of MBD2 in stably knocked down
cells. Expression of wild type MBD2 and an MBD2-C mutant is not observed to the same degree
demonstrating the specificity of stable shMBD2 B expression. Below, a heat map of gene
expression measuring mRNA levels of all MBD2 target genes in MCF-7 demonstrates that rescue
with an MBD-B expression construct leads to resuppression of MBD2 target gene, suggesting
that these genes remain methylated and poised for resuppression in the presence of adequate
levels of MBD2.
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MBD2 down regulates DNMT1
We were interested in the relationship between the epigenetic factors which establish
and maintain tumor suppressor silencing in breast cancer. CpG methylation in normal
and neoplastic cells depends on the activity of the DNA Methyltransferase enzymes
(Klose and Bird 2006). We hypothesized that breast cancer cells would attempt to
maintain pathological silencing of tumor suppressor genes by promoter hypermethylation
due to a survival advantage and might therefore implement or select for compensatory
mechanisms such as upregulation of DNMT1. We examined the feedback regulation of
the DNA methyltransferase, DNMT1, in MBD2 knockdown cells by western blot. We
found that the levels of DNMT1 protein were increased in breast cancer cells that stably
expressed anti MBD2 shRNA (Figure 41). A mechanistic link between MBD2 levels and
DNMT1 remains to be established, however, we envisage a sensor mechanism exists in
tumor cells which upregulates the DNA methyltransferase machinery in order to preserve
the abnormal promoter hypermethylation on which these cells depend for unchecked
proliferation. Such a sensor mechanism may be important for intrinsic or acquired
resistance to anti MBD2 therapy in breast cancer.
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Figure 41. MBD2 knockdown increases DNMT1 protein
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Figure 41. (Above) A preliminary Western blot with antibodies directed against MBD2 and
DNMT1 protein and corresponding densitometry analysis shows an increase of approximately 3
fold in DNMT1 levels in MBD2 knockdown MCF-7 cells compared to scramble controls. This
increase is present, though somewhat less pronounced, in MDA-MB-468 cells as well. (Below)
Scramble control normalized densitometry of the western blot shown above demonstrates a >90%
knockdown of MBD2 protein in both MCF-7 and MDA-MB-468. A corresponding increase of 3
fold in DNMT1 protein was observed in MCF-7 knockdown cells and 1.5 fold in MDA-MB-468.
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MBD2 post transcriptionally down regulates MeCP2 and the two proteins cooperate
in promoting tumor viability.
MBD2 has been shown to bind certain tumor suppressor promoters in combination
with other MBD proteins. MeCP2 in particular is commonly found along with MBD2
bound to methylated tumor suppressors (Lopez-Serra et al. 2006). In addition, MeCP2
was found to be expressed at higher than normal levels in human breast cancers,
suggesting this protein may be playing an exacerbating role (Billard et al. 2002; Muller et
al. 2003). We were interested in determining whether MBD2 and MeCP2 were playing
complementary roles in breast cancer. We considered the possibility that MeCP2 was
compensating for MBD2 knockdown and perhaps there was a mechanism to increase
MeCP2 levels in MBD2 knockdown cells.

We also sought to determine whether

knocking MeCP2 and MBD2 down simultaneously, would more effectively inhibit tumor
cells than knocking either one down alone.
We evaluated changes in MeCP2 protein levels in stable MBD2 knockdown cells
and MBD2 overexpressing cells by western blot analysis. We found that MeCP2 protein
was increased by approximately 3 fold over baseline in MBD2 knockdown cells (Figure
42). Interestingly, MeCP2 levels remained relatively stable when we overexpressed
MBD2. This suggested to us that the feedback inhibition of MBD2 protein was being
mediated indirectly through an MBD2 repressed target. In this scenario, normal levels of
MBD2 are sufficient to maintain complete silencing of the intermediate factor and
overexpression therefore has minimal effect.
We were interested in determining whether a combined knockdown of MBD2 and
MeCP2 would lead to an increased effect in breast cancer. We used transient transfection
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of either MBD2, MeCP2, or both siRNAs into several breast cancer cell lines (MDAMB-231, MDA-MB-468, and SK-BR-3 cells and confirmed individual and combined
knockdown by quantitative real time PCR (Figure 43). We then examined the acute
cytotoxicity of siRNA transformation by measuring cell death and apoptosis
quantitatively using Annexin V/PI flow cytometry. MCF-7 cells were included in the
apoptosis study as well but these cells showed very little baseline or induced annexin V
positivity.

We found that MBD2 or MeCP2 knockdown alone led to an increased

proportion of apoptotic cells (Figure 44).

Furthermore, we found that combined

knockdown of both genes led to an additive increase in apoptotic cells in 2 out of 3 cell
lines. SK-BR-3 cells did not show an additive effect, however this might be explained by
the relatively poor MBD2 knockdown achieved in the double transfected cells. (Figure
43 and 44)
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Figure 42. MBD2 Knockdown up regulates MeCP2 Protein
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Figure 42. A preliminary Western Blot analysis of MBD2 and MeCP2 protein levels in MBD2
knockdown and overexpression demonstrates 2.8 fold increase in the level of MeCP2 protein in
knockdown cells. MeCP2 levels remain relatively unaffected by overexpression of MBD2
suggesting an indirect mechanism of feedback through an unidentified MBD2 target gene which
is fully silenced with normal levels (or overexpression) of MBD2.
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Figure 43. Simultaneous siRNA mediated Knockdown of MBD2 and MeCP2
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Figure 43. qRT-PCR to confirm knockdown of MBD2 and MeCP2 mRNA in siRNA transfected
tumor cells lines at 72hrs post transfection. All siRNA knockdowns were performed using cells at
approximately 80% confluence in a 24 well tissue culture plate. Each transfection was performed
using 20 pico moles of total siRNA (Qiagen) and 1 ul of Lipofectamine 2000 transfection reagent
(Invitrogen) diluted in Opti-MEM serum free media (Gibco). Bars represent cyclophilin
nomalized mean and standard deviation from 3 qRT-PCR replicates for each transfection.
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Figure 44. Annexin V PI Flow Cytometry for Measuring Apoptosis
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Figure 44. Annexin V-FITC and Propidium Iodide (PI) staining was performed to measure
apoptotic and necrotic cells, respectively, in siNeg (control siRNA), siMBD2, siMeCP2 KD and
both siMBD2 and siMBD2 combined. The populations were counted by flow cytometry
(representative flow cytometer scatter plot, above) and results are reported as percent apoptotic
cells (below). These results represent a single FACS experiment, therefore no error bars are
included.
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Discussion

DNA methylation remains stable through changes in transcription
It is widely accepted that an inverse correlation exists between DNA methylation at
promoter proximal CpG sites and transcriptional activity. However recent genome wide
studies cast this association in less absolute terms than previously believed. In particular,
the high resolution bisulfite mapping of methylation and transcription across 3 human
chromosomes has shown that certain promoters are differentially methylated in
ontologically distinct populations; however, DNA methylation was found to be
independent of transcriptional state at as many as two thirds of these genes (Eckhardt et
al. 2006). With regard to the pathological methylation of CpG islands in cancer, an
association between methylation and transcription is more firmly established;
methylation in this particular circumstance is strongly correlated with transcriptional
inactivity (Jones and Baylin 2007; Jones and Baylin 2002; Brock, Herman, and Baylin
2007). However the degree to which this methylation depends on transcription has yet to
be characterized. In addition, the plasticity of promoter methylation at hypermethylated
CpG islands in cancer remains a matter of some speculation.
We have identified a cluster of MBD2 dependent genes whose transcriptional state
can be digitally switched by the presence or absence of MBD2. We recognized that these
genes provide a model for studying the stability of CpG island hypermethylation and the
temporal relationship between transcription and methylation. We began by examining
the basal methylation state of several candidate MBD2 dependent genes: Maspin,
KLK10, and DAPK1 in MCF-7 cells. We found that KLK10 and DAPK1, which have
large CpG islands were heavily methylated. Maspin, which has a relatively smaller non152

canonical CpG island, surprisingly was unmethylated in MCF-7 cells where this gene is
robustly induced by MBD2 knockdown.

This raised our suspicion that the effect of

MBD2 knockdown on Maspin expression might be indirect. In MDA-MB-231 cells the
Maspin promoter was found to be methylated, in contrast to MCF-7 cells. Nevertheless,
we noted that methylation at Maspin promoter‟s CpG rich region did not occur to the
same degree as found at the canonical CpG islands of DAPK1 or KLK10.

This

observation is consistent with checkered reports regarding Maspin‟s somewhat atypical
methylation dependent regulation in breast cancer (Futscher et al. 2002a; Wozniak et al.
2007; Domann et al. 2000).
In order to measure the covariation of methylation and transcription, we examined
CpG methylation in stably knocked down MBD2 breast cancer cells where expression of
corresponding genes was significantly induced. We found that, despite robust increases
in transcription, there were no appreciable changes in the promoter methylation at every
gene we examined. Several inferences can be drawn from these observations which
deserve mention here. First, these data cast doubt on the idea that passive demethylation
invariably occurs at transcribed loci due competition between the transcriptional
machinery, DNA binding proteins, and methyltransferases (Hsieh 1999). Furthermore, it
suggests that methylation in and of itself is not the prime impediment to transcription of
hypermethylated tumor suppressor genes. It implies instead that, as we hypothesized,
recruitment of MBD2 to particular hypermethylated promoters is essential for the
maintenance of their transcriptional inactivity. Put another way, MBD2 is essential for
coupling hypermethylation to transcriptional inhibition, presumably through its role in
directing local changes in chromatin, e.g., histone modifications such as histone
153

deacetylation or other repressive mechanisms. As discussed below, we go on to reinforce
this idea by verifying that MBD2 is bound directly to methylated promoters and showing
that restoration of MBD2 in knockdown cells is sufficient to re-silence these and other
MBD2 dependent genes.

MBD2 acts directly at methylated promoters to affect changes in tumor suppressor
gene expression
We had found that MBD2 was required for target gene repression in breast cancer
cells. However we had not experimentally shown that this gene repression was directly
mediated by the binding of MBD2 to the promoter proximal methylated CpG islands of
tumor suppressor genes. In order to confirm that MBD2 was acting through the accepted
mechanism, i.e., binding to promoter proximal methylCpG, we performed chromatin
immunoprecipitations with antibodies directed against MBD2 and used quantitative PCR
to probe for enrichment of tumor suppressor gene associated chromatin from MCF-7
cells.
We found that MBD2 was indeed bound to the CpG rich promoters of DAPK1 and
KLK10 in MCF-7. We did not see enrichment of Maspin promoter DNA by ChIP, once
again suggesting the MBD2 was not acting directly, at least not at the promoter, to induce
transcription of this gene. At least one other report indicates that the epigenetic silencing
of Maspin, and its reactivation by 5-aza-dC, are not dependent on promoter associated
methylation, leaving lingering questions as to the mechanism of epigenetic silencing of
this tumor suppressor in breast cancer (Wozniak et al. 2007).
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Our results indicate that MBD2 binding is dependent on the presence of extended
stretches of methylated CpGs, such as those found at the promoters of DAPK1 and
KLK10 in MCF-7 cells. The affinity of MBD2 for even a few methylated CpGs is well
established and argues against a requirement for long stretches of methylation for binding
(Fraga et al. 2003; Lopez-Serra et al. 2008b). However, it stands to reason that fewer
MBD2 molecules are able to bind a region with fewer CpG sites.

Moreover, an

equilibrium between bound and unbound MBD2 likely exists and would be shifted
depending on the relative proximity of methylation sites. Therefore we consider it
possible that the relatively low sensitivity of ChIP precludes the detection of MBD2
resident at partially methylated, CpG sparse promoters such as the one found at the
Maspin gene. The sensitivity of ChIP is largely determined by several factors which may
be working against us: the affinity and specificity of the ChIP antibody and the
accessibility of the epitope being recognized. Regarding the latter, it has been shown that
MBD2 has multiple interaction partners in the Mi2/NuRD complex which may be
limiting access to MBD2 and reducing the efficiency of immunoprecipitation. It is
interesting to speculate whether the specific NuRD components in this modular complex
vary from promoter to promoter in a given cell and perhaps lead to differential ChIP
sensitivity. For instance, the MBD2 containing corepressor complex at CpG sparse
promoters may in fact be fundamentally different from the one resident at CpG rich
promoters leading to variation in antibody recognition.
Despite the notable exception of Maspin, taken as a whole our data suggests that
MBD2 functions by directly binding to CpG rich and heavily methylated tumor
suppressor promoters and maintains transcriptional silencing. Because we found that
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transcription was restored while promoter methylation remained intact, we inferred that
MBD2 was indeed an essential link between methylation and transcriptional suppression
at specific tumor suppressor genes in breast cancer.

Transiently restored expression of MBD2 leads to resuppression of target genes
In order to establish that MBD2 is both necessary and sufficient to suppress
transcription of methylated target genes, and given that methylation was stabley
maintained, we reasoned that restoring MBD2 in knockdown cells would re-establish
transcriptional silencing. In order to restore functional levels of MBD2 protein in cells
constitutively expressing anti-MBD2 shRNA, we needed to introduce a silent point
mutation within the shRNA binding site of the expressed mRNA. We found we were
able to transiently express the MBD2 B mutant message and generate significant levels of
MBD2 protein in stable knockdown MCF-7 cells. By incorporating a co-translated V5
affinity tag, we were able to trace the expression and localization of exogenous protein;
we verified that it targeted to the nucleus and further confirmed tight colocalization with
heterochromatic mitotic forms.
We examined the expression levels of MBD2 regulated genes in knockdown and
scramble control cells following restoration of MBD2 protein and found that the
expression of these genes was silenced within 72 hours of transfection with the shRNA
immune MBD2 construct. This finding confirmed the primary importance of MBD2 in
maintaining the transcriptional repression of specific target genes. It further indicates
that all associated elements required for the epigenetic silencing of MBD2 dependent
genes remain intact and poised to resuppress transcription in the presence of MBD2.
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The observation that restored MBD2 leads to restored silencing has dual mechanistic
and clinical implications. First, these data provide indirect confirmation that methylation
remains stable at other tumor suppressor genes despite increases in transcription in
MBD2 knockdown cells. In providing this confirmation, we can discount the possibility
that MBD2 knockdown induced expression changes are due to a „hit and run‟
phenomenon at these loci. In other words, MBD2 knockdown is probably not inducing a
persistent and irreversible change in site specific patterns of gene expression.
Nevertheless, we can not rule out the possibility that irreversible changes are occurring at
other sites and whether or not MBD2 knockdown induces some form of epigenetic
reprogramming in breast cancer remains to be determined.
Finally, it appears for the moment as though any future clinical strategy aimed at
inhibition of MBD2 in breast cancer will have to follow a long term treatment model in
order to prevent the reversal of MBD2 induced expression changes.

However, an

indefinite treatment strategy is not necessarily indicated, with the notable exception of a
preventative approach for high risk patients. A potent short term MBD2 dependent
cytostatic effect may be sufficient to shift the balance between tumor growth and immune
clearance or combinatorial killing, thereby achieving the therapeutic goal of tumor cell
eradication.

MBD2 knockdown upregulates DNMT1 protein
Upon observing that DNA methylation at MBD2 knockdown induced genes
remained methylated, we were intrigued by the possibility that tumor cells may activate
compensatory mechanisms to maintain methylation and methylation dependent gene
silencing. Such compensatory mechanisms would obviously benefit cancer cells which
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depend on the inactivation of tumor suppressor genes for survival and proliferation.
However we considered the possibility that such compensation might originate as benign
feedback regulation intended to maintain methylation directed patterns of expression, for
example during normal development and differentiation. We grew interested in DNMT1
in particular because of several reports linking it to methyl binding domain proteins,
including MBD2, and chromatin modifying enzymes (Kimura and Shiota 2003; Fuks et
al. 2003; Tatematsu, Yamazaki, and Ishikawa 2000).
We examined the levels of DNMT1 protein in control and MBD2 knockdown breast
cancer cells by immunoblot and found that DNMT1 protein was increased following
depletion of MBD2. DNMT1 levels increased by approximately 3 fold and 1.5 fold in
MCF-7 and MDA-MB-468 MBD2 knockdown cells, respectively. At the time of this
writing, we do not know the mechanism of increased DNMT1 in MBD2 knockdowns;
moreover, we currently do not know whether the observed increase in DNMT1 has
functional significance.

Nonetheless, the observation is intriguing and raises the

possibility that a feedback mechanism exists to maintain methylation directed gene
silencing. Such a mechanism might be present in breast cancer cells alone, in other types
of cancer, or perhaps more generally in normal cells.
While there may be a direct interaction underlying the observed relationship between
MBD2 and DNMT1, we consider it more likely that DNMT1 is being induced indirectly
by a methylated MBD2 dependent gene. Such a gene might be acting as a sensor for
methylation directed silencing; a sort of methylation sensitive thermostat to keep
methylation levels within an ideal window. According to this model, changes in the
levels of this MBD2 regulated „thermostat‟ gene would signal the methyltransferase
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machinery to make compensatory changes in global DNA methylation, either increases in
maintenance methylation or passive decreases, as required. It stands to reason that such a
regulatory mechanism would benefit cells by preventing the depletion or pathologic
accumulation of DNA methylation, both of which are known to be detrimental (Li,
Bestor, and Jaenisch 1992a; Roll et al. 2008; Schmidt et al. 2007).

MBD2 knockdown post transcriptionally upregulates MeCP2 protein
Having observed an increase in the levels of DNMT1 in MBD2 knockdown cells, we
grew interested in the effect of MBD2 knockdown on other functionally related proteins.
In particular we were interested in MeCP2, a protein known to bind numerous methylated
tumor suppressors, often simultaneously with MBD2 (Lopez-Serra et al. 2008a; LopezSerra et al. 2006).

Because MeCP2 shares significant tumor suppressor silencing

function with MBD2, we were alert to the possibility that compensatory increases in
MeCP2 may be sufficient to suppress the cytotoxicity and tumor suppressor gene derepression brought on by MBD2 knockdown.
We measured the expression and protein levels of MeCP2 in MBD2 knockdown
MCF-7 cells and found that transcription of MeCP2, which itself has a large promoter
associated CpG island, was not being induced. However, MeCP2 protein levels were
increased by approximately 3 fold over controls in MBD2 knockdown cells. In addition,
MeCP2 protein levels remained at background levels with overexpression of MBD2.
Considered together, these observations imply that that MeCP2 protein is somehow
post-transcriptionally stabilized by MBD2 knockdown.

Because there is was no

significant increase in MeCP2 mRNA in MBD2 knockdown cells, it seems unlikely that
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MBD2 represses MeCP2 transcription, either directly or indirectly through a secondary
target gene. We cannot entirely rule out the possibility that a small increase in MeCP2
mRNA, below the dynamic range of our qPCR assay (approximately 2 fold), could be
mediating a 3 fold increase in MeCP2 protein levels.
An immediate implication of the finding that MeCP2 protein is increased in MBD2
knockdown cells is the possibility that MeCP2 is compensating for reduced levels of
MBD2 and maintaining transcriptional silence of at least those target tumor suppressors
that are jointly bound by both MBDs. Given this possibility, we decided to investigate
whether simultaneous knockdown of both proteins would lead to an enhanced cytotoxic
effect in breast cancer.

Simultaneous knockdown of MBD2 and MeCP2 leads to an increase in apoptosis
In order to investigate whether MBD2 and MeCP2 act cooperatively to maintain
inappropriate survival of breast cancer cells, we needed to knock both proteins down
simultaneously. The most efficient method for the simultaneous knockdown of both
genes was the use of siRNA, which in our hands provided the highest co-transfection
efficiencies (>95%) when compared to plasmid transfection or lentivirus infection
methods. Furthermore, we did not have the ability to segregate coinfected cells with
lentivirus; shMBD2 + shMeCP2 infected cells as well as single virus transduced cells are
GFP positive and FACS based sorting would not distinguish between the two.

In

addition, we made the choice to avoid an extended selection strategy such as that required
for double antibiotic based MBD2+MeCP2 knockdown plasmid selection. As discussed
previously, this approach had the significant disadvantage of selective purification over
time of a population resistant to growth restriction and was therefore not suitable for
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studying acute cytotoxicity. We do however concede that siRNA has its own limitations
including some acute non-specific transfection-associated toxicity (which we controlled
for using negative control siRNA) as well as transient knockdown.
We screened four breast cancer cell lines transfected with either MBD2 or MeCP2
targeted siRNA, or both together.

Importantly, all transfections including negative

control siRNA were conducted with equal amounts of siRNA to account for differences
in toxicity associated with absolute amounts of exogenous double stranded RNA. We
verified that these strategies provided adequate knockdown of target mRNA by
quantitative PCR. Because the effects of transient siRNA transfection are inherently
short lived, we screened for changes in acute toxicity using a hightly quantitative FACS
based apoptosis assay.
We found that either MBD2 or MeCP2 knockdown alone led to increased apoptosis
in 3 out of 4 cell lines tested. Moreover, we found that knocking both out simultaneously
led to increased apoptosis in 2 out of 4 cell lines, i.e., 2 out of 3 sensitive lines. MCF-7
cells showed very little basal apoptosis by Annexin V positivity and no increase with any
siRNA. This is not altogether surprising given a well described apoptotic pathway defect
in these cells, specifically the absence of caspase 3. Furthermore, we can rationalize the
absence of increased apoptosis in siMBD+siMeCP2 transfected SK-BR-3 cells based on
the poor double knockdown achieved in this particular cell line. Interestingly, we found
that all three sensitive cell lines were more responsive to MeCP2 than to MBD2
knockdown with respect to acute apoptotic cell death. It is worthwhile to note that,
unlike MBD2, loss of MeCP2 function is not benign with respect to human development
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and disease, though a post developmental requirement for MeCP2 has not been
demonstrated.
In summary, our results strongly suggest that MBD2 and MeCP2 act cooperatively to
maintain the growth of breast cancer cells. It remains to be determined if long-term,
stable knockdown of both proteins simultaneously is capable of producing a more
significant anti-tumor effect. We conclude that a combination of MeCP2 induced acute
toxicity with MBD2 induced long term cytostasis may provide the maximal benefit to
future breast cancer patients who are treated with methyl binding domain protein
targeting agents.
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Chapter IV: Summary and Perspectives

MBD2 inhibition as an epigenetic therapy in breast cancer
Breast cancer, like many malignancies, collects epigenetic abnormalities during
progression from normal epithelium to frank carcinoma. An important, common, and
early change in breast cancer is hypermethylation of tumor suppressor gene associated
CpG islands. The origin of abnormal methylation in cancer is not completely understood,
but two principal mechanisms are thought to be involved.

The first is targeted

methylation of specific genes by intrinsic dysfunction or irregular recruitment of de novo
DNA methyltransferases (Linhart et al. 2007). The second and probably more common
mechanism is global dysregulation of the epigenetic machinery in malignant and
premalignant cells. This dysregulation leads to widespread methylation changes which
occur at random and are enriched over time for those adaptations which promote survival,
growth, metastases, or resistance to therapy (Jones and Baylin 2007; Widschwendter and
Jones 2002).
The stochastic appearance of abnormal methylation in malignancy has been an
obstacle to the utility and reliability of epigenetic therapies. Not all methylation is
undesirable and therapies incapable of discriminating between normal and pathologic
changes are inherently unpredictable.

A more targeted approach for reactivating

transcription that is specific, effective, and safe in non-neoplastic tissues is necessary.
Methyl DNA Binding Domain (MBD) proteins are recruited to specific sites of CpG
methylation and lead to local transcriptional inhibition. Inhibiting MBD proteins may
provide an alternate, targeted approach for reactivating epigenetically silenced tumor
suppressor genes in cancer. However, the role of MBDs in tumorigenesis must be better
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characterized to validate their potential as therapeutic targets. We recognized this as an
opportunity and initiated a series of studies to examine the function of MBD2 in breast
cancer.
An important factor in choosing to study MBD2 was the knowledge that this protein
is not required for normal mammalian development or for the viability of normal
differentiated epithelial tissue. In addition, previous studies indicated that MBD2 bound
a large number of methylated tumor suppressor CpG islands in tumor cells.

We

hypothesized, therefore, that inhibition of MBD2 was a viable strategy for selectively
targeting tumor cells. We used double stranded shRNA mediated knockdown of MBD2
to study the function of this protein and found that depletion of MBD2 from breast cancer
cells led to changes consistent with the hypothesis that breast cancer cells grow
dependent on this protein. An integrated overview of our findings, a discussion of their
consequences, and opportunities for further study are presented below.

Breast cancer depends on MBD2 for maximal growth
We found that MBD2 knockdown produced a variable and at times profound growth
inhibition in human breast cancer cell lines in culture.

In addition, the ability of

aggressive breast cancer cell lines to form tumors in nude mice was significantly
impaired by MBD2 knockdown. We made several correlative observations regarding the
nature of MBD2‟s effects on growth rate. First, the antiprolifereative effects required a
significant depletion of MBD2 (~80%) before becoming apparent, suggesting MBD2
mediated growth is not strictly speaking a dose dependent type of response.

This

observation implied that MBD2 is present in sufficient excess to adequately perform its
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functions even at less than half of its baseline concentration in breast cancer cells. While
it explains why MBD2 is not commonly found overexpressed in primary breast cancers,
this observation conflicts with the finding of Sansom, Bird and colleagues who showed
that knocking out a single allele of MBD2 reduced adenoma burden in ApcMin mice
(Sansom et al. 2003a). We submit that one reason for this conflict may be somewhat
higher basal levels of MBD2 in cultured breast cancer cell lines than in normal epithelial
cells. In addition, the upregulation of DNMT1 and MeCP2 we have described implies
that compensatory mechanisms must be overcome in order to produce observable
changes. Further studies are required to determine the existence of a dose dependent
relationship between MBD2 and the phenotype of breast cancer, for example in future
pharmacokinetics and pharmacodynamics type studies of MBD2.
We also found that variation existed between cell lines with respect to the degree of
growth suppression produced by MBD2 knockdown. These variations were substantiated
by differences in patterns of CpG island methylation between cell lines as well as
differences in the spectrum of gene expression changes observed in MBD2 knockdown
lines. Undoubtedly the full spectrum of phenotypic changes in a given cell line depends
not only on the function of MBD2 but on the variable methylation, differential expression
of other epigenetic modifiers and on genetic lesions that fundamentally cripple certain
pathways (e.g., cell cycle arrest and apoptosis). The influence of such factors can not be
underestimated and taken together with variability in MBD2 dependent response we
conclude that a certain subset of tumors will ultimately be more susceptible to MBD
inhibitors than others. The dependence of MBD2 induced growth inhibition on patterns
of methylation, particular biochemical pathways, or specific modifying factors in breast
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cancer must be more thoroughly characterized so that we may rationally predict which
tumors will respond best to MBD2 inhibition in patients.

Rapid and Sustained depletion of MBD2 is necessary to inhibit growth
A significant observation regarding the conditions required to reproducibly inhibit
the growth of breast cancer was that a rapid and persistent MBD2 knockdown was
required. When we used transient double stranded siRNA oligonucleotides we achieved
a rapid knockdown, however the depletion of MBD2 was short lived. We found that
MBD2 knockdown by this method induced a slight increased acute toxicity; a relatively
minor in increase in apoptosis was found in MBD2 knockdown cells, which we later
found was augmented by simultaneous knockdown of MeCP2.

On the other hand,

persistent knockdown by antibiotic selection similarly failed to demonstrate significant
growth inhibition. In this latter case, we surmised that during the extended period of
selection and regrowth, we were losing the growth inhibited population and enriching for
cells which at some low frequency were escaping MBD2 knockdown induced cytostasis.
Consistent with this theory was our observation that stable clones were either more
difficult (MDA-MB-231) or not possible to isolate (MDA-MB-435 and SK-BR-3) while
stable Scramble shRNA transformants regrew at higher frequencies.
A lentivirus based shRNA transduction proved to be the ideal method for measuring
the growth restriction imposed by MBD2. While a robust MBD2 knockdown was found
within days of infection the growth inhibition took somewhat longer to fully materialize.
We found that the maximum effect on growth occurred only after FACS purification of
transduced cells and took between 2 and 3 weeks to develop.
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We reasoned that

derepression of downstream effectors and their subsequent cytostatic effects might
require this period to reach peak activity.
It is interesting to speculate whether a gradual epigenetic reprogramming is
occurring in MBD2 knockdown tumor cells, following a delayed onset model analogous
to the reprogramming of iPS cells. Our bisufite sequencing data suggest that if such a
mechanism is in use, it does not rely on the rewrtiting of CpG methylation at tumor
suppressor promoters. However, the availability and cost of global epigenetic profiling
methods is becoming increasingly permissive; looking ahead it will be interesting to
make use of such strategies to examine the broad spectrum epigenetic variation in MBD2
knockdown tumor cells.
We also considered the possibility that an autocrine/paracrine feedback system was
being disrupted by MBD2 knockdown. Tumor cells often secrete growth factors into
their environment that promote their own growth as well as the growth of adjacent cells.
If such a pathway was disrupted, then FACS based purification of knockdown cells may
be a strict requirement for growth disruption. Recall that maximal growth inhibition
occurred shortly after FACS purification, as detailed in our methods and discussed above.
Importantly, our animal studies suggest that if autocrine/paracrine factors are being
eliminated from the media of MBD2 knockdown cells in vitro, a suitable replacement is
not supplied by the stromal environment in animals. Future studies aimed at correlating
population purity with growth and using control cell conditioned media in rescue
experiments will demonstrate whether such a mechanism is in fact at work.
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MBD2’s role in disrupting epithelial morphology and differentiation
We found that MBD2 knockdown resulted in distinct changes in morphology of
breast cancer cells, which began to more closely resemble their normal counterparts in
culture. MCF-7 knockdown clones also demonstrated a change in 3D morphology more
reminiscent of normal epithelial tissue architecture.

Addressing this observation

alongside the growth inhibition which occurs in the same breast cancer cells, we contend
that changes in morphology and proliferation are likely to be fundamentally related. It is
conceivable that the net function of MBD2 knockdown is to restore elements of normal
epithelial differentiation in high grade mammary derived tumors. Put another way,
MBD2 is functioning in tumors to maintain an abnormally dedifferentiated state,
essentially as we hypothesized. Consistent with this assertion is the acknowledged role
of DNA methylation in tissue specific gene expression patterning during development
(Suzuki and Bird 2008; Eckhardt et al. 2006). This normal pattern of expression is
fundamentally dysregulated in tumors in large part through epigenetic modifications. We
conclude that MBD2 knockdown functions to reverse elements of this epigenetic
dysregulation and leads to redifferentiation of breast cancer cells towards a more normal
state.
The attention of the breast cancer research community of late has hovered around
several themes which converge here. This convergence can be distilled to the following
three specific topics: the role of cancer stem cells, the tumor stromal microenvironment,
and the epithelial to mesenchymal transition; each of these topics has been extensively
reviewed elsewhere (Thiery et al. 2009; Weigelt and Bissell 2008; Gupta, Chaffer, and
Weinberg 2009; Polyak and Weinberg 2009). With respect to our work, the proportion of
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mamospheres (i.e., ordered acinar forms in 3D culture) has been associated with the
presence of so called cancer stem cells. Similarly, 2D and 3D morphology changes such
as the ones we have described have been associated with altered tumor-stromal
interactions and pathological epithelial to mesenchymal transition in breast cancer. These
phenomena have significant clinical implications and our observations, while still
rudimentary, suggest that MBD2 may be playing a central role in mediating pathologic
shifts in tumor composition and environment.

Further studies aimed at integrating

MBD2‟s role in maintaining a population of cancer stem cells, in mediating tumor
stromal interactions and in maintaining pathologic EMT in breast cancer are needed.

MBD2 as a component of a combinatorial treatment strategy
Our studies to date have not uncovered a combined treatment approach that
demonstrates bona fide synergy with MBD2 knockdown.

We have tested several

compounds covering the drug classes commonly used as first line chemotherapy in breast
cancer.

They included a nitrogen mustard derivative (cyclophosphamide, Cytoxan),

anthracyclines (Doxorubicin) and taxanes (Paclitaxel). We have also tested the HDAC
inhibitor, Vorinostat, and a platinum compound, Cisplatin. We found that the effect of
MBD2 knockdown and the individual chemotherapies remained largely independent of
each other, i.e., they were neither supra-additive nor did they annul one another. The
consequences of this observation are multiple including the prospect that MBD2 may not
function as a sensitizer in the strictest sense but may be an effective adjunct treatment.
Of pressing importance is the outstanding need to determine the effects of MBD2 on
normal tissues, for example normal epithelium and bone marrow.
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Such normal

mitotically active tissues are the well known sites of off target toxicities that limit the
effectiveness of most chemotherapy. There is good reason to believe MBD2 inhibition
will not affect normal tissues, as discussed extensively throughout this dissertation and
elsewhere (Sansom, Maddison, and Clarke 2007b; Klose and Bird 2006; Berger and Bird
2005a; Martin Caballero et al. 2009; Sansom et al. 2005). However, ongoing and future
studies must experimentally demonstrate the innocuous nature of MBD2 targeting
strategies in normal human tissues, including primary epithelial cells and the
lymphoid/myeloid compartment. Furthermore, additional studies which seek to identify
biochemical and biological anti-neoplastic agents which act synergistically with MBD2
knockdown are needed.

MBD2 dependent gene regulation in breast cancer
Our studies of the gene expression changes induced by MBD2 knockdown in
cultured breast cancer lines reveal insight in to the function of this pleotropic protein and
provide a mechanistic backdrop for our phenotypic observations. Recall our contention
that MBD2 knockdown offers a more targeted approach to methylated tumor suppressor
gene reactivation. In support of this hypothesis, we found that only a subset of the tumor
suppressor genes we examined were transcriptionally reactivated in MBD2 knockdown
breast cancer cells. Further supporting this idea was the observation that patterns of gene
expression in MBD2 knockdown cells overlapped only partially with those induced by 5aza-dC treatment.

ChIP experiments suggest that both direct and indirect tumor

suppressor gene reactivation occurs at methylated promoters, with large CpG islandassociated genes being preferentially reactivated through direct depletion of promoter
170

bound MBD2. Both direct and indirect (secondary) gene expression changes are no
doubt involved in bringing about the full spectrum of phenotypic changes.
Not unlike the variation we have described in the response to MBD2 knockdown,
there were subtle differences in the pattern of gene restoration between different cell
lines. We attribute these changes to several factors; chief among these is the likelihood
of differential methylation in different cells. In addition, we have not yet determined
whether any MBD2 associated corepressor components are aberrantly expressed in
different cell lines. To put it concisely, we do not yet know enough about the spectrum
of CpG methylation, epigenetic defects, or MBD2 occupancy in these various cell lines;
outside of the few genes we have surveyed more thoroughly, we can not be certain where
MBD2 is acting directly and how this changes between cell lines. As the epigenomes of
primary tumors and established cell lines become better characterized, we can revisit our
gene expression data and perhaps glean further insight into the mechanism of differential
response to MBD2 knockdown.
Finally, we remain open to the possibility that MBD2 has regulatory functions in the
cell which are unrelated to its role in transcriptional silencing of methylated genes.
Though no such activity has yet been convincingly attributed to MBD2, the evolutionary
divergence of the MBD family of proteins suggests such function(s) may well exist. In
order to fully evaluate the importance of the methyl DNA binding properties of MBD2 in
mediating phenotypes in breast cancer, further studies are needed. One such study might
involve the restoration of MBD2 with mutant lacking the ability to bind methyl CpG in
stable knockdown cells and determining whether this mutant is capaple of reversing
MBD2 dependent changes.
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MBD2 likely acts through multiple targets to affect the phenotype of breast cancer
A question remains as to the mechanism of the growth inhibition that follows MBD2
knockdown. We have discussed a minor increase in acute toxicity, measurable as crude
cell death (propidium iodide uptake) as well as apoptosis (Annexin V positivity). By far
the greatest effect of MBD2 knockdown appears to be a cytostatic one, which occurs
following an initial refractory period. The phenomenon we observe closely resembles
cellular senescence, including replicative cessation and characteristic changes in
morphology (Adams 2009; Caino, Meshki, and Kazanietz 2009). However we failed to
note any increase in beta galactosidase activity commonly associated with cellular
senscense (not shown). Additional studies to determine if cellular senescence is being
induced are warranted, including assaying telomerase levels and activitiy.
Based on our unsuccessful efforts to identify downstream mediators of MBD2
dependent phenotypes, we are left with the impression that a single downstream target
(direct or indirect) is probably not responsible for the full spectrum of changes. It is
certainly possible that we have not yet found the right gene; admittedly the subset we are
examining is small.

However, it seems intuitively more likely to us that MBD2

dependent gene repression, which to our knowledge is not restricted to any functional
category of tumor suppressor, is holding multiple pathways in check. In other words,
inhibition of MBD2 is initiating a divergent cascade of secondary effects which depend
on more than one, and probably many, downstream targets.
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Based on such a model (MBD2 works through multiple targets), we will revisit the
idea of resistance to MBD2 knockdown imposed growth inhibition in the following
section. For the moment we acknowledge that further studies are required to identify the
precise mechanism of knockdown induced growth inhibition and the key genes which
mediate MBD2 dependent phenotypes.

Considering resistance to MBD2 knockdown
At several points in this dissertation we have described a population of cells which
emerge from MBD2 knockdown imposed growth restriction; specifically, late developing
tumors in mouse xenograft models and stable MBD2 knockdown clones which survive
extended antibiotic selection.

The mechanism of this acquired resistance remains

unknown. As mentioned in the previous section, we interpret our data as a whole to
suggest that MBD2 mediated gene repression is stifling multiple pathways in breast
cancer. However we cannot exclude the possibility that a small group or perhaps even a
single key downstream mediator exists. These mutually exclusive models of MBD2
function suggest one of two processes is required for a given cell to acquire resistance to
MBD2 knockdown.
If a small group or a single gene is mediating MBD2 knockdown imposed growth
restriction, resistance can develop by multiple mechanisms, including high level
compensation for MBD2 by proteins with similar function or low level mutations in key
MBD2 target genes or pathway components. If this was the case, we would expect a
relatively homogeneous population of resistant clones with relatively uniform growth
properties that would be difficult to distinguish from control cells. On the other hand, if
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multiple pathways are involved resistance might develop at various points, including high
level compensation or disruptions in any one of the downstream pathways. In the latter
case, we would expect the population of resistant clones to be more heterogeneous with
varied growth characteristics depending on the particular point of disruption.
In theory, a careful study of resistant clones might glean some insight into the
mechanism underlying MBD2 knockdown imposed growth restriction. We currently do
not have sufficient data vis-à-vis resistance to reliably draw any conclusions and
therefore future studies aimed at better characterizing resistant populations are necessary.
Furthermore, a clearer understanding of the mechanism(s) of resistance will allow us to
better predict the clinical course of future strategies aimed at inhibiting MBD2 in breast
cancer patients.

Promoter CpG island methylation is independent of transcription
DNA methylation is often thought to vary inversely with transcription and to be the
principle mark that nucleates the formation of heterochromatin. However recent reports
have led to the realization that this view is overly simplistic. Trancriptionally silent
heterochromatin persists even in the absence of significant DNA methylation and
conversely high levels of methylation, for example in bodies of actively transcribed
genes, do not appear to affect transcription to any measureable extent (Suzuki and Bird
2008).

It is still widely accepted, however, that promoter CpG island-associated

methylation is a strict barrier to transcription, both at developmentally regulated sites of
differential promoter methylation and pathologically in cancer.
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We found that promoter CpG island methylation remained remarkably stable despite
significant levels of transcriptional induction in MBD2 knockdown cells.

This

observation casts doubt on the idea that transcriptional interference leads to passive
demethylation over time.

Granted these observations are made in the abnormal

environment of a tumor cell and generalizing to normal tissues may be injudicious. We
concede there may pathologic factors at work to maintain CpG island methylation in
cancer cells, nevertheless this observation is provocative. Considering the absence of
methylation from most CpG islands, even in tissues where the respective genes are not
expressed, we suggest that the mechanisms directing DNA methylation are largely
independent of transcription.
This is not to say that the two are unrelated, a great deal of credible evidence exists
linking CpG island hypermethylation to transcriptional silencing in development and
disease. We can safely draw the following conclusion from our data: methyl-binding
proteins such as MBD2 seem to be the primary link between hyper-methylation and
transcription at hyper-methylated tumor suppressors. Further support for this conclusion
is offered by our observation that restoring MBD2 expression in stable knockdown cells
led to the re-silencing of persistently methylated tumor suppressor genes. In order to
evaluate whether persistent methylation of transcribed genes occurs at sites of tissuespecific promoter methylation in normal cells, corresponding studies in normal tissues are
required.
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MBD2 is a component of a dynamic epigenetic network in breast cancer
Our work has largely focused on the specific function of MBD2; however a survey
of the effects of MBD2 knockdown on other elements of the epigenetic landscape has led
to some notable findings. As discussed throughout the present work, MBD2 does not
exist in isolation. While this protein is clearly performing an important pathologic role in
breast cancer, we must consider it in its broader environmental context.
The epigenetic silencing of tumor suppressor genes involves the coordinated action
of methyltransferases, methyl binding proteins, and corepressor complexes; it is therefore
not surprising that we found an element of coregulation exists between these factors.
We suspected that MBD2 knockdown cells may be implementing compensatory
mechanisms to overcome the deleterious effects of knockdown. We found that levels of
DNMT1 and MeCP2 protein were increased in stable knockdown cells. Increased levels
of DNMT1 may be acting to counteract passive demethylation, perhaps accounting for
the stability of CpG methylation at transcriptionally active tumor suppressor genes.
Similarly, increases in other methyl binding proteins such as MeCP2 may be
compensating to some degree for the loss of MBD2. In support of a compensation
model, we found that simultaneous knockdown of MBD2 and MeCP2 led to an increase
in apoptosis in breast cancer cell lines. These knockdown studies were performed with
transient siRNA; long term stable knockdown studies to fully evaluate the requirement
for MeCP2 in breast cancer cells are needed.
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Conclusion
In conclusion, the body of work presented here strongly supports a pathological role
for MBD2 in the growth and in vivo survival of breast cancer. We find that MBD2
depletion by targeted shRNA leads to reexpression of methylated tumor suppressor genes
without a corresponding change in DNA methylation. Restored gene expression in turn
leads to growth inhibition, organized growth in 3D culture models, and tumor clearance
in animals. While further studies are needed to evaluate the effects of MBD2 inhibition in
normal tissues, based on the studies reported here we conclude that targeting MBD2 is a
viable strategy for inhibiting the proliferation of human breast cancer. A model of the
function of MBD2 and a summary of MBD2 dependent effects in breast cancer cells is
given below in Figure 45.
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Figure 45. Summary and Model: The effects of MBD2 knockdown on CpG
methylation, tumor suppressor gene expression, growth and in vivo clearance of
breast cancer.

Figure 45. MBD2 depletion by targeted shRNA leads to reexpression of methylated tumor
suppressor genes without a corresponding change in DNA methylation. Restored gene
expression in turn leads to growth inhibition, organized growth in 3D culture models, and tumor
clearance in animals.
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Appendix A: Tumor Suppressor Genes Hyper-Methylated in Breast Cancer and their Function
Name
ADAM23

Extended Name
ADAM metallopeptidase
domain 23

Function(s)
Metalloprotease

APC

adenomatosis polyposis coli

Non-motor
microtubule binding
protein

ATM

ataxia telangiectasia
mutated (includes
complementation groups A,
C and D)

Nucleic acid binding;
Non-receptor
serine/threonine
protein kinase;
Nucleotide kinase

BAX

BCL2-associated X protein

signaling molecule

BRCA1

breast cancer 1, early onset

Zinc finger
transcription factor

CCND2

cyclin D2

Kinase activator

Biological Process(s)
Proteolysis; Cell adhesionmediated signaling; Neuronal
activities
receptor mediated signaling
pathway; intracellular
signaling cascade; Cell
adhesion; Apoptosis; Cell
cycle control; Tumor
suppressor
DNA repair; Protein
phosphorylation; Stress
response; Induction of
apoptosis; Cell cycle control

Pathway(s)

Induction of apoptosis;
Gametogenesis;
Hematopoiesis; Cell cycle
control; Cell proliferation and
differentiation; Tumor
suppressor
DNA repair; mRNA
transcription regulation; Cell
cycle control; Tumor
suppressor
Cell cycle control; Mitosis;
Cell proliferation and
differentiation

p53 pathway->BCL2-associated X protein;
Apoptosis signaling pathway->Bcl-2
associated x protein; Huntington disease>Bcl-2-associated X protein;
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Angiogenesis->Adenomatous Polyposis of
the Colon; Wnt signaling pathway>Adenomatous Polyposis Coli;

p53 pathway feedback loops 2->ATM; EGF
receptor signaling pathway>phosphatidylinositol 3-kinase; p53
pathway->Ataxia telangiectasia mutated
(ATM) and Rad3-related (ATR);

Wnt signaling pathway->Wnt Target Genes;
Cell cycle->Cyclin D; PI3 kinase pathway>Cyclin d;

Name
CDH1

Extended Name
cadherin 1, type 1, Ecadherin (epithelial)

Function(s)
Cadherin

Biological Process(s)
Cell adhesion-mediated
signaling; Cell adhesion

CDH13

cadherin 13, H-cadherin
(heart)

Cadherin

CDKN2A

cyclin-dependent kinase
inhibitor 2A (melanoma,
p16, inhibits CDK4)

Kinase inhibitor

Cell adhesion-mediated
signaling; Cell adhesion;
Oncogenesis
Cell cycle control; Tumor
suppressor

CLCA2

chloride channel, calcium
activated, family member 2
DAB2 interacting protein

Ion channel

Miscellaneous

Molecular function
unclassified
Non-receptor
serine/threonine
protein kinase
Molecular function
unclassified

Biological process
unclassified
Protein phosphorylation;
Induction of apoptosis

DAB2IP
DAPK1

death-associated protein
kinase 1

DIRAS3

DIRAS family, GTP-binding
RAS-like 3

Biological process
unclassified
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Pathway(s)
Alzheimer disease-presenilin pathway->Ecadherin transmembrane fragment;
Alzheimer disease-presenilin pathway->Ecadherin C-terminal fragment; Wnt
signaling pathway->Cadherin; Alzheimer
disease-presenilin pathway->E-cadherin Nterminal fragment; Alzheimer diseasepresenilin pathway->E-cadherin; Cadherin
signaling pathway->Cadherin; Alzheimer
disease-presenilin pathway->E-cadherin
intracellular fragment;
Wnt signaling pathway->Cadherin;
Cadherin signaling pathway->Cadherin;
Ras Pathway->p14/19 ARF; p53 pathway
feedback loops 2->p14/19 ARF; p53
pathway->Alternative reading frame
(tumor-suppresor protein); p53 pathway>ARF;

EGF receptor signaling pathway->GAP;

Name
ESR1

Extended Name
estrogen receptor 1

Function(s)
Nuclear hormone
receptor; Transcription
factor; Nucleic acid
binding

ESR2

estrogen receptor 2 (ER
beta)

Nuclear hormone
receptor; Transcription
factor; Nucleic acid
binding

FHIT

fragile histidine triad gene

GPC3

glypican 3

GSTP1
HIC1

glutathione S-transferase pi
hypermethylated in cancer
1

HOXA5

homeobox A5

KLK10

kallikrein-related peptidase
10
laminin, alpha 5

Nucleotide
phosphatase
Cell adhesion
molecule; Extracellular
matrix glycoprotein
transferase
Zinc finger
transcription factor;
DNA-binding protein
Homeobox
transcription factor;
Nucleic acid binding
Serine protease

LAMA5

Extracellular matrix
linker protein

Biological Process(s)
mRNA transcription
regulation; Steroid hormonemediated signaling; neuronal
activity; Oogenesis; Cell cycle
control; Mitosis; Cell
proliferation and
differentiation; Cell motility
mRNA transcription
regulation; Steroid hormonemediated signaling; neuronal
activity; Oogenesis; Cell cycle
control; Mitosis; Cell
proliferation and
differentiation; Cell motility
Biological process
unclassified
Cell adhesion

Pathway(s)

Detoxification
mRNA transcription
regulation
mRNA transcription
regulation; Segment
specification; Neurogenesis
Proteolysis

Wnt signaling pathway->Wnt Target Genes;

Cell adhesion-mediated
signaling; Extracellular matrix
protein-mediated signaling

Integrin signalling pathway->Laminin;

181

Name
MGMT

Extended Name
O-6-methylguanine-DNA
methyltransferase

Function(s)
DNA
methyltransferase;
DNA methyltransferase
Nucleotide kinase

Biological Process(s)
DNA repair

Pathway(s)

NME1

non-metastatic cells 1,
protein (NM23A) expressed
in

Pyrimidine metabolism

De novo purine biosynthesis->GDP kinase;
De novo pyrimidine deoxyribonucleotide
biosynthesis->dTDP kinase; De novo purine
biosynthesis->dADP kinase; De novo
pyrmidine ribonucleotides biosythesis>UDP kinase; De novo pyrimidine
deoxyribonucleotide biosynthesis->dCDP
kinase; De novo pyrmidine ribonucleotides
biosythesis->CDP kinase; De novo
pyrimidine deoxyribonucleotide
biosynthesis->dUDP kinase; De novo purine
biosynthesis->dGDP kinase;

PAX5

paired box gene 5 (B-cell
lineage specific activator)

pleiomorphic adenoma
gene-like 1

Homeobox
transcription factor;
DNA-binding protein
Nuclear hormone
receptor; Transcription
factor; Nucleic acid
binding
zinc finger
transcription factor

PRDM2

PR domain containing 2,
with ZNF domain

KRAB box transcription
factor

mRNA transcription
regulation; Neurogenesis;
Gut mesoderm development
mRNA transcription
regulation; Steroid hormonemediated signaling; neuronal
activity; oncogenesis
mRNA transcription
regulation; developmental
process
Biological process
unclassified

PGR

progesterone receptor

PLAGL1

PRSS8

protease, serine, 8
(prostasin)

Serine protease

PTCH1

patched homolog 1
(Drosophila)

Molecular function
unclassified

Proteolysis; Immunity and
defense; Spermatogenesis
and motility
Biological process
unclassified
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Hedgehog signaling pathway->Patched;

Name
PTEN

Extended Name
phosphatase and tensin
homolog (mutated in
multiple advanced cancers
1)

Function(s)
Protein phosphatase;
phosphatase

Biological Process(s)
Phospholipid metabolism;
Protein phosphorylation;
Signal transduction; Cell
adhesion; Immunity and
defense; Induction of
apoptosis; Cell cycle control;
Cell proliferation and
differentiation; Tumor
suppressor

PYCARD

PYD and CARD domain
containing
retinoic acid receptor, beta

Protease inhibitor

Proteolysis; Apoptosis

Nuclear hormone
receptor; Transcription
factor; Nucleic acid
binding

Ras association (RalGDS/AF6) domain family 1
retinoblastoma 1 (including
osteosarcoma)

G-protein modulator

mRNA transcription
regulation; Cell
communication;
Developmental processes;
Oncogenesis
Signal transduction;
Apoptosis
mRNA transcription
regulation; Developmental
processes; Cell cycle control;
Tumor suppressor
Proteolysis

RARB

RASSF1
RB1

MASPIN serpin peptidase inhibitor,
SERPINB5 clade B (ovalbumin),
member 5

transcription factor;
Nucleic acid binding

Serine protease
inhibitor
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Pathway(s)
Insulin/IGF pathway-protein kinase B
signaling cascade->Phosphatase and tensin
homolog; Hypoxia response via HIF
activation->phospatase and tensin
homologue; PI3 kinase pathway->PTEN;
p53 pathway->PTEN; Insulin/IGF pathwayprotein kinase B signaling cascade->PTEN;
Inflammation mediated by chemokine and
cytokine signaling pathway->Phosphatase
and tensin homologue; p53 pathway>Phosphatase and tensin homolog deleted
on chromosome 10; p53 pathway feedback
loops 2->PTEN; p53 pathway feedback
loops 2->PTEN;

Vitamin D metabolism and pathway>Retinoid X Receptor, Alpha;

p53 pathway feedback loops 2->Rb;

p53 pathway->Maspin;

Name
SFN

Extended Name
stratifin

Function(s)
chaperones

Biological Process(s)
Signal transduction; protein
targeting and localization;
Cell cycle

SNCG

synuclein, gamma (breast
cancer-specific protein 1)

MAPKKK cascade; apoptosis;
oncogenesis

SOCS1

suppressor of cytokine
signaling 1
spleen tyrosine kinase

signaling molecule;
cytoskeletal proteins;
miscellaneous function
protein
Kinase inhibitor

SYK

TFAP2A

TGFBR2

THBS1

transcription factor AP-2
alpha (activating enhancer
binding protein 2 alpha)
transforming growth factor,
beta receptor II (70/80kDa)

thrombospondin 1

Non-receptor tyrosine
protein kinase

transcription factor

cytokine receptor;
Serine/threonine
protein kinase
receptor; Protein
kinase

signaling molecule;
enzyme regulator;
extracellular matrix

Cytokine and chemokine
mediated signaling pathway
Protein phosphorylation;
Intracellular signaling
cascade; immune and
defense; Embryogenesis; Cell
proliferation and
differentiation
mRNA transcription
regulation; Ectoderm
development; Oncogenesis
Protein phosphorylation;
Cytokine and chemokine
mediated signaling pathway;
Receptor protein
serine/threonine kinase
signaling pathway;
developmental process
Blood clotting;
developmental process
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Pathway(s)
EGF receptor signaling pathway->14-3-3;
FGF signaling pathway->14-3-3; p53
pathway->14-3-3 sigma; Parkinson disease>14-3-3; p53 pathway->14-3-3; PI3 kinase
pathway->14-3-3;
Parkinson disease->gamma-Synuclein;

JAK/STAT signaling pathway->Suppressors
of cytokine signaling;
B cell activation->Syk;

TGF-beta signaling pathway>TGFbetareceptor II; TGF-beta signaling
pathway->TGFbetareceptors;

p53 pathway->Thrombospondin-1;

Name
THRB

Extended Name
thyroid hormone receptor,
beta (erythroblastic
leukemia viral (v-erb-a)
oncogene homolog 2, avian)

Function(s)
Nuclear hormone
receptor; Transcription
factor

TIMP3

TIMP metallopeptidase
inhibitor 3 (Sorsby fundus
dystrophy,
pseudoinflammatory)

Metalloprotease
inhibitor

TNFSF10

tumor necrosis factor
(ligand) superfamily,
member 10

Tumor necrosis factor
family member

TP53

tumor protein p53 (LiFraumeni syndrome)

transcription factor

TWIST1

twist homolog 1
(acrocephalosyndactyly 3,
Saethre-Chotzen syndrome)
(Drosophila)

Basic helix-loop-helix
transcription factor;
Nucleic acid binding

Biological Process(s)
mRNA transcription
regulation; Steroid hormonemediated signaling; Sensory
perception; Developmental
processes
Proteolysis

Pathway(s)

Cytokine and chemokine
mediated signaling pathway;
Ligand-mediated signaling;
Immunity and defense;
Induction of apoptosis
DNA repair; mRNA
transcription regulation;
Induction of apoptosis; Cell
cycle control; Cell
proliferation and
differentiation; Tumor
suppressor

Apoptosis signaling pathway->TNF-related
apoptosis inducing ligand;

mRNA transcription
regulation; Developmental
processes; Cell proliferation
and differentiation
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P53 pathway feedback loops 1->P53;
Huntington disease->P53 tumor suppressor
phosphoprotein; Apoptosis signaling
pathway->Tumor protein p53; p53
pathway by glucose deprivation->p53; p53
pathway->p53; p53 pathway->p53; p53
pathway feedback loops 2->p53; Wnt
signaling pathway->Tumor suppressor p53;

Appendix B: Quantitative RT-PCR Primers
Gene

refseq

Forward

Reverse

ACTB

NM_001101 CCTTGCACATGCCGGAG

GCACAGAGCCTCGCCTT

ADAM23

NM_003812 ACTGTGGTTTCCCATTTTCG

AATAAGGCTGTCCATCTGGC

APC

NM_000038 TCTCCATCTTCAGTGCCTCA

GGAGACAGAATGGAGGTGCT

ATM

NM_000051 TCATGGTCCAGTCAAAGAGTG

ACGGGTGTTGAAGGTGTCTT

BAX

NM_004324 CAGCCCATGATGGTTCTGAT

GACATGTTTTCTGACGGCAA

BCSG1

NM_003087 GATGGCCTCAAGTCCTCCTT

AGTGGCCGAGAAGACCAAG

BRCA1

NM_007294 GAAGGCCCTTTCTTCTGGTT

AGAGTGTCCCATCTGTCTGGA

CCND2

NM_001759 GCTTGGTCCAGTTCATCCTC

TGAGCTGCTGGCTAAGATCA

CDH1

NM_004360 GTCGAGGGAAAAATAGGCTG

GCCGAGAGCTACACGTTCAC

CDH13

NM_001257 CCTCAATGAATTCAGCTGGC

CTCGTTCTGTGCGTTCTCCT

CLCA2

NM_006536 CTGCGGCTTGTTGTAGTTGA

CCATGAATGGGACTGAGCTT

DAB2IP

NM_032552 GACTCGTGGGAGCGAGACT

GACCGCAACCACAGCTTC

DAPK1

NM_004938 CTCACGGCATTTCTTCACAA

TGGTGAGGCGTGACAGTTTA

DIRAS3

NM_004675 GCAGCTTCTGTTCCTTGGAG

CTTCTAGGCTGCTTGGTTCG

ESR1

NM_000125 AGGATCTCTAGCCAGGCACA

AAGCTTCGATGATGGGCTTA

ESR2

NM_001437 ATCACCCAAACCAAAGCATC

CCATGATCCTGCTCAATTCC

FHIT

NM_002012 ACCACTGTCCCGACTCTCTG

CTGTCCTTCGCTCTTGTGAA

GAPD

NM_002046 TTAAAAGCAGCCCTGGTGAC

CTCTGCTCCTCCTGTTCGAC

GPC3

NM_004484 CTTGAACATGGCATTGGTGT

ACAGCACGATTGAACATGGA

GSTP1

NM_000852 AATGAAGGTCTTGCCTCCCT

GACCTCCGCTGCAAATACAT

HIC1

NM_006497 ACAGGTTGTCACCGAAGCTC

CGACGACTACAAGAGCAGCA

HOXA5

NM_019102 TGGAACTCCTTCTCCAGCTC

AGATCTACCCCTGGATGCG

KLK10

NM_002776 CCGTTGAAGAGCGAGACCT

CTGCTGATGGCGCAACT

LAMA5

NM_005560

AACGTCACCCTGGACCTG

MASPIN

NM_002639 CCAGTGGCTCCTTTTCACAT

CTGTTCCTTTTCCACGCATT

MBD1

NM_015846 GCTGGATAGCACAAGATGCC

TGTGGACGCTCAGACACCTA

MBD2

NM_003927 AAGTGCTGGCAAGAGCGATGTCTA

TTTCCCAGGTACCTTGCCAACTGA

MBD3

NM_003926 CGGCTCTTGTTCATCTTGCT

GGCCACAGGGATGTCTTTTA

TTGGAGGAGGCAAAGAACTG
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MeCP2

NM_004992 TGGACACGGAAGCTTAAGCAAAGG

CTCTCCCAGTTACCGTGAAGTCAA

NME1

NM_000269 GGCCCTGAGTGCATGTATTT

TTTGAGCAGAAAGGATTCCG

p16/CDKN2A

NM_058195 GTGAGAGTGGCGGGGTC

TCGTGCTGATGCTACTGAGG

PAX5

NM_016734 ACACTGCTCCCGATGTCAG

CATCTTCACCACCACAGAGC

PGR

NM_000926 CGATGCAGTCATTTCTTCCA

AATCTGTGGGGATGAAGCAT

PLAGL1

NM_002656 TTCCGGTTGAACGTCTTCTC

CAAACTTCTGGGAGGACTCG

PRDM2

NM_012231 CTTTGAAGAATGGTCCCTGG

CAAGCAGGAGCTGAAGGACT

PRSS8

NM_002773 ACGCCTTCATAGGTGATGCT

ATCTTGGATTACTCCGGTCG

PTCH1

NM_000264 TCTCCAATCTTCTGGCGAGT

CTCATATTTGGGGCCTTCG

PTEN

NM_000314 CGGTGTCATAATGTCTTTCAGC

TGAAGGCGTATACAGGAACAAT

PTEN

NM_002412 GAAATAGGCATTCAGCCAGG

GGGTCTGCACGAAATAAAGC

PYCARD

NM_013258 TGGTACTGCTCATCCGTCAG

CCCTCCTCAGTCGGCAG

RARB

NM_000965 ATCGTCCAACTCAGCTGTCA

TGCCAATACTGTCGACTCCA

RASSF1

NM_007182 AGGTGTCTCCCACTCCACAG

TGCAAGTTCACCTGCCACTA

RASSF1

NM_007182 GTCTCCCACTCCACAGGCT

AAGTTCACCTGCCACTACCG

RB1

NM_000321 CCTTCTCGGTCCTTTGATTG

CAGAAGGCAACTTGACAAGAGA

SCGB3A1

NM_052863 CTTCAGCGGGTTGAGGGT

CTCTGCGTGGCCCTGTC

SFN

NM_006142 GAGGAAACATGGTCACACCC

TGAGAACTGGACAGTGGCAG

SOCS1

NM_003745 AGAGGTGAGAAGGGGTCTGC

CTGGGATGCCGTGTTATTTT

SYK

NM_003177 AAAGAAGGGCAGGTGGTTG

GAGAGCGAGGAGGAGCG

TFAP2a

NM_003220 ATTGACCTACAGTGCCCAGC

TCCATGAAAATGCTTTGGAA

TGFBR2

NM_003242 CAGTTGCTCATGCAGGATTT

GCACGTTCAGAAGTCGGTTA

THBS1

NM_003246 TTGCCACAGCTCGTAGAACA

CAATGCCACAGTTCCTGATG

THRB

NM_000461 CAACCAGAAGGAAATCGCA

AAAGAGACCTCCTGCTCCG

TIMP3

NM_000362 GGTGAAGCCTCGGTACATCT

AGGACGCCTTCTGCAACTC

TNFSF10

NM_003810 CTCTCTTCGTCATTGGGGTC

TGCAGTCTCTCTGTGTGGCT

TP53

NM_000546 GCTCGACGCTAGGATCTGAC

CAGGTAGCTGCTGGGCTC

TWIST1

NM_000474 TCCATTTTCTCCTTCTCTGGAA

GGCTCAGCTACGCCTTCTC
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Appendix C: Selected Vector and Gene Maps
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shRNA B Binding Site
shRNA C Binding Site
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poly A tail

Fragment of hMaspin genomic

917 bp (molecule 37742 bp)
ChIP Forward Bisulfite Forward
Exon 1

ChIP Re v erse
CpG - 102bp

Bisulfite Rev e rse

Fragment of hDAPK1 Genomic

Bisulfite Forward

1473 bp (molecule 235946 bp)

ChIP Forward

Exon1

ChIP Reverse
CpG Island

Bisulfite Reverse

Fragment of hKLK10 Genomic

1756 bp (molecule 11147 bp)
ChIP Forward
Bisulfite Forward

Exon 1

CpG Island
Bisulfite Reverse
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